Polysubunit opioid prodrugs resistant to overdose and abuse

ABSTRACT

The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

CROSS-REFERENCE

This application is a continuation of U.S. patent application Ser. No.15/683,356, filed Aug. 22, 2017, now U.S. Pat. No. ______, which is acontinuation of U.S. patent application Ser. No. 15/284,269, filed Oct.3, 2016, now U.S. Pat. No. 9,808,452, which claims priority to U.S.Provisional Patent Application Ser. No. 62/236,048, filed Oct. 1, 2015,the entirety of which are incorporated herein by reference and to whichapplications we claim priority under 35 U.S.C. § 120.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with the support of the United States governmentunder SBIR Grant number 1R44DA037900 by the National Institute on DrugAbuse (NIDA), one of the National Institutes of Health (NIH) in the U.S.Department of Health and Human Services.

TECHNICAL FIELD

The present invention relates to compounds, methods and formulations forthe prevention and/or treatment of pain. More particularly, theinvention relates to pharmaceutical agents that interact with analgesicreceptors, methods of preparing these agents, and their use foranalgesia, pain, and other conditions, while protecting against overdoseand abuse.

BACKGROUND

Pharmacologically, opioid agonists represent an important class ofagents for the management of pain. The high abuse liability of opioidagonists often limits their use in the treatment of patients, andresults in the under-treatment of pain, and severe social and financialcosts. The U.S. Food and Drug Administration has recently describedprescription opioid analgesics as being at the center of a major publichealth crisis of addiction, misuse, abuse, overdose, and death(FDA/Center for Drug Evaluation and Research, Joint Meeting of theAnesthetic and Life Support Drugs Advisory Committee and the Drug Safetyand Risk Management Advisory Committee, Meeting Transcript, Jul. 23-4,2010).

The class of drugs exhibiting opium or morphine-like properties arereferred to as opioid agonists, or opioids, and they interact withopioid receptors in the brain, the peripheral nervous system and othertissues. The three major opioid receptor subtypes are mu, delta, andkappa. Each of these receptors has a unique anatomical distribution inthe central nervous system, the peripheral nervous system and thegastrointestinal tract. Most of the clinically used opioids exert theirdesired therapeutic action (i.e. analgesia) at the mu receptor subtype.

Opioids include morphine, codeine, oxycodone, hydrocodone,hydromorphone, and the like. Examples of marketed opioid products in theUnited States include OxyContin®, Vicodin®, and Percocet®. Opioids havediverse effects, including analgesia, euphoria, drowsiness, changes inmood and alterations of the endocrine and autonomic nervous systems.Opioid analgesics comprise the major class of drugs used in themanagement of moderate to severe pain. As a class, opioids are among themost prescribed drugs in the US. Data provided by IMS Health, Inc. showsthat about 9 billion hydrocodone containing pills are prescribedannually. However, several concerns exist regarding the nonmedical useand abuse of opioids. There exists a need for pharmaceutical productswhich provide the therapeutic benefits of opioids to a subject but thatis not susceptible to abuse.

SUMMARY OF THE INVENTION

Provided herein are unimolecular polysubunit compositions comprising atleast one GI enzyme-labile opioid releasing subunit capable of releasingan opioid agonist upon the action of a GI enzyme, wherein the at leastone GI enzyme-labile opioid releasing subunit is covalently linked to atleast one non-opioid releasing GI enzyme subunit capable of beingcleaved by said GI enzyme. In some embodiments, the at least one GIenzyme-labile opioid releasing subunit and the at least one non-opioidreleasing GI enzyme subunit are covalently linked via a scaffold moiety.For example, the scaffold moiety comprises a peptide, polypeptide, orpolysaccharide.

Also provided herein are unimolecular compositions comprising at leastone GI enzyme-labile opioid releasing subunit capable of releasing anopioid agonist upon the action of a GI enzyme, wherein the at least oneGI enzyme-labile opioid releasing subunit is covalently linked to atleast one GI enzyme inhibitor moiety. In some embodiments, the at leastone GI enzyme-labile opioid releasing subunit and the at least one GIenzyme inhibitor moiety are covalently linked via a scaffold moiety. Forexample, the scaffold moiety can comprises a peptide, polypeptide, orpolysaccharide.

Also provided herein is a pharmaceutical composition, the compositioncomprising: an opioid prodrug; a gastrointestinal enzyme inhibitor; anda scaffold, wherein the opioid prodrug and the inhibitor are covalentlyattached to the scaffold. In some embodiments, the at least onenon-opioid releasing GI enzyme subunit is an inverse-substrate. In someembodiments, the at least one non-opioid releasing GI enzyme subunit isa GI enzyme inhibitor.

In some embodiments, the GI enzyme is trypsin or chymotrypsin.

In some embodiments, the GI enzyme-labile opioid releasing subunitsrelease an opioid agonist. For example, the opioid agonist encompassesfull-, partial-, mixed-, inverse- or biased-agonists, and the like. Theycan include, without limitation, morphine, heroin, hydromorphone,oxymorphone, buprenorphine, levorphanol, butorphanol, codeine,dihydrocodeine, hydrocodone, oxycodone, meperidine, methadone,nalbulphine, opium, pentazocine, propoxyphene, as well as less widelyemployed compounds such as alfentanil, allylprodine, alphaprodine,anileridine, benzylmorphine, bezitramide, clonitazene, cyclazocine,desomorphine, dextromoramide, dezocine, diampromide, dihydromorphine,dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate,dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene,ethylmorphine, etonitazene, fentanyl, hydroxypethidine, isomethadone,ketobemidone, levallorphan, levophenacylmorphan, lofentanil, meptazinol,metazocine, metopon, myrophine, narceine, nicomorphine, norpipanone,papvretum, phenadoxone, phenomorphan, phenazocine, phenoperidine,piminodine, propiram, sufentanil, tapentadol, tramadol, tilidine, PZM021and analogs thereof, TRY130 and analogs thereof, BU08028 and analogsthereof, as well as salts, prodrugs and mixtures thereof.

In some embodiments, the non-opioid releasing GI enzyme subunit is moresusceptible to cleavage by the digestive enzyme than the GIenzyme-labile opioid releasing subunit and is capable of saturating orinhibiting the GI enzyme. In some embodiments, the GI enzyme inhibitorsubunit is capable of inhibiting the GI enzyme. In some embodiments, thenon-opioid releasing GI enzyme subunit is susceptible to cleavage by theGI enzyme and is capable of saturating the GI enzyme. In someembodiments, the non-opioid releasing GI enzyme subunit is capable ofreducing the expected systemic exposures of delivered opioid agonistwhen doses greater than the prescribed dose are orally co-ingested. Insome embodiments, the appended GI enzyme inhibitor is capable ofinhibiting the digestive enzyme. In some embodiments, the GI enzymeinhibitor is capable of reducing the expected systemic exposures ofdelivered opioid agonist when doses greater than the prescribed dose areorally co-ingested.

In some embodiments, compounds of the invention have the formula:

wherein:each S₁ is independently a non-opioid releasing GI enzyme subunit or GIenzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzyme subunit;each S₃ is an opioid antagonist releasing moiety;M is a covalent scaffold;each Z is independently a linking moiety;each r, m, n, is independently an integer ranging from 1 to 10, 1 to100, 1 to 1,000, 1 to 100,000, 1 to 1,000,000, or 1 to 1,000,000,000;p is an integer ranging from 0 to 10, 0 to 100, 0 to 1,000, 0 to100,000, 0 to 1,000,000, or 0 to 1,000,000,000

In some embodiments, compounds of the invention have the formula:

wherein:each S₁ is independently a non-opioid releasing GI enzyme subunit or GIenzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzyme subunit;each S₃ is an opioid antagonist releasing moiety;each Z is independently a linking moiety;each n is independently an integer ranging from 1 to 10;m is an integer ranging from 1 to 10; andp and r are independently integers ranging from 0 to 10.

In some embodiments, the S₁—Z— subunit is selected from the groupconsisting of:

Wherein:

Y is an amidine, guanidine, benzylamine, alkyl substituted amidine,alkyl substituted guanidine, alkyl substituted benzylamine,benzylamidine, benzylguanidine, alkyl substituted benzylamidine, oralkyl substituted benzylguanidine;Z is a linking moiety;each K_(o) is independently hydrogen or methyl;A is an amino acid side chain;r is an integer from 0-10;m is an integer from 1-10;o is an integer from 0-6p is an integer from 1-10;n is an integer from 0-10;each R is alkyl, alkylene, alkynyl, or aryl, or substituted alkyl,substituted alkylene, substituted alkynyl, substituted aryl group;each R′ is independently alkyl, aryl, substituted alkyl, substitutedaryl, acyl, substituted acyl group, or polyethylene glycol containingacyl, aryl, or alkyl group; andeach R″ is independently a hydrogen, methyl, alkyl, or aryl group.

In some embodiments, at least one of Z and Ko comprises an electrondonating or electron withdrawing group. For instance, the electrondonating group is alkyl, substituted alkyl, —OH, —OR, —NH₂, —NR₂, —SH,—SR, or —NHC(O)R. Alternatively, the electron withdrawing group is:—C(O)OH, —C(O)OR, —C(O)NH₂, —C(O)NR₂, —NO₂, —NR₃ ⁺, —C(O)CF₃, halogen,—CF₃, cyano, —SO₃H, —SO₃R, —CHO, —COR, —C(NH)NH₂, or —NHC(═NH)NH₂.

In some embodiments, m is 1-10 and r and p are 0.

In some embodiments the S₂ subunit can be a reversible or non-reversible(i.e. covalent bond forming) trypsin inhibitor.

In some embodiments, the S₂ subunit has the structure:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety (Z); andA₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a GI enzyme.

In some embodiments, the S₂ subunit has the structure:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety (Z); and

A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a GI enzyme.

In some embodiments, the S₂ subunit has the structure:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;R¹, R² and R³ can be R′, orR² and R³ can be joined to form an optionally substituted spirocyclicring;R² or R³ can be joined with R¹ to form an optionally substitutedheterocyclic ring;R² or R³ can be joined with R′ to form an optionally substituted ring,orR′ can be joined with a geminal R′ so as to from an optionallysubstituted spirocyclic ring;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a polyethyleneglycol, or polyethylene glycol containing moiety, or a linking moiety—Z; or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is as defined herein;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing alkyl, or a natural or        unnatural amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)    -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10; and        each A₂ is independently an amino acid side chain or an amino        acid side-chain mimic that is capable of being recognized by a        digestive enzyme.

In some embodiments, A₂ is:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or        -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or            methyl; or

-   -   wherein A₂ is a natural or unnatural amino acid side chain, or        an amino acid side-chain mimic that is capable of being        recognized by a digestive enzyme that directs the regiospecific        hydrolysis of the S₂ subunit prior to the release of the        appended opioid agonist from the S₂ subunit and can be, but is        not limited to, the amino acid side chain of arginine,        homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine,        or structural/functional mimics thereof; R″ is as defined above.

In some embodiments, the S₂ subunit has the structure:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety Z as previously defined;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid side chain, an amino acid side-chain mimic, or a linking moiety Zas defined herein; andeach A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;

In some embodiments, A₂ is:

-   -   Wherein R is each or independently hydrogen or methyl; R″ is as        defined above; r is each or independently an integer from 1 to        6; n is an integer from 0 to 10; R′″ is hydrogen, methyl,        —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   wherein A₂ is a natural or unnatural amino acid side chain, or        an amino acid side-chain mimic that is capable of being        recognized by a digestive enzyme that directs the regiospecific        hydrolysis of the S₂ subunit prior to the release of the        appended opioid agonist from the S₂ subunit and can be, but is        not limited to, the amino acid side chain of arginine,        homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine,        or structural/functional mimics thereof; R″ is as defined above;        and        m is an integer from 0 to 10        n is an integer from 0 to 10        p is an integer from 0 to 4.

In some embodiments, the S₃—Z— subunit is selected from the groupconsisting of:

Wherein:

R is cyclopropylmethyl or allyl; R′ is hydrogen, methyl, alkyl, aryl,substituted alkyl, or substituted aryl, acyl or substituted acyl; and Zis a linker as defined herein.

In some embodiments, the opioid antagonist is naltrexone or naloxone.

In some embodiments, the S₂ subunit has a structure selected from thegroup consisting of:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R¹ and R² is independently R or R′; or wherein R¹ and R² can bejoined to form an optionally substituted spirocyclic ring;R³ is R″; or wherein R³ is joined with R¹ or R² to form an optionallysubstituted heterocyclic ring;each R is independently hydrogen, methyl, or alkyl, for example loweralkyl;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, or—Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing alkyl, or a natural or        unnatural amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n);    -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        R⁴ is hydrogen, methyl, —C(═NR)—NR₂ (where each R is        independently hydrogen or methyl), or a group of formula:

each A₂ independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;n is an integer ranging from 1 to 10; and

r is an integer ranging from 1 to 6.

In some embodiments, the S₂ subunit has a structure selected from thegroup consisting of:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R¹ and R² is independently R or R′; or wherein R¹ and R² can bejoined to form an optionally substituted spirocyclic ring;R³ is R″; or wherein R³ is joined with R¹ or R² to form an optionallysubstituted heterocyclic ring;each R is independently hydrogen, methyl, or alkyl, for example loweralkyl;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, or—Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing alkyl, or a natural or        unnatural amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n);    -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        R⁴ is hydrogen, methyl, —C(═NR)—NR₂ (where each R is        independently hydrogen or methyl), or a group of formula:

each A₂ independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;n is an integer ranging from 1 to 10; andr is an integer ranging from 1 to 6.

In some embodiments, Z is represented by one of the formulae:

wherein:each F is independently:

each R is independently hydrogen, methyl, lower alkyl, aryl, orarylalkyl;X can be carbon, oxygen, or nitrogen;L can be a covalent bond or a linear, branched, or a multivalentscaffold comprised of alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, polyalkylene glycol, peptide,polypeptide, amide, polyamide, carbamate, polycarbamate, urea, polyurea,carbonate, polycarbonate, or a combination thereof.

For example, the linking moiety F forms a substituted ester, amide,amine, carbamate, ether, alkylane, arene, or urea; and L is a covalentbond or a linear, branched, or a multivalent scaffold comprised ofalkyl, aryl, substituted alkyl, substituted aryl, heteroalkyl,polyalkylene glycol, polypeptide, or polyamide.

In some embodiments, D is a morphone, codone, or morphine.

In some embodiments, the scaffold is an oligomeric or polymericscaffold.

For example, the scaffold is a polyalkylene oxide, a polypeptide, apolysaccharide or a biopolymer. Alternatively, the scaffold is a linear,branched, brush (or comb) polymer. In some embodiments, the scaffold ispolycationic.

Also provided herein is a method of treating pain in a subject in needthereof, the method comprising administrating to the subject atherapeutically-effective amount of a unimolecular polysubstrate of theinvention. Further provided are pharmaceutical compositions comprising apolysubstrate.

In one aspect, the present disclosure provides a compound represented bythe structure of Formula (I):

[R¹-L¹_(n)QL²-R²]_(m)  (I)

or a salt thereof, wherein:

Q is independently selected from optionally substituted heteroalkyl andoptionally substituted alkyl;

L¹ is independently at each occurrence absent or a cleavable ornon-cleavable linker;

L² is independently at each occurrence absent or a cleavable ornon-cleavable linker;

R¹ is independently selected at each occurrence from a GI enzymesubstrate, a GI enzyme inhibitor, and an opioid antagonist;

R² is an opioid agonist covalently bound to a GI enzyme substrate; and

m and n are independently selected at each occurrence from 1 to1,000,000.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted heteroalkyl group.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted peptide.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted peptide with from 1 to 500 amino acids. In someembodiments, for the compound or salt of Formula (I), Q is an optionallysubstituted peptide with from 1 to 50 amino acids. In some embodiments,for the compound or salt of Formula (I), Q is an optionally substitutedpeptide with from 1 to 10 amino acids. In some embodiments, for thecompound or salt of Formula (I), Q is an optionally substituted peptidewith from 1 to 3 amino acids.

In some embodiments, a compound or salt of Formula (I) is represented bya structure of Formula (IA), (IB), or (IC):

wherein W is selected from hydrogen, optionally substituted alkyl,optionally substituted acyl, and optionally substituted alkoxycarbonyl.

In some embodiments, a compound or salt of Formula (I) is represented bya structure of Formula (ID), (IE), or (IF):

In some embodiments, the compound or salt, wherein R¹ is independentlyselected at each occurrence from a GI enzyme inhibitor. In someembodiments, for the compound or salt of Formula (I), R¹ at eachoccurrence is a serine protease inhibitor. In some embodiments, for thecompound or salt of Formula (I), Q at each occurrence is a trypsininhibitor.

In some embodiments, for the compound or salt of Formula (I), R¹-L¹ isindependently selected at each occurrence from:

wherein:

Y is independently selected from an amidine, guanidine, benzylamine,alkyl substituted amidine, alkyl substituted guanidine, alkylsubstituted benzylamine, benzylguanidine, alkyl substitutedbenzylamidine, or alkyl substituted benzyl; and

Z is independently selected from hydrogen, cyano, nitro, halogen, alkyland alkoxy.

In some embodiments, for the compound or salt of Formula (I), Y isamidine.

In some embodiments, for the compound or salt of Formula (I), R¹-L¹ isrepresented by the formula:

In some embodiments, for the compound or salt of Formula (I), L¹ at eachoccurrence is selected from a cleavable or non-cleavable linkerincluding from 2 to 15 atoms.

In some embodiments, for the compound or salt of Formula (I), L¹ is—O—CH²⁻CH₂—NH— or —O—CH²⁻CH₂—O—.

In some embodiments, for the compound or salt of Formula (I), n isselected from 1 to 20. In some embodiments, for the compound or salt ofFormula (I), n is selected from 1 to 10. In some embodiments, for thecompound or salt of Formula (I), n is selected from 1 to 3.

In some embodiments, for the compound or salt of Formula (I), R²-L² isindependently selected at each occurrence from:

wherein:

D is an opioid agonist;

R¹⁰¹ and R¹⁰² are independently selected from optionally substitutedalkyl, an amino acid side chain and an amino acid side-chain mimic.

In some embodiments, for the compound or salt of Formula (I), R¹⁰¹ isselected from an amino acid side chain and R¹⁰² is optionallysubstituted alkyl. In some embodiments, for the compound or salt ofFormula (I), R¹⁰¹ is selected from an arginine or lysine side chain andR¹⁰² is optionally substituted methyl. In some embodiments, for thecompound or salt of Formula (I), R¹⁰² is methyl substituted with—NH-acetyl.

In some embodiments, for the compound or salt of Formula (I), D isselected from morphine, hydromorphone, hydrocodone, oxycodone, codeine,levorphanol, meperidine, methadone, oxymorphone, dihydrocodeine,tramadol, tapentadol, and buprenorphine. In some embodiments, for thecompound or salt of Formula (I), D is represented by the formula:

In some embodiments, for the compound or salt of Formula (I), m isselected from 1 to 20. In some embodiments, for the compound or salt ofFormula (I), m is selected from 1 to 10. In some embodiments, for thecompound or salt of Formula (I), m is 1 to 3.

In some embodiments, for the compound or salt of Formula (I), thecompound is represented by the formula:

or a salt thereof.

In some embodiments, for the compound or salt of Formula (I), thecompound is represented by the formula

or a salt thereof.

In one aspect, the present disclosure provides a method of treating painin a subject in need thereof, the method comprising administrating tothe subject a therapeutically-effective amount of the compound or saltof Formula (I).

In one aspect, the present disclosure provides the compound or salt ofFormula (I) and a pharmaceutically acceptable excipient.

In one aspect, the present disclosure provides a pharmaceuticalformulation comprising:

an opioid prodrug;

a gastrointestinal enzyme inhibitor; and

a scaffold, wherein the opioid prodrug and the inhibitor are covalentlyattached to the scaffold.

In one aspect, the present disclosure provides a pharmaceuticalcomposition, the composition comprising:

an opioid prodrug comprising an opioid covalently bonded to a promoietycomprising a gastrointestinal enzyme-cleavable moiety; and

a gastrointestinal enzyme inverse substrate wherein the opioid prodrugand the inverse substrate are covalently attached to a scaffold.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE FIGURES

The novel features of the invention are set forth with particularity inthe appended claims. A better understanding of the features andadvantages of the present invention will be obtained by reference to thefollowing detailed description that sets forth illustrative embodiments,in which the principles of the invention are utilized, and theaccompanying drawings of which:

FIG. 1 illustrates the effects of competitive enzyme inhibition.

FIG. 2 illustrates the kinetics of enzyme saturation.

FIG. 3 illustrates a predicted enzyme pathway when an intended dose of apolysubstrate of the disclosure is ingested (black font).

FIG. 4 illustrates saturation of the predicted enzyme pathway whenexcessive doses of a polysubstrate of the disclosure are ingested (blackfont).

FIG. 5 is a graph illustrating an example of the predictedpharmacodynamic and pharmacokinetic parameters of (A) an opioid agonist,and (B) an opioid agonist delivered by a polysubstrate of thedisclosure.

DETAILED DESCRIPTION

Typically, opioids pass rapidly through the blood-brain-barrier (BBB)and rapidly reach peak concentrations that produce the euphoria or“high” experienced by opioid abusers. Strategies to reduce opioid abusehave focused on formulation or alternative delivery strategies; such asorally administered delayed release tablets and transdermal patches.Abusers can easily defeat these formulations by crushing, chewing, ordissolving these formulations in commonly available household solvents,thereby enabling them to achieve the desired pharmacokinetic profile,and/or non-oral routes of administration, useful for achieving a “high”.None of these technologies address the primary route of prescriptionopioid abuse—oral overdose. Thus, there exists a need for opioid drugproducts with lower abuse potential than currently available opioidproducts used in analgesia. In particular, there exists a need for newopioid drugs that (i) offer safe and effective pain relief to patientswhen taken as prescribed and (ii) prevent high plasma concentrationsresulting from the co-ingestion of multiple pills, while (iii)effectively deterring non-oral abuse.

The present disclosure seeks to address these and other needs byproviding a novel class of polysubstrate or polysubunit opioid analogs.The present disclosure provides unimolecular polysubstrate orpolysubunit compositions comprising a GI enzyme-labile opioid releasingsubstrate or GI enzyme-labile opioid releasing substrates, covalentlyattached directly, or indirectly, via a molecular, oligomeric, orpolymeric architecture, to a non-opioid releasing GI enzyme substrate ornon-opioid releasing GI enzyme substrates, and an optional opioidantagonist releasing moiety or optional opioid antagonist releasingmoieties. The present disclosure also provides unimolecular polysubunitcompositions comprising a GI enzyme-labile opioid releasing substrate orGI enzyme-labile opioid releasing substrates, covalently attacheddirectly, or indirectly, via a molecular, oligomeric, or polymericarchitecture, to a non-opioid releasing GI enzyme inhibitor ornon-opioid releasing GI enzyme inhibitors, and an optional opioidantagonist releasing moiety or optional opioid antagonist releasingmoieties. These novel unimolecular polysubunit molecules are designed to(i) release effective levels of the covalently attached opioid agonistfor the treatment of pain when ingested by compliant patients at theintended dose, (ii) prevent oral overdose or abuse of the compositionvia novel enzyme saturation or inhibition processes when multiple pillscontaining the composition are co-ingested by potential abusers (oraccidentally by children), and may (iii) produce a safe, non-abusablemixture of opioid agonist and opioid antagonist when potential abuserstamper with pills containing the composition.

These polysubunit opioid analogs can be further designed to have a highmolecular weight and/or possess a highly charged state at physiologicalpH ranges to prevent or minimize absorption from the GI tract, thereby(i) reducing their systemic exposures (and resulting safety risks) tothe subject, and (ii) maximizing the efficiency of both the opioiddelivery and overdose protection mechanisms.

In one aspect, the invention provides a pharmaceutical compositioncomprising a GI enzyme-labile opioid releasing substrate or GIenzyme-labile opioid releasing substrates, and a non-opioid releasing GIenzyme substrate or non-opioid releasing GI enzyme substrates, whereinthe GI enzyme-labile opioid releasing substrate(s), and the non-opioidreleasing GI enzyme substrate(s) are covalently attached directly toeach other or to a molecular scaffold. In another aspect, the inventionprovides a pharmaceutical composition comprising a GI enzyme-labileopioid releasing substrate or GI enzyme-labile opioid releasingsubstrates, and a non-opioid releasing GI enzyme inhibitor or non-opioidreleasing GI enzyme inhibitors, wherein the GI enzyme-labile opioidreleasing substrate(s), and the non-opioid releasing GI enzymeinhibitor(s) are covalently attached directly to each other or to amolecular scaffold. When patients ingest the pharmaceutical compositionsdefined herein, endogenous GI enzymes release targeted therapeuticlevels of the opioid agonist. When excessive doses of pharmaceuticalcompositions defined herein are ingested, the GI enzyme that releasesthe opioid agonist becomes saturated or inhibited so that increases indoses ingested do not lead to proportional increases in the amount ofopioid agonist released. The opioid agonist can be selected from thegroup consisting of morphine, hydromorphone, hydrocodone, oxycodone,codeine, levorphanol, meperidine, methadone, oxymorphone,dihydrocodeine, tramadol, tapentadol, and pharmaceutically acceptablesalts, prodrugs, and mixtures thereof. The opioid antagonist is selectedfrom naltrexone and naloxone. In some embodiments, the molecularscaffold is an oligomeric scaffold. In other embodiments, the molecularscaffold is a polymeric scaffold.

Definitions

Unless otherwise stated, the following terms used in this application,including the specification and claims, have the definitions givenbelow. Definition of standard chemistry terms may be found in referenceworks, including Carey and Sundberg (2004) “Advanced Organic Chemistry4rd Ed.” Vols. A and B, Springer, New York. The practice of the presentinvention will employ, unless otherwise indicated, conventional methodsof mass spectroscopy, protein chemistry, biochemistry, synthetic organicchemistry, and pharmacology, within the skill of the art.

The term “alkyl” or “lower alkyl” means the monovalent branched orunbranched saturated hydrocarbon radical, consisting solely of carbonand hydrogen atoms, having from one to twelve carbon atoms inclusive,unless otherwise indicated. Examples of alkyl radicals include, but arenot limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.

The term “alkylene” as used herein means the divalent linear or branchedsaturated hydrocarbon radical, consisting solely of carbon and hydrogenatoms, having from one to eight carbon atoms inclusive, unless otherwiseindicated. Examples of alkylene radicals include, but are not limitedto, methylene, ethylene, trimethylene, propylene, tetramethylene,pentamethylene, ethylethylene, and the like.

The term “alkenylene” means the divalent linear or branched unsaturatedhydrocarbon radical, containing at least one double bond and having fromtwo to eight carbon atoms inclusive, unless otherwise indicated. Thealkenylene radical includes the cis or trans ((E) or (Z)) isomericgroups or mixtures thereof generated by the asymmetric carbons. Examplesof alkenylene radicals include, but are not limited to ethenylene,2-propenylene, 1-propenylene, 2-butenyl, 2-pentenylene, and the like.

The term “aryl” means the monovalent monocyclic aromatic hydrocarbonradical consisting of one or more fused rings in which at least one ringis aromatic in nature, which can optionally be substituted with hydroxy,cyano, lower alkyl, lower alkoxy, thioalkyl, halogen, haloalkyl,hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, dialkylamino,aminocarbonyl, carbonylamino, aminosulfonyl, sulfonylamino, and/ortrifluoromethyl, unless otherwise indicated. Examples of aryl radicalsinclude, but are not limited to, phenyl, naphthyl, biphenyl, indanyl,anthraquinolyl, and the like.

The term “agonist” means a molecule such as a compound, a drug, anenzyme activator or a hormone that enhances the activity of anothermolecule or the activity of the target receptor.

The term “amino acid” refers to either natural and/or unnatural orsynthetic amino acids, and both the D- or L-optical isomers, the N-acyland N-methyl derivatives thereof, and amino acid analogs, isosteres, andpeptidomimetics. The natural amino acids include alanine, arginine,asparagine, cysteine, glutamic acid, glutamine, glycine, histidine,isoleucine, leucine, methionine, phenylalanine, proline, serine,threonine, tryptophan, tyrosine, valine, selenocysteine, andpyrrolysine.

Naturally occurring amino acids are those encoded by the genetic code,as well as those amino acids that are later modified, e.g.,hydroxyproline, carboxyglutamate, and O-phosphoserine. Amino acidanalogs refers to compounds that have the same basic chemical structureas a naturally occurring amino acid, i.e., an α-carbon that is bound toa hydrogen, a carboxyl group, an amino group, and an R group, e.g.,homoserine, norleucine, methionine sulfoxide, methionine, and methylsulfonium. Such analogs have modified side-chain groups, such asnorleucine, homoarginine, homolysine, ε-N-methyl lysine,ε,ε-N,N-dimethyl lysine, ε,ε,ε-N,N,N-trimethyl lysine, ornithine, andthe like, or modified peptide backbones, but retain the same basicchemical structure as a naturally occurring amino acid. Amino acidmimetics (or mimics) refers to chemical compounds that have a structurethat is different from the general chemical structure of an amino acid,but functions in a manner similar to a naturally occurring amino acid.For example, the unnatural amino acidL-(7-hydroxycoumarin-4-yl)ethylglycine (or7-hydroxycoumarin-ethylglycine) finds use with the invention.

The terms “enzymatically degradable” or “enzyme-labile” refer to amolecular entity that is subject to degradation by one or more enzymesunder ordinary physiological conditions.

The term GI refers to “gastrointestinal.” The term “gastrointestinalenzyme” or “GI enzyme” refers to an enzyme located in, derived from, oron, the gastrointestinal tract (GI tract), such as trypsin,chymotrypsin, elastase, tryptase, and the like.

The term “polysubstrate” or “polysubunit” refers to a compound of theinvention designed to release an opioid agonist when administered to asubject. The release profile of the opioid agonist from a polysubstrateor polysubunit can be attenuated in vivo when overdoses are ingested viaan enzyme saturation mechanism. In addition, polysubstrates orpolysubunits of the invention may also release an opioid antagonist whensubjected to chemical tampering by, or when administered via non-oralroutes to, potential abusers.

“Gastrointestinal enzyme substrate” or “GI enzyme substrate” refers to agroup comprising a site susceptible to cleavage by a GI enzyme. Forexample, a “trypsin-substrate” refers to a group comprising a sitesusceptible to cleavage by trypsin. Specifically, GI enzyme hydrolysisof a non-opioid-releasing GI enzyme substrate does not result in opioidrelease, and enzyme-mediated hydrolysis of an opioid-releasing GI enzymesubstrate results directly, or indirectly, in opioid release.

The term “opioid-releasing gastrointestinal enzyme substrate subunit” or“opioid-releasing GI enzyme substrate subunit” refers to a groupcomprising an opioid and a site susceptible to cleavage by a GI enzyme.For example, an “opioid releasing trypsin-substrate” refers to a groupcomprising a site susceptible to cleavage by trypsin that directly, orindirectly, releases an opioid after being hydrolyzed by trypsin.

The term “non-opioid-releasing gastrointestinal enzyme substrate” or“non-opioid-releasing GI enzyme substrate” refers to a group comprisinga site susceptible to cleavage by a GI enzyme. For example, a“non-opioid releasing trypsin-substrate” refers to a group comprising asite susceptible to cleavage by trypsin that does not directly, orindirectly, release an opioid after being hydrolyzed by trypsin. Alsoincluded are inverse substrates. Inverse substrates refer to any agentcapable of acting as an inverse substrate for a digestive enzyme.Inverse substrates are designed to bind to, and be hydrolyzed by,enzymes in a manner that is “inverse” to “normal” substrates. With“normal” substrates, the amino acid (or amino acid mimic) recognized bythe enzyme connects to the C-terminus of carbonyl containing group to behydrolyzed (e.g. amide, ester, etc.), which is further connected to aleaving group (e.g. amine or alcohol, etc.). In contrast, inversesubstrates have the amino acid, or amino acid mimic, recognized by theenzyme directly connected to the leaving group of the carbonyl groupundergoing hydrolysis by the enzyme. The term also encompasses salts ofgastrointestinal enzyme inverse substrates. For example, a “trypsininverse substrate” refers to any agent capable of acting as an inversesubstrate for trypsin.

The term “halogen” as used herein refers to fluorine, bromine, chlorineand/or iodine.

The term “inhibitor” refers to any agent capable of inhibiting theaction of an enzyme on a substrate. For example, a trypsin inhibitorrefers to any agent capable of inhibiting the action of trypsin on asubstrate.

The term “modulator” means a molecule that interacts with a target. Theinteractions include, but are not limited to, agonist, antagonist, andthe like, as defined herein.

“PEG” or “polyethylene glycol,” as used herein, is meant to encompassany water-soluble poly(akylene oxide). Typically, PEG oligomers for usein the present invention contain —(CH₂CH₂O)_(n)— or—(CH₂CH₂O)_(n)—CH₂CH₂—, but can also include polyalkylene glycolsincluding, but not limited to polypropylene- or polybutylene glycolswhere the number of monomer units can be from about 2 to 1000, or about2 to about 200.

As used herein, the terms “treat” and “treatment” are usedinterchangeably and are meant to indicate a postponement of developmentof diseases and/or a reduction in the severity of such symptoms thatwill or are expected to develop. The terms further include amelioratingexisting symptoms, preventing additional symptoms, and ameliorating orpreventing the underlying symptoms.

As used herein, the term “subject” encompasses mammals and non-mammals.Examples of mammals include, but are not limited to, any member of theMammalian class: humans, non-human primates such as chimpanzees, andother apes and monkey species; farm animals such as cattle, horses,sheep, goats, swine; domestic animals such as rabbits, dogs, and cats;laboratory animals including rodents, such as rats, mice and guineapigs, and the like. Examples of non-mammals include, but are not limitedto, birds, fish and the like. The term does not denote a particular ageor gender.

In one aspect of the invention, compositions comprising a GIenzyme-labile opioid agonist releasing substrate (S₂ subunit) or GIenzyme-labile opioid agonist releasing substrates (S₂ subunits), and anon-opioid releasing GI enzyme substrate (S₁ subunit) or non-opioidreleasing GI enzyme substrates (S₁ subunits), and an optional opioidantagonist releasing moiety (S₃ subunits), or optional opioid antagonistreleasing moieties (S₃ subunits), are administered to a patient for theprevention and/or treatment of pain. The GI enzyme-labile opioid agonistreleasing substrates (S₂ subunits) and the non-opioid releasinggastrointestinal (GI) enzyme substrates (S₁ subunits) and the optionalopioid antagonist releasing moieties (S₃ subunits) can be covalentlyattached to each other via suitable linkers (Z), or assembled onto, orindependently attached to, a suitably functionalized oligomer,macromolecule, or polymer via covalent linkages. In some embodiments,the release of the opioid agonist is mediated by a specific GI enzyme,whereby the opioid agonist is released concomitant with, or subsequentto, the action of a specific GI enzyme on a specific portion of thepolysubstrate molecule.

In another aspect of the invention, compositions comprising a GIenzyme-labile opioid agonist releasing substrate (S₂ subunits) or GIenzyme-labile opioid agonist releasing substrates (S₂ subunits), and anon-opioid releasing GI enzyme inhibitor or non-opioid releasing GIenzyme inhibitors (S₁ subunits), and an optional opioid antagonistreleasing moiety (S₃ subunits), or optional opioid antagonist releasingmoieties (S₃ subunits), are administered to a patient for the preventionand/or treatment of pain. The GI enzyme-labile opioid agonist releasingsubstrates (S₂ subunits) and the non-opioid releasing gastrointestinal(GI) enzyme inhibitors (S₁ subunits) and the optional opioid antagonistreleasing moieties (S₃ subunits) can be covalently attached to eachother via suitable linkers (Z), or assembled onto, or independentlyattached to, a suitably functionalized oligomer, macromolecule, orpolymer via covalent linkages. In some embodiments, the release of theopioid agonist is mediated by a specific GI enzyme, whereby the opioidagonist is released concomitant with, or subsequent to, the action of aspecific GI enzyme on a specific portion of the polysubstrate molecule.

The opioid agonist releasing GI enzyme substrate (S₂) can releasealfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine,bezitramide, buprenorphine, butorphanol, clonitazene, codeine,desomorphine, dextromoramide, dezocine, diampromide, diamorphone,dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol,dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine,ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene,etorphine, dihydroetorphine, fentanyl and derivatives, heroin,hydrocodone, hydromorphone, hydroxypethidine, isomethadone,ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine,meptazinol, metazocine, methadone, metopon, morphine, myrophine,narceine, nicomorphine, norlevorphanol, normethadone, nalorphine,nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone,papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine,phenoperidine, piminodine, piritramide, propheptazine, promedol,properidine, propoxyphene, sufentanil, tapentadol, tilidine, tramadol,mixtures of any of the foregoing, salts thereof, prodrugs thereof, andderivatives, analogs, homologues, and polymorphs thereof. The opioidagonist releasing substrates and the non-opioid releasing GI enzymesubstrates or inhibitors can be targeted by trypsin, and can be analkylguanidine, alkylamidine, alkylamine, arylguanidine, arylamidine, orarylamine-based substrate, and salts thereof. The GI enzyme labileopioid releasing S₂ substrates and the non-opioid releasing S₁ GI enzymeinverse-substrates or inhibitors are preferably covalently linked toeach other directly, or linked to each other indirectly via attachmentto the same molecular scaffold in a suitable ratio, or co-assembled viacovalent attachment to the same oligomer or polymer, such as poly-aminoacid, poly-D-amino acid, poly N-methyl (D-, or L-) amino acid, a“biopolymer”, or polyalkylene glycol (e.g. PEG).

Linking moieties, or linkers “Z”, are utilized for purposes of theinvention for covalently conjoining one or more of the componentsdefined herein (e.g. the S₁, S₂, S₃, and I subunits; and the molecular,oligomeric, or polymeric scaffolds). Based on this definedfunctionality, the scope of useful linkers for the present invention isintended to be broad. In an effort to define the broad scope of usefullinkers, and provide non-limiting specific examples of linkers of usefor the in the present invention, an array of the terminalfunctionalities that may be present on representative linkers, and theirchemical composition are presented below. The specific choice of linkerunit, or units, incorporated into particular embodiments of theinvention will vary based on the molecular structures of the entitiesthat they conjoin, with specific regard to the available atoms orfunctional groups present on the specific elements that they covalentlyconjoin. Thus, it is intended that the specific composition of linkingmoieties useful for the invention can vary widely with regard tocomposition, size (i.e. length), geometry, valency, and functionalgroups present on their termini. Linking moieties can bedivalent—covalently adjoining two polysubstrate components, ortrivalent—adjoining several polysubstrate components, or can bemultivalent—adjoining a multiplicity of polysubstrate components.

In some embodiments, linking moieties “Z” of use for the invention aredescribed by the general formulae:

and can also be defined by

Exemplary terminal linker functionalities “F” can each or independentlybe as shown below:

wherein:each R is independently hydrogen, methyl, lower alkyl, aryl, orarylalkyl;X is carbon, oxygen, or nitrogen;L is a linear, branched, or multivalent scaffold which is alkyl, aryl,substituted alkyl, substituted aryl, heteroalkyl, substitutedheteroalkyl, polyalkylene glycol, polypeptide, polyamide, polycarbamate,polyurea, or polycarbonate.

In some embodiments, L is formed of 0-100 atoms. In some embodiments, Lis formed of 1-50 non-hydrogen atoms as well as additional hydrogenatoms. Such atoms may be, for example, C, N, O, P or S. In otherembodiments, L may connect two or more groups comprising 1 to 50consecutive bonds between the groups. L may have 1 to 40, 1 to 30, 1 to20, 1 to 10, 1 to 5, 5 to 25, or 5 to 20 such consecutive bonds.

In some embodiments, compounds or compositions of the invention may havethe advantages that they and their post-enzyme hydrolysis products areminimally or not absorbed by the subject, and the expected enzymatichydrolysis of compounds of the invention can be designed to producesystemic exposures of only the opioid analgesic, and generally regardedas safe (GRAS) metabolites following oral ingestion.

Further, the compositions of the invention prevent overdose via the oralroute. If multiple pharmaceutical oral dosage forms are co-ingested,such as co-ingestion of tablets or capsules containing compositions ofthe invention, the resulting concentration reaches a high enough levelin the small intestine to effectively saturate or inhibit the digestiveenzyme that mediates the release of the opioid. This saturation orinhibition of the digestive enzyme that mediates opioid release resultsfrom careful tuning of the kinetics attending the enzyme hydrolysis of,(i) the non-opioid releasing (S₁) substrate subunits, and (ii) theopioid releasing (S₂) substrate subunits that are covalently assembled.In some preferred embodiments of the invention, the digestive enzyme(e.g. trypsin) recognizes and interacts with, the non-opioid releasingsubstrate moieties much more rapidly than it recognizes and interactswith the opioid releasing substrate moieties. Importantly, the resultingsaturation of the digestive enzyme that mediates release of the opioidagonist under overdose conditions can be extensive and sustained due tothe very low absorbability of the opioid releasing polysubstrateanalogs, and the fact that the covalently assembled non-opioid releasing(S₁) substrate subunits and the (S₂) opioid-releasing substrate subunitscannot separately partition away from each other. Thus, intentionalingestion of multiple pills of the invention will not enable abusers toachieve the desired pharmacokinetic profile for achieving a “high” oreuphoric state. Furthermore, accidental co-ingestion of multiple pillsby young children, the elderly, or the subjects will be less likely toproduce toxic or lethal effects.

Without being limited by theory, the current invention provides opioidreleasing compositions that can protect individuals from opioidoverdoses via an enzyme saturation mechanism. Enzyme inhibition andenzyme saturation are highly distinct processes that have been describedin detail, for example, in: “Enzymes: A Practical Introduction toStructure, Mechanism, and Data Analysis by Robert A. Copeland, 2000,Wiley-VCH, Inc”; incorporated herein by reference in its entirety.

Mechanistic differences between enzyme inhibition and enzyme saturationare graphically illustrated in FIG. 1 and FIG. 2. The solid “control”line in FIG. 1 shows the relationship between substrate concentrationand enzyme activity (i.e. the rate or “velocity” at which substrate isprocessed by the enzyme) for a given enzyme plus substrate system.V_(max) is the maximum velocity that the enzyme can achieve and isrealized at substrate concentrations whereby the enzyme becomessaturated. K_(m) refers to the concentration of substrate where thevelocity of the enzyme is equal to V_(max)/2, or when 50% of the enzymeactive sites are occupied by substrate. The dashed line in FIG. 1represents how enzyme activity as a function of substrate concentrationis perturbed via the addition of a separate enzyme inhibitor molecule(e.g. competitive inhibitor). It is important to note that under theconditions of competitive inhibition, the value for Km is increasedwhile the value for V_(max) remains unchanged.

The process of enzyme saturation, described graphically in FIG. 2, isdistinct from enzyme inhibition. As represented by the curved line inFIG. 2, the rate (i.e. velocity) at which a specific enzyme reacts witha specific substrate, increases as the substrate concentration increasesthrough the concentration defined as K_(m), at which point half of theenzyme active sites are occupied by substrate molecules and a rate ofV_(max)/2 is achieved, until the substrate concentration reaches a levelat which the enzyme becomes “saturated” and the maximal rate of V_(max)is realized. At the point of saturation, further increases in substrateconcentration do not produce further increases in the rate that theenzyme can process the substrate and excess substrate molecules begin toaccumulate.

The opioid releasing polysubstrates of the present invention provideoverdose protection via the mechanism of enzyme saturation. When aprescribed dose of a polysubstrate is ingested, the rate at which thetargeted digestive enzyme mediates opioid agonist release from the S₂subunits will be sufficient to provide the compliant patient with theintended opioid agonist exposure.

The enzyme kinetics attending the digestive enzyme-mediated delivery ofopioid agonist following ingestion of a single prescribed dose, and ofan overdose, of polysubstrate are presented in FIG. 3 and FIG. 4. Bydesign, recognition of the S₁ subunits by the targeted digestive enzymeproceeds at a significantly greater rate than recognition of the S₂substrate subunit (k₁>>k₂). This renders the pathway involving steps g,h, and k (shaded gray in FIGS. 3 and 4) as an unlikely, or very minor,pathway for the release of opioid agonist from the S₂ subunits of thepolysubstrate following ingestion. By design, release of opioid agonistfrom the S₂ subunits of a polysubstrate likely proceeds via themultistep pathway described by a, b, d, and e in FIG. 3. By design, thepredominant pathway for enzyme hydrolysis of polysubstrates of theinvention involve the hydrolysis of the S₁ subunits via the pathwaydefined as a, b, and c. An important aspect of the design ofpolysubstrates, more specifically the design of the S₁ substratesubunits, is that step c is a slow process (k₃ is very small). At theintended dose of polysubstrate, the concentration of the polysubstratein the lumen of the gastrointestinal tract is such that there is asufficient surplus of active enzyme available after steps b and c arecompleted to mediate steps d and e resulting in the efficient deliveryof opioid agonist from the S₂ subunits of the polysubstrate molecule. Incontrast, when excessive doses of polysubstrate are ingested (FIG. 4),the concentration of the polysubstrate in the lumen of thegastrointestinal tract is such that there is an insufficient surplus ofactive enzyme available after steps b and c are completed to effectivelymediate steps d and e (now shaded gray in FIG. 4). Under overdoseconditions, the pathway defined by a, b, and c effectively saturates theenzyme. As a result, the delivery of opioid agonist from the S₂ subunitsof the polysubstrate molecule is attenuated. Importantly, the criticalrelationships between k₁, k₂, and k₃ can be tuned by chemicalmodifications (presented herein) to the S₁ and S₂ subunits, to providemeaningful oral overdose protection. Note that the optional opioidantagonist releasing S₃ subunit that can be present in polysubstrates ofthe invention, is not a digestive enzyme substrate and has been omittedfrom the polysubstrates illustrated in FIGS. 3 and 4 for mechanisticclarity.

By design, the rate of opioid agonist release will not be proportionalto the number of doses (aka pills) co-ingested. FIG. 5 graphicallycompares representative opioid agonist plasma exposures (Cmax) andpharmacodynamic effect profiles common to all current generic andemerging abuse-resistant opioid drug products (line A), to arepresentative polysubstrate of the invention that provides oraloverdose protection (curve B).

Advantages of the subject polysubunit approaches include:

(i) The ability to readily tune the “saturation profile” (i.e. V_(max)and the saturation concentration), and thereby the overdose protectionprofile, of polysubstrates of the invention using chemical modificationsto the nature and/or number of the S₁ and/or S₂ subunits contained inthe polysubstrate molecules. In addition, the ability to readily tunethe “inhibition profile” (i.e. V_(max)), and, thereby, the overdoseprotection profile, of polysubunits of the invention using chemicalmodifications to the nature and/or number of the S₁ and/or S₂ subunitscontained in the polysubunit molecules.(ii) Compounds of the invention are unimolecular and thereby preventpartitioning of the covalently linked S₁ and S₂ substrate subunits invivo. Consequently, the overdose protection afforded by compounds of theinvention can be persistent during the time required for transportthrough the gastrointestinal tract where the digestive enzymes capableof effecting opioid agonist release are present.(iii) By design, the enzymatic pathways for hydrolysis of polysubstratesand polysubunits are chemoselective, and mediated primarily by theaction of the digestive enzyme they are designed to target/saturatewithin the gastrointestinal tract.(iv) Compounds of the invention can be high molecular weight, and/orpoly-charged molecules. In such embodiments, absorption ofpolysubstrates or polysubunits, or their resulting post-hydrolysisproducts, from the gastrointestinal tract into the systemic circulationis minimized. This serves to maximize drug delivery efficiency aseffective opioid agonist delivery requires that the polysubstrate orpolysubunit be exposed to digestive enzymes accessed primarily in thelumen of the gastrointestinal tract. Further, minimizing the systemicexposure of polysubstrates and polysubunits can provide importantbenefits from both safety and clinical development perspectives.(v) Compounds of the invention can be designed to release opioidantagonist molecules when subjected to chemical tampering methods bypotential abusers, or when exposed to enzymes found in the plasma,blood, liver, or other systemically accessible tissues.

Enzyme-Labile Opioid Agonist Releasing Polysubunit Analogs

The disclosure provides for compounds and compositions comprisingsubunits that interact with gastrointestinal (GI) or digestive enzymes.Such a composition can be specifically hydrolyzed by at least one of anyof the GI enzymes disclosed herein. The GI enzyme can be, for example,pepsin, trypsin, chymotrypsin, colipase, elastase, aminopeptidases,dipeptidylaminopeptidase IV, tripeptidase, enteropeptidases,carboxypeptidases, dipeptidal aminopeptidases, pteroyl polyglutamatehydrolyase, gamma-glutamyl transferase, aminoaspartate aminopeptidases,amino-oligopeptidase, membrane Gly-Leu peptidase, and zinc stableAsp-Lys peptidase).

An example of a GI enzyme subunit is a protease substrate, such as atrypsin substrate, or a chymotrypsin substrate.

As used herein, the term “trypsin substrate” refers to any agent capableof being hydrolyzed by the action of trypsin, and includes salts oftrypsin substrates. The ability of an agent to be a substrate fortrypsin can be measured using assays well known in the art. For example,in a typical assay, one can directly measure the rate and extent ofexpected hydrolysis products formed in incubations containing specifiedconcentrations of digestive enzymes and substrates using common HPLC orspectrophotometric detection methods.

There are many trypsin substrates or inhibitors known in the art, andinclude substrates or inhibitors that are specific to trypsin and thosethat are specific to other proteases such as chymotrypsin. Trypsinsubstrates or inhibitors include natural, synthetic, and semi-syntheticcompounds. The disclosure provides for trypsin substrates or inhibitorsthat are proteins, peptides, and small molecules. The disclosure alsoprovides for trypsin substrates that are hydrolyzed via “normal” or“inverse” substrate mechanisms. A trypsin substrate or inhibitor can bean arginine mimic or lysine mimic. In certain embodiments, the trypsinsubstrate or inhibitor is an arginine mimic or a lysine mimic, whereinthe arginine mimic or lysine mimic is a synthetic compound. As usedherein, an arginine mimic or lysine mimic can include moieties capableof binding to the specificity pocket of trypsin and/or interacting withthe trypsin active site functionalities. The arginine or lysine mimiccan comprise a cleavable moiety. In some embodiments, cleavage of thecleavable moiety will directly, or indirectly result in release of anopioid agonist from the substrate moiety. In some embodiments, cleavageof the cleavable moiety will not result in release of an opioid agonistfrom the substrate moiety. In some cases, when supra-therapeutic doses(overdoses) are ingested, the cleavage of S₁ subunits will saturate thecapacity of the enzyme to cleave the cleavable moieties that directly,or indirectly, release opioid agonists resulting in overdose protection.In some cases, when supra-therapeutic doses (overdoses) are ingested,progressive enzyme inhibition by the S₁ subunits results in overdoseprotection.

Examples of trypsin substrates which are arginine mimics and/or lysinemimics include a cationic specificity pocket binding moiety designed tobind to the negatively charged specificity pocket of the enzyme and ahydrolysable functionality that is cleaved by the active site of theenzyme. Cationic specificity pocket binding moieties include, but arenot limited to, alkyl-amines, alkylguanidines, alkylamidines,arylguanidines, benzamidines, benzylamines, naphthylamidines,naphthylguanidines, naphthylamines, and the like. Hydrolysablefunctionalities include, but are not limited to, amide, ester,carbamate, thioester, carbonate, and the like.

In one aspect of the invention, the opioid agonist releasing GI enzymesubstrate S₂ subunit(s) and the non-opioid releasing GI enzyme substrateor enzyme inhibitor S₁ subunit(s) are covalently attached to a scaffold,for example a polymeric, oligomeric, or molecular scaffold. The S₁ or S₂components can be linked directly, or indirectly, via a wide range oflinkers as described herein. The particular linkage and linkagechemistry employed will depend upon the specific functional groupsavailable on the S₁, S₂, and scaffold components. The presence ofsuitable functional groups within the S₁, S₂, and scaffold components,and useful chemistry for linking strategies involving these suitablefunctional groups can be readily determined by one skilled in the artbased upon the guidance presented herein. Particular examples ofunimolecular compositions comprised of linkers (Z), S₁ subunits, S₂subunits, and/or S₃ subunits, and/or molecular, oligomeric or polymericscaffolds are disclosed herein.

In another aspect of the invention, compositions of the invention arenot required to be, and preferably are not, orally bioavailable. Thus,in one aspect of the invention, a composition in accordance with theinvention will demonstrate low (from about 0% to about 30%) oralbioavailability. Oral bioavailability can be determined using suitablein-vivo or in-vitro assays. Thus, a polysubstrate of the invention willpossess oral bioavailability of about or less than about 0%, 0.25%,0.5%, 0.75%, 1%, 2%, 5%, 10%, 15%, 25%, or 30%, when measured in asuitable model.

In one aspect, a composition of the invention is represented by thefollowing formula:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor subunit;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₃ is independently an opioid antagonist releasing moiety;each Z is independently a linking moiety;each n is independently an integer ranging from 1 to 10;m is an integer ranging from 1 to 10; andp and r are independently integers ranging from 0 to 10.

In another aspect, a composition of the invention is represented by thefollowing formula:

wherein:S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₂ is an opioid agonist releasing GI enzyme substrate subunit;S₃ is an optional opioid antagonist releasing moiety;M is a covalent scaffold;Z is a linking moiety;each r, m, and n is independently an integer ranging from 1 to 10, 1 to100, 1 to 1,000, 1 to 100,000, 1 to 1,000,000, or 1 to 1,000,000,000;p is an integer ranging from 0 to 10, 0 to 100, 0 to 1,000, 0 to100,000, 0 to 1,000,000, or 0 to 1,000,000,000.

In some embodiments, the linking moieties Z between the covalentscaffold M and the S₁, S₂, and S₃ subunits are sufficiently stable priorto, and subsequent to, administration to a subject.

Compositions of the invention are not required to have, and preferablydo not have opioid agonist activity prior to enzymatic processing of theopioid agonist releasing GI enzyme substrate subunit. Thus, in oneaspect of the invention, a composition in accordance with the inventionwill retain from about 0% to about 30% of the specific activity of thedelivered opioid agonist compound. Such activity may be determined usingsuitable in-vivo, or in-vitro assays, depending upon the known activityof the particular opioid parent compound. For example, a functionalopioid receptor based assay, or an in vivo hot-plate or tail-flickanalgesia assay can be used to assess the level of agonist activity ofthe polymer conjugates of the invention. Thus, compositions of theinvention will possess a specific activity of about 0% or less thanabout 0.25%, 0.5%, 0.75%, 1% 2%, 5%, 10%, 15%, 25%, 30% or 50% relativeto that of the delivered opioid agonist, when measured in a suitablemodel, such as those well known in the art.

In another aspect of the invention, compositions of the invention arenot required to be, and preferably are not, orally bioavailable and/ordo not traverse the blood-brain barrier. For example, compositions ofthe invention do not penetrate the central nervous system (CNS). Thus,in one aspect of the invention, a composition in accordance with theinvention will retain from about 0% to about 30% of the oralbioavailability or CNS penetration of the delivered opioid agonist. Oralbioavailability and CNS penetration can be determined using suitablein-vivo assays. Thus, a composition of the invention will possess oralbioavailability or CNS penetration of about 0% or less than about 0.25%,0.5%, 0.75%, 1% 2%, 5%, 10%, 15%, 25%, or 30% relative to that of theunmodified parent opioid, when measured in a suitable model, such asthose well known in the art.

Opioid Agonists

Any opioid agonist known in the art may be used. The terms “opioidagonist” and “opioid” are used interchangeably herein to refer to anydrug, whether natural and synthetic, which has morphine-like mechanismof action. Opioid agonists useful in the present invention include, butare not limited to, alfentanil, allylprodine, alphaprodine, anileridine,benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene,codeine, desomorphine, dextromoramide, dezocine, diampromide,diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol,dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone,eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine,etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives,heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone,ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine,meptazinol, metazocine, methadone, metopon, morphine, myrophine,narceine, nicomorphine, norlevorphanol, normethadone, nalorphine,nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone,papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine,phenoperidine, piminodine, piritramide, propheptazine, promedol,properidine, propoxyphene, sufentanil, tapentadol, tilidine, tramadol,mixtures of any of the foregoing, salts thereof, prodrugs thereof, andderivatives, analogs, homologues, and polymorphs thereof. In certainembodiments, the amount of the opioid agonist released can be from about0.25 nmols to about 2.5 mmols. The specified amount of opioid releasedby polysubstrate compositions of the invention will likely vary as afunction of the potency and bioavailability of the specific opioidagonist released.

In some embodiments, a pharmaceutical composition of the presentinvention includes one or more opioids such as hydrocodone,hydromorphone, morphine, oxycodone, oxymorphone, and/or salts orprodrugs thereof, as the therapeutically active ingredient.

In some embodiments, a unit dose form includes an amount of opioidagonist that is about 0.003 mmols, about 0.015 mmols, about 0.03 mmols,about 0.045 mmols, about 0.075 mmols, about 1.50 mmols, about 0.225mmols, about 0.3 mmols, about 0.375 mmols, about 0.45 mmols, about 0.525mmols or about 0.6 mmols. More typically, the drug can be present in anamount from about 0.003 mmols to about 1.66 mmols, preferably about0.015 mmols to 0.6 mmols. As will be understood by one of skill in theart, a dosage form preferably contains an appropriate amount of drug toprovide a therapeutic effect. Dose units of the invention may alsoinclude co-formulations with additional therapeutically active drugssuch as acetaminophen, ibuprofen, naltrexone, etc.

Opioid Antagonists

The term “opioid antagonist”, as used herein, refers to any moleculethat blocks the action of an opioid agonist at one or more opioidreceptor types. Opioid antagonists include so-called“agonist-antagonist” molecules that act as an antagonist for one opioidreceptor type and an agonist for another receptor type, such as, forexample, naloxone, naltrexone, nalorphine or pentazocine.

When co-administered with opioid agonists, opioid antagonists arecapable of blocking the effects of the opioid agonist. Antagonists suchas naltrexone, naloxone or buprenorphine are often used to combat theabuse and the overdose effects of an opioid agonist. For example,naltrexone is commonly prescribed to help fight addiction to eitheralcohol or opioid drugs.

Suitable opioid antagonists include, but are not limited to,buprenorphine, cyclazocine, cyclorphan, naloxone, N-methylnaloxone,naltrexone, N-methylnaltrexone, nalmephene, 6-amino-6-desoxo-naloxone,levallorphan, nalbuphine, naltrendol, naltrindole, nalorphine,nor-binaltorphimine, oxilorphan, pentazocine,piperidine-N-alkylcarboxylate opioid antagonists such as those describedin U.S. Pat. Nos. 5,159,081, 5,250,542, 5,270,328, and 5,434,171, andderivatives, mixtures, salts, polymorphs, or prodrugs thereof.

In one aspect of the invention, the opioid antagonist includesnaltrexone, naloxone, nalmefene, cyclazacine, levallorphan and mixturesthereof. In another aspect of the invention, the opioid antagonist isnaltrexone or naloxone.

In one aspect of the invention, the antagonist is naloxone. Naloxone isalmost devoid of agonist effects. Subcutaneous doses of up to 12 mg ofnaloxone produce no discernable subjective effects, and 24 mg naloxonecauses only slight drowsiness. Small doses (0.4-0.8 mg) of naloxonegiven intramuscularly or intravenously, in man, prevent or reverse theeffects of morphine-like opioid agonists. One mg of naloxoneadministered intravenously has been reported to completely block theeffect of 25 mg of heroin. The effects of naloxone are seen almostimmediately after intravenous administration. The drug is absorbed afteroral administration but has been reported to be rapidly and extensivelymetabolized into an inactive form via first-pass metabolism. Therefore,it has been demonstrated to have significantly lower potency whendelivered orally than when parenterally administered.

Other exemplary opioid antagonists include cyclazocine and naltrexone,both of which have cyclopropylmethyl substitutions on the nitrogen,retain much of their efficacy by the oral route and their durations ofaction are much longer, approaching 24 hours after oral doses.

In another aspect of the invention, the antagonist is naltrexone.Naltrexone works by blocking the opioid receptors in the brain andblocking the feeling of euphoria felt when alcohol or an opioid agonistis ingested. This in turn decreases the craving for the substance,according to the National Institute of Health. Naltrexone can bedelivered both orally and by intravenous injection. Naltrexone is knownas a synthetic congener of oxymorphone with no opioid agonistproperties, and differs in structure from oxymorphone by replacement ofthe methyl group located on the nitrogen atom of oxymorphone with acyclopropylmethyl group. As a result, the physicochemical properties ofnaltrexone (and chemically related antagonists) are nearly identical tothose inherent to structurally related opioid agonists. This renders thephysical separation of naltrexone-opioid agonist mixtures essentiallyimpossible without the employment of highly sophisticated chemicalseparation techniques (e.g. high-performance liquidchromatography—HPLC). The hydrochloride salt of naltrexone is soluble inwater up to about 100 mg/mL. Following oral administration, naltrexoneis rapidly absorbed (within 1 hour) and has an oral bioavailabilityranging from 5-40%.

It is known that when co-administered with morphine, heroin or otheropioid agonists, naltrexone blocks the development of physicaldependence to opioid agonists, reduces “drug liking” by recreationalabusers, can precipitate withdrawal symptoms in opioid dependentsubjects, and can completely block the effects of the co-deliveredopioid agonist. In the treatment of patients previously addicted toopioids, naltrexone has been used to prevent the euphorigenic effects ofopioid agonists. Naltrexone is commercially available in oral tabletform (Revia®) for the treatment of alcohol dependence and for theblockade of exogenously administered opioids. An oral dosage of 50 mgRevia blocks the pharmacological effects of 25 mg of IV administeredheroin for up to 24 hours.

When present, the molar ratio of the opioid antagonist to the opioidagonist in compositions of the invention can be from about 0.001:1 toabout 10:1, preferably about 0.01:1 to about 3:1. As will be understoodby one of skill in the art, compositions of the invention preferablycontain an appropriate amount of opioid antagonist to provide thedesired abuse-deterrent effects when released.

Non-Opioid Releasing GI Enzyme S₁ Subunits

Compositions of the invention comprise a covalently linked non-opioidreleasing digestive enzyme substrate or inhibitor S₁ subunit, ormultiple non-opioid releasing digestive enzyme substrate or inhibitor S₁subunits. In some embodiments, the non-opioid releasing digestive enzymesubstrate S₁ subunit is a GI enzyme inverse substrate ester. Forexample, the non-opioid releasing substrate is attached to a linkingmoiety Z via the carboxylate-containing component of the ester and canbe represented by one of the following moieties shown below:

wherein:Y is an amidine, guanidine, benzylamine, alkyl substituted amidine,alkyl substituted guanidine, alkyl substituted benzylamine,benzylamidine, benzylguanidine, alkyl substituted benzylamidine, oralkyl substituted benzylguanidine;Z is a linking moiety;each K_(o) is independently hydrogen or methyl;A is an amino acid side chain;r is an integer from 0-10;m is an integer from 1-10;p is an integer from 1-10;n is an integer from 0-10;each R′ is independently alkyl, aryl, substituted alkyl, substitutedaryl, acyl, substituted acyl group, or polyethylene glycol containingacyl, aryl, or alkyl group; andeach R″ is independently a hydrogen, methyl, alkyl, or aryl group.

In some embodiments, at least one of Z and K_(o) comprises an electrondonating, or electron withdrawing, atom or functionality that influencesthe formation, or the hydrolysis, of the acyl enzyme intermediateresulting from the interaction of the S₁ subunit by the targeteddigestive enzyme. For example, electron donating groups include alkyl,substituted alkyl, —OH, —OR, —NH₂, —NR₂, —SH, —SR, and —NHC(O)R. Forexample, electron withdrawing groups include —C(O)OH, —C(O)OR, —C(O)NH₂,—C(O)NR₂, —NO₂, —NR₃ ⁺, —C(O)CF₃, halogen, —CCl₃, cyano, —SO₃H, —SO₃R,—CHO, —COR, —C(NH)NH₂, and —NHC(NH)NH₂.

In other embodiments, the S₁ subunit is connected to a scaffold orlinking moiety via the phenol component of the ester. Examples include,but are not limited to those described below:

wherein:Y is an amidine, guanidine, benzylamine, alkyl substituted amidine,alkyl substituted guanidine, alkyl substituted benzylamine,benzylamidine, benzylguanidine, alkyl substituted benzylamidine, oralkyl substituted benzylguanidine;Z is a linking moiety;each K_(o) is independently hydrogen or methyl;A is an amino acid side chain;r is an integer from 0-10;m is an integer from 1-10;p is an integer from 1-10;n is an integer from 0-10;each R is alkyl, alkylene, alkynyl, or aryl, or substituted alkyl,substituted alkylene, substituted alkynyl, substituted aryl group;each R′ is independently alkyl, aryl, substituted alkyl, substitutedaryl, acyl, substituted acyl group, or polyethylene glycol containingacyl, aryl, or alkyl group; andeach R″ is independently a hydrogen, methyl, alkyl, or aryl group.

In some embodiments, at least one of Z and K_(o) can comprises anelectron donating, or electron withdrawing, atom or functionality thatinfluences the formation, or the hydrolysis, of the acyl enzymeintermediate resulting from the interaction of the S₁ subunit by thetargeted digestive enzyme. For example, electron donating groups includealkyl, substituted alkyl, —OH, —OR, —NH₂, —NR₂, —SH, —SR, and —NHC(O)R.For example, electron withdrawing groups include: —C(O)OH, —C(O)OR,—C(O)NH₂, —C(O)NR₂, —NO₂, —NR₃ ⁺, —C(O)CF₃, halogen, —CCl₃, cyano,—SO₃H, —SO₃R, —CHO, —COR, —C(NH)NH₂, and —NHC(NH)NH₂.

GI enzyme hydrolysis (e.g. by trypsin) of the ester S₁ substratesubunits listed above results in the formation of a carboxylic acid,amino acid, or benzoic acid metabolites. In some embodiments, GI enzymehydrolysis (e.g. by trypsin) of ester S₁ substrate subunits may bedesigned to produce an acid metabolite that is generally regarded assafe (GRAS). The hydrolysis of a representative S₁ substrate subunit bya GI enzyme resulting in the release of a GRAS acid metabolite isillustrated by the general mechanism below:

“GRAS” stands for “generally recognized as safe” and refers to acompound as defined by sections 201(s) and 409 of the Federal Food,Drug, and Cosmetic Act. Exemplary GRAS acid metabolites include, but arenot limited to: benzoic acid, salicylic acid, aspirin, 3-hydroxybenzoicacid, 4-hydroxybenzoic acid, gallic acid, 2,3,4-trihydroxybenzoic acid,2,3,6-trihydroxybenzoic acid, 2,4,5-trihydroxy benzoic acid,6-methylsalicylic acid, o-cresotinic acid, (alkyl)-anacardic acids,o-thymotic acid, 3-O-methylgallic acid, 4-O-methylgallic acid, syringicacid, 3,4,5-trimethoxybenzoic acid, diflusinal, p-anisic acid,2,3-dihydroxybenzoic acid, alpha-resorcylic acid, anthranilic acid,3-aminobenzoic acid, 4,5-dimethylanthranilic acid, N-methylanthranilicacid, protocatechuic acid, gentisic acid, piperonylic acid,3-methoxysalicylic acid, fenamic acid, toifenamic acid, mefenamic acid,flufenamic acid, vanillic acid, isovanillic acid, veratric acid,3,5-dimethoxybenzoic acid, 2,4-diaminobenzoic acid, N-acetylanthranilicacid, 2-acetylamino-4-aminobenzoic acid, 2,4-diacetylaminobenzoic acid,4-aminosalicylic acid, 3-hydroxyanthranilic acid, 3-methoxyanthranilicacid, nicotinic acid, isonicotinic acids, and cinnamic acids.

In one aspect of the invention, the compositions, pharmaceuticalformulations, and methods disclosed herein comprise S₁ inverse substrateester subunits for GI enzymes, such as trypsin, chymotrypsin, ortryptase. Thus, when trypsin is an exemplary GI enzyme, trypsin cleavesC-terminal peptide bonds of arginine and lysine, both of which arepositively charged amino acids. The specificity pocket of trypsin has anaspartic acid residue (Asp-189), which has a negative charge, resultingin a negative electrostatic field in the substrate binding pocket,thereby attracting the positively charged arginine and lysine substrateside chains. The negative electrostatic field in the substrate bindingpocket also helps stabilize the positive charge in the enzyme-substratecomplex.

Mechanistically, the GI enzyme catalyzed hydrolysis of ester basedinverse substrate S₁ subunits can be described using the followingscheme:

Where E is a GI enzyme. K_(s) is the association constant ofenzyme-substrate complex, k₂ is the rate constant of the acylation step,and k₃ is the rate constant of the deacylation step. In the initialstep, the ester substrate and the enzyme bind to form anenzyme-substrate complex. The inverse substrate ester S₁ subunit is thenirreversibly hydrolyzed to produce an alcohol (or phenol) fragment andan active-site acyl-enzyme intermediate. The acyl-enzyme intermediatesubsequently dissociates to a free enzyme (E) and an acid fragment witha rate constant of k₃. The rate at which the deacylation step occurs,k₃, determines the lifetime of the acyl-enzyme intermediate and theproclivity of specific S₁ subunits to saturate trypsin.

Thus, in one aspect of the invention, the compositions, pharmaceuticalformulations, and methods disclosed herein comprise a non-opioidreleasing ester substrate, or non-opioid releasing ester substrates,where the ester substrate has an enzyme recognition moiety covalentlylinked to a carbonyl group that is capable of acylating the active siteof the enzyme.

Thus, in one aspect of the invention, the products produced by thehydrolysis of S₁ ester-based non-opioid releasing inverse substrates arean acid and an alcohol, such as a substituted phenol, where the phenolcan remain covalently attached to a polysubstrate of the invention andas a result will generally not be systemically absorbed, but rather passthrough the gastrointestinal system and are excreted. Such estercontaining polysubstrates of the invention can be designed to releaseGRAS acids and thereby have the advantage that GRAS acids havewell-characterized safety profiles. In addition, these ester substratesare chemically stable in vivo and are not easily hydrolyzed by acid inthe stomach, nor hydrolyzed non-specifically by digestive enzymes, ofthe patient.

Representative non-limiting S₁ subunit examples include:

wherein Z is a linking moiety as described herein; andX can be hydrogen, an amino acid, alkyl, heteroalkyl, aryl, substitutedaryl, acyl, substituted acyl, terminally functionalized polyethyleneglycol chain, or X is a substituent (or substituents) on a GRAScarboxylic acid as described above.In some embodiments, the non-opioid releasing digestive enzyme S₁subunit is a GI enzyme inhibitor. The non-opioid releasing S₁ GI enzymeinhibitor subunit is attached to a linking moiety Z as represented byany one of the following non-limiting examples described below.

The S₁ subunit can be derived from amidinophenylpyruvate (APPA)including, but not limited to:

Wherein Y can be O, NH, NR or S; Z is a linker as defined above.

In another aspect of the invention, the S₁ subunit can be derived froman activated ketone derivative, including, but not limited to thefollowing:

Wherein Y is N, O, N—R, or carbon, and R is methyl, ethyl, alkyl,substituted alkyl, acyl, substituted acyl, aryl, substitutes aryl, anatural or non-natural amino acid, or a polypeptide chain comprisingnatural or non-natural amino acids. The arginine side chain in the abovestructure can be substituted for a lysine side chain, or a natural ornon-natural lysine or arginine side chain mimic.

In another aspect of the invention, the S₁ subunit can be derived fromchloroketone or aldehyde analogs as shown below:

The chloroketone and aldehyde analogs illustrated above can alsocomprise natural or non-natural lysine-mimic or arginine-mimicside-chain variants.In another non-limiting aspect of the invention, the S₁ subunitinhibitor can have cycloheteroalkyl groups, naphthylamidines,arylguanidines, arylamidines, benzylamines, 4-guanidinopiperazines, andpeptide based structures, as illustrated below:

The S₁ subunits illustrated above can also comprise natural ornon-natural lysine-mimic or arginine-mimic side-chain variants.

Preparation of Non-Opioid Releasing GI Enzyme S₁ Subunits

Multiple synthetic procedures useful for the preparation of S₁ subunitshave been reported in the literature (see for example: Tanizawa, K., etal, Chem. Pharm. Bull. 1999, 47(1), 104-110, Aoyama, T., et al, Chem.Pharm. Bull. 1985, 33(4), 1458-1471, Bordusa, F., et al, Biochemistry,1999, 38, 6056-6062, Tanizawa, K., et al, Chem. Pharm. Bull. 1996, 44,1577-1579, 1585-1587, Lal, B., et al, Tetrahedron Lett. 1996, 37,2483-2486, Sekizaki, H., et al, Bioorganic & Medicinal ChemistryLetters, 2003, 13, 3809-3812, Tanizawa, K., et al, Acc. Chem. Res. 1987,20, 337-343) and commonly involve the coupling between an alcohol (orphenol) synthon and a carboxylic acid (e.g. benzoic acid) moieties thatis pre-activated for coupling by first conversion to an acid chloride,or the like; or activated for coupling in situ with an appropriatecoupling reagent (e.g. DCC) to form the desired ester functionality.Amidine substituted phenol synthons are commonly used in an unprotectedsalt form, while guanidine containing esters are often prepared viasimilar coupling reactions using a protected form (e.g. the bis-Cbzprotected form) of the aryl guanidine synthon. Purification of theresulting esters can be accomplished using standard purificationprocedures involving normal or reverse phase HPLC, crystallization,trituration, etc. The chemical identity of the S₁ esters can be readilyestablished by LC/MS and/or NMR analysis.

Some representative synthetic routes useful for the preparation of S₁subunits are depicted below.

wherein:each R′ is independently alkyl, aryl, substituted alkyl, substitutedaryl, acyl, substituted acyl group, or polyethylene glycol containingacyl, aryl, or alkyl group;each R is independently a hydrogen, methyl, alkyl, or aryl group;W is hydrogen or an atom or substituent that renders the benzoic acidmetabolite of the S₁ subunit a GRAS compound, or W is an electrondonating or withdrawing atom or functionality that influences theformation, or the hydrolysis, of the acyl enzyme intermediate resultingfrom the interaction of the S₁ subunit by the targeted digestive enzyme.Z is a linking moiety;X is a covalent bond or an atom such as oxygen or nitrogen, or afunctional group suitable for the attachment of, or incorporated by, thelinker group Z; and(P) is an optional protecting group present on the terminus of thelinker Z distal to the S₁ subunit that may be employed to enhance thechemical efficiency of the desired ester forming coupling reaction.

Opioid Agonist Releasing GI Enzyme S₂ Subunits

Compositions of the invention comprise a covalently linked opioidagonist releasing digestive enzyme substrate S₂ subunit, or opioidagonist releasing digestive enzyme substrate S₂ subunits. The releasedopioid agonist can be morphine, a morphone or other phenol containingopioid agonist, or a codone or other ketone containing opioid agonist,such as illustrated by the formulae below. The opioid agonist releasingsubstrates may be linked via phenol, alcohol, or ketone (e.g. enol)functionalities as shown below.

In some embodiments, D is a phenol-linked opioid agonist. For example, Dis selected from buprenorphine, dihydroetorphine, diprenorphine,etorphine, hydromorphone, levorphanol, morphine, oxymorphone,tapentadol, and the like.

In some embodiments, D is an enol-linked opioid agonist. For example, Dis selected from acetylmorphone, hydrocodone, hydromorphone, oxycodone,oxymorphone, pentamorphone, ketobemidone, methadone, and the like.

According to one aspect, the invention provides pharmaceuticalcompositions that comprise an opioid agonist releasing digestive enzymeS₂ substrate. The disclosure provides novel digestive enzyme substratemoieties attached to an opioid agonist through a functional grouppresent on the opioid agonist, where the functional group present on theopioid agonist comprises a reactive group. Any type of reactive group onan opioid agonist can provide a handle for a point of attachment to theS₂ substrate moiety. Examples of reactive groups on an opioid agonistinclude, but are not limited to, alcohol, phenol, ketone, amino, andamide. An alcohol or phenol on an opioid agonist can provide a point ofattachment by reaction to form a linkage, such as a carbamate. A ketoneon an opioid agonist can provide a point of attachment via reaction toform a linkage, such as an enol carbamate. An amino group on an opioidagonist can provide a point of attachment by reaction to form an aminolinkage, including quaternary salts, or an amide. An amide on an opioidagonist can provide a point of attachment by reaction to form a linkage,such as an amide enol or an N-alkylated or N-acylated amide.

A S₂ substrate moiety can be linked via an alcoholic or phenolic opioidagonist via modification of the alcohol or phenol moiety, through theenolic oxygen atom of the ketone moiety, to an amino-containing opioidagonist through the amino moiety, to an amide-containing opioid agonistthrough the enolic oxygen of the amide moiety or its imine tautomer. Ineach case, the opioid agonist releasing digestive enzyme substratecomprises an enzyme-cleavable moiety that is susceptible to cleavage bya GI enzyme. Release of the opioid agonist is mediated by enzymaticcleavage by a digestive enzyme. Such cleavage can initiate, contributeto, or immediately effect drug release.

Examples of opioid agonist releasing digestive enzyme S₂ substratemoieties comprising releasable opioid agonists designated as D are shownbelow.

In some embodiments, the S₂ subunit has one of the formulas:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R is independently hydrogen, methyl, or alkyl, or a linking moietyZ;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, or alinking moiety Z;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety Z;each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme; andp is an integer from 0-10.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific digestive enzyme mediated hydrolysisof the S₂ substrate prior to the release of the appended opioid agonistfrom the S₂ subunit. In some embodiments, the amino acid side chain canbe, but is not limited to, the amino acid side chain of arginine,homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine, orstructural/functional mimics thereof.

In some embodiments, the S₂ subunit has one of the formulas:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, or alinking moiety Z;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid side chain, an amino acid side-chain mimic, or a linking moiety(Z);each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme; andr is an integer from 0-10;n is an integer that can range from 0-28.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

In some embodiments, the S₂ subunit has one of the formulas:

wherein D is an opioid agonist, for example wherein D is a morphone, acodone, or morphine;each R is independently hydrogen, methyl, or alkyl;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety Z;each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme; andR′″ is hydrogen or methyl or —C(═NR)—NR₂ wherein R is each orindependently hydrogen or methyl;r is an integer from 1-6; andn is an integer from 0 to 10.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

In some embodiments, the S₂ subunit has the formula:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety (Z); andA₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

In some embodiments, the S₂ subunit has the formula:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety (Z); andA₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

As will be evident to one of skill in the art, the opioid agonistreleasing digestive enzyme substrates can be covalently attached to forma polysubstrate of the invention via one or more linking moieties Z atany substitution point on the S₂ subunit as long as the attachment(s)do(es) not preclude either the requisite hydrolytic action of thedigestive enzyme on, or the subsequent release of opioid agonist from,the S₂ substrate subunit.

In one aspect of the invention, the opioid agonist is an alcohol, phenolor ketone containing opioid agonist. Accordingly, an alcohol, phenol, orketone containing opioid agonist is attached through a hydroxylic,phenolic, or enolic oxygen to a linker, which is further attached to anenzyme cleavable moiety. A single enzymatic hydrolysis of a cleavablemoiety, or a cascade of enzymatic hydrolyses of cleavable moieties, mayrelease the opioid agonist by (i) directly cleaving the bond between theenzyme cleavable moiety and the opioid agonist, or (ii) revealing alatent nucleophile, such as an amine or carboxylate, that subsequentlyundergoes an intramolecular cyclization-release reaction, or (iii)revealing an additional enzyme substrate, or substrates, that arefurther cleaved by the digestive enzyme ultimately resulting in releaseof the appended opioid agonist.

Mechanisms of enzyme-mediated opioid agonist release from representativeS₂ substrate subunits are presented in the Schemes below.

General mechanism of enzyme-mediated opioid agonist release fromrepresentative 2,5-diketopiperazine forming S₂ subunits:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative lactam forming S₂ subunits:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative “multiple-activation” S₂ subunits:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative 2,4-oxazolidinedione forming S₂ subunits:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative amino-acid ester S₂ subunits:

Representative non-limiting S₂ subunit examples include, but are notlimited to:

wherein R′ and R″ are as defined above and X is hydrogen or —OH.

Representative synthetic routes useful for the preparation of S₂substrate subunits are depicted below. The syntheses utilize readilyobtained peptide-derived synthons, well-established peptide-basedcouplings, and known protecting group strategies. Enol-ester andenol-carbamate forming opioid attachment strategies are also employed.(P) is an optional protecting group present on the terminus of thelinker Z distal to the S₂ subunit that may be employed to enhancechemical efficiency. Purification of the resulting S₂ subunits can beaccomplished using standard purification procedures involving normal orreverse phase chromatography, crystallization, trituration, etc. Thechemical identity of the S₂ subunits can be established by LC/MS and/orNMR analysis.

In some embodiments, the S₂ subunit has one of the formulas:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety Z;In some embodiments, R′ can also form a spirocyclic or fused aliphaticring with a geminal or vicinal R′ group;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid functional or structural mimic, or a linking moietyZ;each A₂ is independently an amino acid side chain or an amino acidside-chain functional or structural mimic that is capable of beingrecognized by a digestive enzyme.

In some embodiments, the amino acid side-chain or amino acid side-chainfunctional or structural mimic A₂ directs the regiospecific digestiveenzyme mediated hydrolysis of the S₂ substrate prior to the release ofthe appended opioid agonist from the S₂ subunit. In some embodiments,the amino acid side chain can be, but is not limited to, the amino acidside chain of arginine, homoarginine, lysine, homolysine, ε-N-methyllysine, ornithine, or structural/functional mimics thereof.

In some embodiments, the S₂ subunit has one of the formulas:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety (Z);each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid functional or structural mimic, or a linking moiety(Z);each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;

In some embodiments, A₂ is:

-   -   wherein:    -   each R is independently hydrogen or methyl;    -   each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing moiety, or a natural or        unnatural amino acid, an amino acid functional or structural        mimic, or a linking moiety (Z);    -   each r is independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, —C(═NR)—NR₂ wherein R is each or        independently hydrogen or methyl; or

-   -   wherein A₂ is a natural or unnatural amino acid side chain, or        an amino acid side-chain mimic that is capable of being        recognized by a digestive enzyme that directs the regiospecific        hydrolysis of the S₂ substrate prior to the release of the        appended opioid agonist from the S₂ subunit and can be, but is        not limited to, the amino acid side chain of arginine,        homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine,        or structural/functional mimics thereof;    -   R″ is as defined above; and        m is an integer from 0-10        r is an integer from 0-10        q is an integer from 0-27.

In some embodiments, the amino acid side-chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

In some embodiments, the S₂ subunit has the formula:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety (Z);each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid mimic, or a linking moiety (Z);each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme; and

In some embodiments, A₂ is:

each R is independently hydrogen or methyl;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid, an amino acid functional or structural mimic, or a linking moiety(Z);each r is independently an integer from 1 to 6;n is an integer from 0 to 10;R′″ is hydrogen, methyl, —C(═NR)—NR₂ wherein R is each or independentlyhydrogen or methyl; or

-   -   wherein A₂ is a natural or unnatural amino acid side chain, or        an amino acid side-chain mimic that is capable of being        recognized by a digestive enzyme that directs the regiospecific        hydrolysis of the S₂ substrate prior to the release of the        appended opioid agonist from the S₂ subunit and can be, but is        not limited to, the amino acid side chain of arginine,        homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine,        or structural/functional mimics thereof; R″ is as defined above;        and        n is an integer from 0 to 10.

In some embodiments, the amino acid side chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

In some embodiments, the S₂ subunit has the formula:

whereinD is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety Z as previously defined;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid side chain, an amino acid side-chain mimic, or a linking moiety Zas previously defined; andeach A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;

In some embodiments, A₂ is:

-   -   wherein:    -   each R is independently hydrogen or methyl;    -   each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing moiety, or a natural or        unnatural amino acid, an amino acid functional or structural        mimic, or a linking moiety (Z);    -   each r is independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, —C(═NR)—NR₂ wherein R is each or        independently hydrogen or methyl; or

-   -   wherein A₂ is a natural or unnatural amino acid side chain, or        an amino acid side-chain mimic that is capable of being        recognized by a digestive enzyme that directs the regiospecific        hydrolysis of the S₂ substrate prior to the release of the        appended opioid agonist from the S₂ subunit and can be, but is        not limited to, the amino acid side chain of arginine,        homoarginine, lysine, homolysine, ε-N-methyl lysine, ornithine,        or structural/functional mimics thereof; R″ is as defined above;        and        m is an integer from 0 to 10        n is an integer from 0 to 10        p is an integer from 0 to 4.

In some embodiments, the amino acid side chain or amino acid side-chainmimic A₂ directs the regiospecific hydrolysis of the S₂ substrate priorto the release of the appended opioid agonist from the S₂ subunit. Insome embodiments, the amino acid side chain can be, but is not limitedto, the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof.

As will be evident to one of skill in the art, the opioid agonistreleasing digestive enzyme substrates can be covalently attached to forma polysubstrate of the invention via one or more linking moieties Z atany substitution point on the S₂ subunit as long as the attachment(s)do(es) not preclude either the requisite hydrolytic action of thedigestive enzyme on, or the subsequent release of opioid agonist from,the S₂ substrate subunit.

In one aspect of the invention, the opioid agonist is an alcohol, phenolor ketone containing opioid agonist. Accordingly, an alcohol, phenol, orketone containing opioid agonist is attached through a hydroxylic,phenolic, or enolic oxygen to a linker, which is further attached to anenzyme cleavable moiety. A single enzymatic hydrolysis of a cleavablemoiety, or a cascade of enzymatic hydrolyses of cleavable moieties, mayrelease the opioid agonist by (i) directly cleaving the bond between theenzyme cleavable moiety and the opioid agonist, or (ii) revealing alatent nucleophile, such as an amine or carboxylate, that subsequentlyundergoes an intramolecular cyclization-release reaction, or (iii)revealing an additional enzyme substrate, or substrates, that arefurther cleaved by the digestive enzyme ultimately resulting in releaseof the appended opioid agonist.

The mechanisms of enzyme-mediated opioid agonist release from therepresentative S₂ substrates subunits are presented below:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative cyclic urea forming S₂ subunit example:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative aliphatic fused-ring cyclic urea forming S₂ subunitexample:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative heterocyclic fused-ring cyclic urea forming S₂ subunitexample:

General mechanism of enzyme-mediated opioid agonist release fromrepresentative aromatic fused-ring cyclic urea forming S₂ subunitexamples:

Representative non-limiting S₂ subunit examples include, but are notlimited to:

wherein:X is hydrogen or hydroxyl;each R′ is independently hydrogen, methyl, alkyl, aryl, substitutedalkyl, substituted aryl, heteroalkyl, substituted heteroalkyl, a naturalor unnatural amino acid side chain, an amino acid side-chain mimic, apolyethylene glycol, or polyethylene glycol containing moiety, or alinking moiety Z;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing moiety, or a natural or unnatural aminoacid side chain, an amino acid side-chain mimic, or a linking moiety Z.

Representative synthetic routes useful for the preparation of S₂substrate subunits are depicted below. The syntheses utilize readilyobtained peptide-derived synthons, well-established peptide-basedcouplings, and known protecting group strategies.

Phenol- and enol-carbamate forming opioid attachment strategiespublished in the art are also employed (see, for example: U.S. Pat. Nos.8,802,681, 8,685,916, 8,217,005, and 8,163,701, 8,685,916, 8,569,228,8,497,237 and U.S. Patent Application Nos. 2014016935). (P) is anoptional protecting group present on the terminus of the linker Z distalto the S₂ subunit that may be employed to enhance chemical efficiency.Purification of the resulting S₂ subunits can be accomplished usingstandard purification procedures involving normal or reverse phasechromatography, crystallization, trituration, etc. The chemical identityof the S₂ subunits can be established by LC/MS and/or NMR analysis.

Combinations of S₁ and S₂ Subunits

In some embodiments the disclosure provides a compound comprising:

One S₁ subunit conjoined to one S₂ subunit.

wherein:

R can be

R′ can be methyl, lower alkyl, substituted alkyl, aryl, substitutedaryl, heteroalkyl, a natural or non-natural amino acid, a polypeptidechain comprising natural and/or non-natural amino acids up to 10 aminoacids in length, a linear or branched polyethylene glycol chain up to 5kDa, benzyloxy, and the like; R″ can be an acetyl, substituted acyl, anatural or non-natural amino acid, or a polypeptide chain comprisingnatural and/or non-natural amino acids up to 10 amino acids in length;AA is a natural or non-natural amino acid side chain capable of beingrecognized by trypsin; X is hydrogen or OH.

In some embodiments the disclosure provides a compound comprising:

One S₁ subunit conjoined to two S₂ subunits:

wherein:

R can be

R′ can be methyl, lower alkyl, substituted alkyl, aryl, substitutedaryl, heteroalkyl, a natural or non-natural amino acid, a polypeptidechain comprising natural and/or non-natural amino acids up to 10 aminoacids in length, a linear polyethylene glycol chain up to 5 kDa,benzyloxy, and the like; R″ can be an acetyl, substituted acyl, anatural or non-natural amino acid, or a polypeptide chain comprisingnatural and/or non-natural amino acids up to 10 amino acids in length;AA is a natural or non-natural amino acid side chain capable of beingrecognized by trypsin; X is hydrogen or OH.

In some embodiments the disclosure provides a compound comprising:

One S₁ subunit conjoined to three S₂ subunits:

wherein:

R can be

R′ can be methyl, lower alkyl, substituted alkyl, aryl, substitutedaryl, heteroalkyl, a natural or non-natural amino acid, a polypeptidechain comprising natural and/or non-natural amino acids up to 10 aminoacids in length, a linear polyethylene glycol chain up to 5 kDa,benzyloxy, and the like; R″ can be an acetyl, substituted acyl, anatural or non-natural amino acid, or a polypeptide chain comprisingnatural and/or non-natural amino acids up to 10 amino acids in length;AA is a natural or non-natural amino acid side chain capable of beingrecognized by trypsin; X is hydrogen or OH.

In some embodiments the disclosure provides one or more of theaforementioned compounds wherein:

R can be

R′ can be methyl or benzyloxy; R″ can be an acetyl or a substitutedacyl, a natural or non-natural amino acid or a di- or tri-peptidecomprising natural or non-natural amino acids; AA is a natural ornon-natural amino acid side chain capable of being recognized bytrypsin; X is hydrogen or OH.

In yet other embodiments the disclosure provides one or more of theaforementioned compounds wherein:

R can be

R′ can be methyl or benzyloxy; R″ can be an acetyl, a natural ornon-natural amino acid or a dipeptide comprising natural or non-naturalamino acids; AA is the side chain of lysine or arginine; X is hydrogenor OH.

In yet another embodiment the disclosure provides one or more of theaforementioned compounds wherein:

R can be

R′ can be methyl or benzyloxy; R″ can be acetyl, -Ala-NAc or -Gly-NAc;AA is the side chain of lysine or arginine; X is hydrogen or OH.

Table 3 Illustrates Various Compounds Contemplated by the PresentDisclosure

TABLE 3 AA (side Compound R R′ R″ chain) X 10

Methyl Acetyl Lysine Hydrogen 11

Methyl Acetyl Lysine —OH 12

Methyl Acetyl Arginine Hydrogen 13

Methyl Acetyl Arginine —OH 14

Methyl -Ala-NAc Lysine Hydrogen 15

Methyl -Ala-NAc Lysine —OH 16

Methyl -Ala-NAc Arginine Hydrogen 17

Methyl -Ala-NAc Arginine —OH 18

Methyl -Gly-NAc Lysine Hydrogen 19

Methyl -Gly-NAc Lysine —OH 20

Methyl -Gly-NAc Arginine Hydrogen 21

Methyl -Gly-NAc Arginine —OH 22

Benzyloxy Acetyl Lysine Hydrogen 23

Benzyloxy Acetyl Lysine —OH 24

Benzyloxy Acetyl Arginine Hydrogen 25

Benzyloxy Acetyl Arginine —OH 26

Benzyloxy -Ala-NAc Lysine Hydrogen 27

Benzyloxy -Ala-NAc Lysine —OH 28

Benzyloxy -Ala-NAc Arginine Hydrogen 29

Benzyloxy -Ala-NAc Arginine —OH 30

Benzyloxy -Gly-NAc Lysine Hydrogen 31

Benzyloxy -Gly-NAc Lysine —OH 32

Benzyloxy -Gly-NAc Arginine Hydrogen 33

Benzyloxy -Gly-NAc Arginine —OH 34

Methyl Acetyl Lysine Hydrogen 35

Methyl Acetyl Lysine —OH 36

Methyl Acetyl Arginine Hydrogen 37

Methyl Acetyl Arginine —OH 38

Methyl -Ala-NAc Lysine Hydrogen 39

Methyl -Ala-NAc Lysine —OH 40

Methyl -Ala-NAc Arginine Hydrogen 41

Methyl -Ala-NAc Arginine —OH 42

Methyl -Gly-NAc Lysine Hydrogen 43

Methyl -Gly-NAc Lysine —OH 44

Methyl -Gly-NAc Arginine Hydrogen 45

Methyl -Gly-NAc Arginine —OH 46

Benzyloxy Acetyl Lysine Hydrogen 47

Benzyloxy Acetyl Lysine —OH 48

Benzyloxy Acetyl Arginine Hydrogen 49

Benzyloxy Acetyl Arginine —OH 50

Benzyloxy -Ala-NAc Lysine Hydrogen 51

Benzyloxy -Ala-NAc Lysine —OH 52

Benzyloxy -Ala-NAc Arginine Hydrogen 53

Benzyloxy -Ala-NAc Arginine —OH 54

Benzyloxy -Gly-NAc Lysine Hydrogen 55

Benzyloxy -Gly-NAc Lysine —OH 56

Benzyloxy -Gly-NAc Arginine Hydrogen 57

Benzyloxy -Gly-NAc Arginine —OH 58

Methyl Acetyl Lysine Hydrogen 59

Methyl Acetyl Lysine —OH 60

Methyl Acetyl Arginine Hydrogen 61

Methyl Acetyl Arginine —OH 62

Methyl -Ala-NAc Lysine Hydrogen 63

Methyl -Ala-NAc Lysine —OH 64

Methyl -Ala-NAc Arginine Hydrogen 65

Methyl -Ala-NAc Arginine —OH 66

Methyl -Gly-NAc Lysine Hydrogen 67

Methyl -Gly-NAc Lysine —OH 68

Methyl -Gly-NAc Arginine Hydrogen 69

Methyl -Gly-NAc Arginine —OH 70

Benzyloxy Acetyl Lysine Hydrogen 71

Benzyloxy Acetyl Lysine —OH 72

Benzyloxy Acetyl Arginine Hydrogen 73

Benzyloxy Acetyl Arginine —OH 74

Benzyloxy -Ala-NAc Lysine Hydrogen 75

Benzyloxy -Ala-NAc Lysine —OH 76

Benzyloxy -Ala-NAc Arginine Hydrogen 77

Benzyloxy -Ala-NAc Arginine —OH 78

Benzyloxy -Gly-NAc Lysine Hydrogen 79

Benzyloxy -Gly-NAc Lysine —OH 80

Benzyloxy -Gly-NAc Arginine Hydrogen 81

Benzyloxy -Gly-NAc Arginine —OH 82

Methyl Acetyl Lysine Hydrogen 83

Methyl Acetyl Lysine —OH 84

Methyl Acetyl Arginine Hydrogen 85

Methyl Acetyl Arginine —OH 86

Methyl -Ala-NAc Lysine Hydrogen 87

Methyl -Ala-NAc Lysine —OH 88

Methyl -Ala-NAc Arginine Hydrogen 89

Methyl -Ala-NAc Arginine —OH 90

Methyl -Gly-NAc Lysine Hydrogen 91

Methyl -Gly-NAc Lysine —OH 92

Methyl -Gly-NAc Arginine Hydrogen 93

Methyl -Gly-NAc Arginine —OH 94

Benzyloxy Acetyl Lysine Hydrogen 95

Benzyloxy Acetyl Lysine —OH 96

Benzyloxy Acetyl Arginine Hydrogen 97

Benzyloxy Acetyl Arginine —OH 98

Benzyloxy -Ala-NAc Lysine Hydrogen 99

Benzyloxy -Ala-NAc Lysine —OH 100

Benzyloxy -Ala-NAc Arginine Hydrogen 101

Benzyloxy -Ala-NAc Arginine —OH 102

Benzyloxy -Gly-NAc Lysine Hydrogen 103

Benzyloxy -Gly-NAc Lysine —OH 104

Benzyloxy -Gly-NAc Arginine Hydrogen 105

Benzyloxy -Gly-NAc Arginine —OH 106

Methyl Acetyl Lysine Hydrogen 107

Methyl Acetyl Lysine —OH 108

Methyl Acetyl Arginine Hydrogen 109

Methyl Acetyl Arginine —OH 110

Methyl -Ala-NAc Lysine Hydrogen 111

Methyl -Ala-NAc Lysine —OH 112

Methyl -Ala-NAc Arginine Hydrogen 113

Methyl -Ala-NAc Arginine —OH 114

Methyl -Gly-NAc Lysine Hydrogen 115

Methyl -Gly-NAc Lysine —OH 116

Methyl -Gly-NAc Arginine Hydrogen 117

Methyl -Gly-NAc Arginine —OH 118

Benzyloxy Acetyl Lysine Hydrogen 119

Benzyloxy Acetyl Lysine —OH 120

Benzyloxy Acetyl Arginine Hydrogen 121

Benzyloxy Acetyl Arginine —OH 122

Benzyloxy -Ala-NAc Lysine Hydrogen 123

Benzyloxy -Ala-NAc Lysine —OH 124

Benzyloxy -Ala-NAc Arginine Hydrogen 125

Benzyloxy -Ala-NAc Arginine —OH 126

Benzyloxy -Gly-NAc Lysine Hydrogen 127

Benzyloxy -Gly-NAc Lysine —OH 128

Benzyloxy -Gly-NAc Arginine Hydrogen 129

Benzyloxy -Gly-NAc Arginine —OH 130

Methyl Acetyl Lysine Hydrogen 131

Methyl Acetyl Lysine —OH 132

Methyl Acetyl Arginine Hydrogen 133

Methyl Acetyl Arginine —OH 134

Methyl -Ala-NAc Lysine Hydrogen 135

Methyl -Ala-NAc Lysine —OH 136

Methyl -Ala-NAc Arginine Hydrogen 137

Methyl -Ala-NAc Arginine —OH 138

Methyl -Gly-NAc Lysine Hydrogen 139

Methyl -Gly-NAc Lysine —OH 140

Methyl -Gly-NAc Arginine Hydrogen 141

Methyl -Gly-NAc Arginine —OH 142

Benzyloxy Acetyl Lysine Hydrogen 143

Benzyloxy Acetyl Lysine —OH 144

Benzyloxy Acetyl Arginine Hydrogen 145

Benzyloxy Acetyl Arginine —OH 146

Benzyloxy -Ala-NAc Lysine Hydrogen 147

Benzyloxy -Ala-NAc Lysine —OH 148

Benzyloxy -Ala-NAc Arginine Hydrogen 149

Benzyloxy -Ala-NAc Arginine —OH 150

Benzyloxy -Gly-NAc Lysine Hydrogen 151

Benzyloxy -Gly-NAc Lysine —OH 152

Benzyloxy -Gly-NAc Arginine Hydrogen 153

Benzyloxy -Gly-NAc Arginine —OH 154

Methyl Acetyl Lysine Hydrogen 155

Methyl Acetyl Lysine —OH 156

Methyl Acetyl Arginine Hydrogen 157

Methyl Acetyl Arginine —OH 158

Methyl -Ala-NAc Lysine Hydrogen 159

Methyl -Ala-NAc Lysine —OH 160

Methyl -Ala-NAc Arginine Hydrogen 161

Methyl -Ala-NAc Arginine —OH 162

Methyl -Gly-NAc Lysine Hydrogen 163

Methyl -Gly-NAc Lysine —OH 164

Methyl -Gly-NAc Arginine Hydrogen 165

Methyl -Gly-NAc Arginine —OH 166

Benzyloxy Acetyl Lysine Hydrogen 167

Benzyloxy Acetyl Lysine —OH 168

Benzyloxy Acetyl Arginine Hydrogen 169

Benzyloxy Acetyl Arginine —OH 170

Benzyloxy -Ala-NAc Lysine Hydrogen 171

Benzyloxy -Ala-NAc Lysine —OH 172

Benzyloxy -Ala-NAc Arginine Hydrogen 173

Benzyloxy -Ala-NAc Arginine —OH 174

Benzyloxy -Gly-NAc Lysine Hydrogen 175

Benzyloxy -Gly-NAc Lysine —OH 176

Benzyloxy -Gly-NAc Arginine Hydrogen 177

Benzyloxy -Gly-NAc Arginine —OH 178

Methyl Acetyl Lysine Hydrogen 179

Methyl Acetyl Lysine —OH 180

Methyl Acetyl Arginine Hydrogen 181

Methyl Acetyl Arginine —OH 182

Methyl -Ala-NAc Lysine Hydrogen 183

Methyl -Ala-NAc Lysine —OH 184

Methyl -Ala-NAc Arginine Hydrogen 185

Methyl -Ala-NAc Arginine —OH 186

Methyl -Gly-NAc Lysine Hydrogen 187

Methyl -Gly-NAc Lysine —OH 188

Methyl -Gly-NAc Arginine Hydrogen 189

Methyl -Gly-NAc Arginine —OH 190

Benzyloxy Acetyl Lysine Hydrogen 191

Benzyloxy Acetyl Lysine —OH 192

Benzyloxy Acetyl Arginine Hydrogen 193

Benzyloxy Acetyl Arginine —OH 194

Benzyloxy -Ala-NAc Lysine Hydrogen 195

Benzyloxy -Ala-NAc Lysine —OH 196

Benzyloxy -Ala-NAc Arginine Hydrogen 197

Benzyloxy -Ala-NAc Arginine —OH 198

Benzyloxy -Gly-NAc Lysine Hydrogen 199

Benzyloxy -Gly-NAc Lysine —OH 200

Benzyloxy -Gly-NAc Arginine Hydrogen 201

Benzyloxy -Gly-NAc Arginine —OH 202

Methyl Acetyl Lysine Hydrogen 203

Methyl Acetyl Lysine —OH 204

Methyl Acetyl Arginine Hydrogen 205

Methyl Acetyl Arginine —OH 206

Methyl -Ala-NAc Lysine Hydrogen 207

Methyl -Ala-NAc Lysine —OH 208

Methyl -Ala-NAc Arginine Hydrogen 209

Methyl -Ala-NAc Arginine —OH 210

Methyl -Gly-NAc Lysine Hydrogen 211

Methyl -Gly-NAc Lysine —OH 212

Methyl -Gly-NAc Arginine Hydrogen 213

Methyl -Gly-NAc Arginine —OH 214

Benzyloxy Acetyl Lysine Hydrogen 215

Benzyloxy Acetyl Lysine —OH 216

Benzyloxy Acetyl Arginine Hydrogen 217

Benzyloxy Acetyl Arginine —OH 218

Benzyloxy -Ala-NAc Lysine Hydrogen 219

Benzyloxy -Ala-NAc Lysine —OH 220

Benzyloxy -Ala-NAc Arginine Hydrogen 221

Benzyloxy -Ala-NAc Arginine —OH 222

Benzyloxy -Gly-NAc Lysine Hydrogen 223

Benzyloxy -Gly-NAc Lysine —OH 224

Benzyloxy -Gly-NAc Arginine Hydrogen 225

Benzyloxy -Gly-NAc Arginine —OH

Opioid Antagonist Releasing S₃ Subunits

Polysubstrates of the invention may optionally contain none, one, ormore covalently linked opioid antagonist releasing S₃ subunits. Theopioid antagonist releasing S₃ subunits preferably do not substantiallyrelease the appended opioid antagonist upon oral ingestion by a subject.By design, S₃ subunits preferably are not digestive enzyme substrates,but may be substrates for enzymes found in blood, plasma, liver, orother systemically accessible tissues. The opioid antagonist releasingGI enzyme substrates are designed to efficiently release the appendedopioid antagonist in the systemic circulation (i.e. upon exposure toenzymes found in the plasma, liver, red blood cells, or other tissueslocated outside the gastrointestinal tract) and/or when subjects attemptto abuse polysubstrates of the invention via unintended non-oral routes(e.g. intravenous injection and/or snorting).

Specifically, the opioid antagonist releasing substrates are designed torelease the appended opioid antagonist upon chemical tampering bypotential abusers. Chemical tampering methods capable of hydrolyzing theester functionalities contained within the S₁ subunits in polysubstratesof the invention aimed at destroying the S₁ subunits that saturate thedigestive enzyme that mediate the release of the opioid agonist whenoral overdoses are ingested, will also efficiently liberate the opioidantagonist from the S₃ subunits. As a result, both non-oral routes ofabuse and tampering methods aimed at liberating the opioid agonist ordefeating the oral overdose protection can be effectively thwarted bythe presence of S₃ subunits in polysubstrates of the invention. Suitableopioid antagonists include, but are not limited to, buprenorphine,cyclazocine, cyclorphan, naloxone, naltrexone, nalmephene,6-amino-6-desoxo-naloxone, levallorphan, nalbuphine, naltrendol,naltrindole, nalorphine, nor-binaltorphimine, oxilorphan, pentazocine,piperidine-N-alkylcarboxylate opioid antagonists such as those describedin U.S. Pat. Nos. 5,159,081, 5,250,542, 5,270,328, and 5,434,171, andderivatives, mixtures, salts, polymorphs, or prodrugs thereof.

The opioid antagonist-releasing substrates may be linked via an ester,or alternative chemically labile functionality, to the phenol, alcohol,or ketone (e.g. enol) functionalities found in naltrexone or naloxone asillustrated below.

Non-limiting generic examples of opioid antagonist releasing S₃ subunitscomprising chemically releasable opioid antagonists designated as NX anda linking moiety Z are shown below:

wherein:NX is an opioid antagonist as defined above and can preferably benaltrexone or naloxone;R is hydrogen or alkyl; andZ is a linking moiety.

A general mechanism of chemically-mediated opioid antagonist releasefrom generic S₃ subunits is shown below:

In some embodiments, the S₃—Z— subunit is selected from the groupconsisting of:

Wherein:

R is cyclopropylmethyl or allyl; R′ is hydrogen, methyl, alkyl, aryl,substituted alkyl, or substituted aryl, acyl or substituted acyl; and Zis a linker as defined herein.

In some embodiments, the opioid antagonist is naltrexone or naloxone.

Representative synthetic routes useful for the preparation of S₃subunits are depicted below. The syntheses utilize readily obtainedsynthons, well-established chemistry, and known protecting groupstrategies. Reported enol-carbamate forming opioid attachment strategiesare also employed (see: U.S. Pat. Nos. 8,802,681, 8,685,916, 8,217,005,and 8,163,701, 8,685,916, 8,569,228, 8,497,237 and U.S. PatentApplication Nos. 2014016935). P′, a phenol protecting group used toenhance chemical efficiency, can be easily removed during the course ofsubsequent polysubstrate synthesis. (P) is an optional protecting grouppresent on the terminus of the linker Z distal to the S₃ subunit thatmay be employed to enhance chemical efficiency. Purification of theresulting S₃ subunits can be accomplished using standard purificationprocedures involving normal or reverse phase chromatography,crystallization, trituration, etc. The chemical identity of the S₃subunits can be established by LC/MS and/or NMR analysis.

Scaffolds

In some embodiments, scaffolds (referred to interchangeably herein as“covalent scaffolds” used in the preparation of compounds of theinvention are oligomeric or polymeric, such as, for example, PEG (orother polyalkylene oxide), polypeptides, polysaccharides andbiopolymers. Oligomers or polymers suitable for construction ofpolymeric analogs of the invention include, but are not limited to,linear, dendrimeric, branched, brush (or comb) polymers. In one aspectof the invention, the polymer can be a polycationic material includingnatural and unnatural polyamino acids having net positive charge atneutral pH, positively charged polysaccharides, and positively chargedsynthetic polymers. The polymers can be prepared from monomersincluding, N-vinylpyrrolidone, acrylamide, N,N-dimethylacrylamide, vinylacetate, dextran, L-glutamic acid, L-aspartic acid, L-lysine,L-threonine, L-tyrosine, D-glutamic acid, D-aspartic acid, D-lysine,D-threonine, D-tyrosine, styrene, maleic anhydride,N-(2-hydroxypropyl)methacrylamide, N-(2-hydroxyethyl)methacryalte,N-(2-hydroxyethyl)methacrylamide, ethylene glycol, ethylene oxide,propylene glycol, propylene oxide, tetrahydrofuran, butylene glycol,tetrahydropyran, ethyl vinyl ether, nonpeptide polyamines such aspoly(aminostyrene), poly(aminoacrylate), poly (N-methyl aminoacrylate),poly (N-ethylaminoacrylate), poly(N,N-dimethyl aminoacrylate),poly(N,N-diethylaminoacrylate), poly(aminomethacrylate), poly(N-methylamino-methacrylate), poly(N-ethyl aminomethacrylate), poly(N,N-dimethylaminomethacrylate), poly(N,N-diethyl aminomethacrylate),poly(ethyleneimine), polymers of quaternary amines, such aspoly(N,N,N-trimethylaminoacrylate chloride),poly(methyacrylamidopropyltrimethyl ammonium chloride), and natural orsynthetic polysaccharides such as chitosan, and copolymers of theprevious, including random, alternating, block, multi-block linearcopolymers, and star polymers. The polymers may be isotactic,syndiotactic, or atactic as appropriate. Methods for synthesis ofbiopolymers and for conjugating them to biological materials are wellknown in the art (see, for example, published U.S. Patent Application20040043030; U.S. Pat. Nos. 5,177,059; 6,716,821; 5,824,701; 6,664,331;5,880,131; Kameda, Y. et al., Biomaterials 25: 3259-3266, 2004; Thanou,M. et al, Current Opinion in Investigational Drugs 4(6): 701-709, 2003;Veronese, F. M., et al., Il Farmaco 54: 497-516, 1999).

In addition, dendritic polymers may be used for preparation of compoundsof the invention. Appropriate dendrimers include, but are not limitedto, polyamido amine (PAMAM) (Gunatillake et al., Macromolecules, 1988,21, 1556; U.S. Pat. No. 4,507,466), polyethyleneimine (U.S. Pat. No.4,631,337), polypropyleneimine (U.S. Pat. No. 5,530,092), andFrechet-type dendrimers (U.S. Pat. No. 5,041,516; Hawker et al., J. Am.Chem. Soc., 1991, 113, 4583) terminated with amines, alcohols, orcarboxylic acid surface groups. A recent review on dendrimer synthesisis Tomalia et al., J. Polym. Sci., Part A: Polym. Chem., 2002, 40, 2719.The polymers can be prepared by methods known in the art, or they can beobtained from commercial sources.

In one aspect of the invention, the molecular weight of the scaffoldpolymer portion of a polymer conjugate of the invention is greater thanabout 500 Daltons (Da), and more preferably is greater than about 2,000Da. In another aspect of the invention, the polymer has a molecularweight of about 10,000 Da to about 250,000 Da. Thus, the ranges ofmolecular weights for the polymer portion of the conjugate can be fromabout 2,000 Da to about 200,000 Da, preferably about 5,000 Da to about50,000 Da, more preferably about 7,000 Da to about 50,000 Da, or fromabout 10,000 Da to about 50,000 Da. The polymer backbones having anaverage molecular weight of about 5,000 Da, about 7,000 Da, about10,000, about 15,000 Da, about 17,500 Da, about 20,000 Da, about 30,000Da, about 35,000 Da, about 40,000 Da, about 45,000 Da, and about 50,000Da are particularly preferred.

Commercially available polymers suitable for use in the inventioninclude, but are not limited to, mPEG-NH₂ (M_(w) ˜10 kDa, ˜20 KDa),mPEG-OH (M_(w) ˜1 kDa, 2 KDa, ˜3 KDa, ˜5 KDa, ˜10 KDa, ˜12 KDa, ˜20KDa), 3-arm PEG-triol (M_(w) ˜10 kDa glycerol core, 15 kDa glycerolcore, ˜20 kDa glycerol core), 4-arm PEG-tetrol (M_(w) ˜2 kDapentaerythritol core, ˜10 kDa pentaerythritol core, ˜15 kDapentaerythritol core, ˜20 kDa pentaerythritol core), 8-arm PEG-octol(M_(w) ˜2 kDa hexaglycerine, ˜10 kDa hexaglycerine, ˜15 kDahexaglycerine, ˜20 kDa hexaglycerine, ˜40 kDa hexaglycerine); such asPoly(acrylic acid), M_(w) ˜50 kDa, Poly(1-glycerol methacrylate),Poly(acrylamide-co-acrylic acid), Poly(ethylene oxide-block-propyleneoxide), Poly(L-lysine) hydrobromide, Poly(styrenesulfonic acid),Poly(vinyl alcohol), Poly(vinyl amine) hydrochloride, poly(caprolactone)diol; O,O′-bis(2-carboxyethyl)dodecaethylene glycol, Poly(allyl amine),Poly(antholesulfonic acid, sodium salt), Poly(caprolactone) triol1,1,1-tris(hydroxymethyl)propane core, Poly(di(ethylene glycol)phthalate) diol, Poly(di(ethylene glycol)/trimethylolpropane-alt-adipicacid), polyol, PEG-bis(3-aminopropyl) terminated, PEG-bis(carboxymethyl)ether M_(w) ˜250 Da, PEG-bis(carboxymethyl) ether M_(w) ˜600 Da,PEG-block-PPG-block-PEG diol (M_(w) ˜1,100 Da, ˜1,900 Da, ˜2,000 Da,˜2,800 Da, ˜2,900 Da, ˜4,400 Da, ˜5,800 Da, ˜8,400 Da, ˜14,600 Da),PEG-ran-PPG diol (M_(w) ˜2,500 Da, ˜12,000 Da, ˜970 Da, ˜1,700 Da,˜3,900 Da), PEG-tetrahydrofurfuryl ether, Poly(2-hydroxyethylmethacrylate), Polyoxyethylene bis(amine) M_(w) ˜2,000 Da,Polyoxyethylene bis(amine) M_(w) ˜20,000 Da, PPG diol (M_(w) ˜425 Da,˜725 Da, ˜1,000 Da, ˜2,000 Da, ˜2,700 Da, ˜3,500 Da), Poly(DL-lysine)hydrobromide (M_(w) ˜1,000-4,000 Da, ˜30,000-70,000 Da, ˜500-2,000 Da,˜1,000-4,000 Da, ˜4,000-15,000 Da, ˜15,000-30,000 Da, ˜30,000-70,000Da), Poly(D-lysine) hydrobromide (M_(w) ˜1,000-4,000 Da, ˜4,000-15,000Da, ˜15,000-30,000 Da, ˜30,000-70,000 Da), Poly(L-tyrosine) M_(w)˜10,000-40,000 Da, Poly(L-serine) M_(w) ˜5,000-10,000 Da,Poly(L-threonine) M_(w) ˜5,000-15,000 Da, PAMAM Dendrimer G(0)-NH₂,ethylenediamine core (surface groups: 4, 8, 16, 32, or 64), PAMAMDendrimer G(2)-OH, ethylenediamine core (surface groups: 16, 32, 64),DAB-AM-4, polypropyleneimine tetraamine dendrimer (surface groups: 4, 8,16, 32, 64), PAMAM-tris(hydroxymethyl)amidomethane dendrimer, Generation2, ethylenediamine core (surface groups: 48),PAMAM-tris(hydroxymethyl)amidomethane dendrimer, Generation 3,ethylenediamine core (surface groups: 96), PAMAM-succinamic aciddendrimer, ethylenediamine core, Generation 2 (surface groups: 16),Amino-dPEG₂ ™ t-butyl ester, Amino-dPEG₄ ™ t-butyl ester, Amino-dPEG₈™t-butyl ester, Amino-dPEG₁₂ ™ t-butyl ester, Amino-dPEG₂₄ ™ t-butylester, m-dPEG₄ ™ amine, m-dPEG₁₂ ™ amine, m-dPEG₂₄ ™ amine,Hydroxy-dPEG₄ ™ t-butyl ester, Hydroxy-dPEG₈™ t-butyl ester, m-dPEG₁₁™alcohol, dPEG₁₂ ™ diol, Mono-N-t-boc-amido-dPEG₃™-amine,Mono-N-t-boc-amido-dPEG₁₁™-amine, Mono-N-t-CBZ-amido-dPEG₃™-amine,N-t-boc-amido-dPEG₄ ™ alcohol, N-t-boc-amido-dPEG₁₂ ™ alcohol, Bis-dPEG₅™ acid, Bis-dPEG₇ ™ acid, Bis-dPEG₅™ half benzyl half acid, Bis-dPEG₉™half benzyl half acid, N-Fmoc-amido-dPEG₂™ acid, N-Fmoc-amido-dPEG₄ ™acid, N-Fmoc-amido-dPEG₈™ acid, N-Fmoc-amido-dPEG₁₂ ™ acid,N-Fmoc-amido-dPEG₂₄ ™ acid, N-CBZ-amido-dPEG₄™-acid,N-CBZ-amido-dPEG₈™-acid, N-CBZ-amido-dPEG₁₂™-acid,N-CBZ-amido-dPEG₂₄™-acid, N-t-boc-amido-dPEG₄™-acid, and the like.

Non-limiting examples of polymers for use in the present inventioninclude: polyesters, polyethers, poly(orthoesters), poly(vinylalcohols), polyamides, polycarbonates, polyacrylamides, polyalkyleneglycols, polyalkylene oxides, polyalkylene terephthalates, polyolefins,polyvinyl ethers, polyvinyl esters, polyvinyl halides,polyvinylpyrrolidone, polyglycolides, polysiloxanes, polylactides,polyurethanes, polyethylenes, polyanhydrides, polyhydroxyacids,polypropylfumerates, polycaprolactones, polyacetals, polyurethanes,polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates,polyureas, polystyrenes, polyamines, olefinic polymers derived frommetatheses reactions with functionalized monomers, and block- orco-polymers thereof.

Non-limiting examples of biopolymers for use in the present inventioninclude: polyesters such as polyhyroxyalkanoates, polylactic acid andthe like; proteins such as silks, collagens, gelatins, elastin, resilin,adhesives, polyamino acids, soy, zein, wheat gluten, casein, serumalbumin and the like; polysaccharides such as xanthan, dextran, gellan,levan, curd ian, polygalactosamine, cellulose, pullulan, elsinan, yeastglucans, starch, agar, alginate, carrageenan, pectin, konjac, andvarious gums (e.g. guar), chitin, chitosan, hyaluronic acid, and thelike; lipids/surfactants such as acetoglycerides, waxes, emulsions, andthe like; polyphenols such as lignin, tannin, humic acid and the like;specialty polymers such as shellac, poly-gamma-glutamic acid, naturalrubbers, synthetic rubbers from natural fats, and the like. Alsoincluded are chemically modified versions (to enhancesolubility/functionality in the drug product formulation, resistdigestion/degradation, facilitate chemical modification with antagonistsynthons, etc.) of the above biopolymers.

In one aspect of the invention, the polymer is a “charged polymer”wherein the polymer can have one or more charged groups. Chargedpolymers can include a wide range of species, including polycations andtheir precursors (e.g., polybases, polysalts, etc.), polyanions andtheir precursors (e.g., polyacids, polysalts, etc.), polymers havingmultiple anionic and cationic groups (e.g., polymers having multipleacidic and basic groups such as are found in various proteins), ionomers(charged polymers in which a small but significant proportion of theconstitutional units carry charges), and so forth. Typically, the numberof charged groups is so large that the polymers are soluble in polarsolvents (particularly water) when in ionically dissociated form (alsocalled polyions). Some charged polymers have both anionic and cationicgroups (e.g., proteins) and may have a net negative charge (e.g.,because the anionic groups contribute more charge than the cationicgroups—referred to herein as polyanions), a net positive charge (e.g.,because the cationic groups contribute more charge than the anionicgroups—referred to herein as polycations), or may have a neutral netcharge (e.g., because the cationic groups and anionic groups contributeequal charge). In this regard, the net charge of a particular chargedpolymer may change with the pH of its surrounding environment. Chargedpolymers containing both cationic and anionic groups may be categorizedherein as either polycations or polyanions, depending on which groupspredominate.

Specific examples of suitable polycations may be selected, for instance,from the following: polyamines, including polyamidoamines, poly(aminomethacrylates) including poly(dialkylaminoalkyl methacrylates) such aspoly(dimethylaminoethyl methacrylate) and poly(diethylaminoethylmethacrylate), polyvinylamines, polyvinylpyridines including quaternarypolyvinylpyridines such as poly(N-ethyl-4-vinylpyridine),poly(vinylbenzyltrimethylamines), polyallylamines such aspoly(allylamine hydrochloride) (PAH) and poly(diallyidialklylamines)such as poly(diallyidimethylammonium chloride), spermine, spermidine,hexadimethrene bromide(polybrene), polyimines includingpolyalkyleneimines such as polyethyleneimines, polypropyleneimines andethoxylated polyethyleneimines, basic peptides and proteins, includinghistone polypeptides and homopolymer and copolymers containing lysine,arginine, ornithine and combinations thereof including poly-L-lysine,poly-D-lysine, poly-L,D-lysine, poly-L-arginine, poly-D-arginine,poly-D,L-arginine, poly-L-ornithine, poly-D-ornithine, andpoly-L,D-ornithine, gelatin, albumin, protamine and protamine sulfate,and polycationic polysaccharides such as cationic starch and chitosan,as well as copolymers, derivatives and combinations of the preceding,among various others. The preferred polymers for use in the inventioninclude poly(d-glutamic acid), poly(dl-glutamic acid), poly(l-asparticacid), poly(d-aspartic acid), poly(dl-aspartic acid), poly(l-lysine),poly(d-lysine), poly(dl-lysine), and copolymers of the polyamino acids,and the polymers of the N-methyl derivatives of the amino acids. Otherpreferred polymers include polyethylene glycol (PEG), as well aspoly(2-hydroxyethyl 1-glutamine), chitosan, carboxymethyl dextran,hyaluronic acid, human serum albumin and alginic acid.

Specific examples of suitable polyanions may be selected, for instance,from the following: polysulfonates such as polyvinylsulfonates,poly(styrenesulfonates) such as poly(sodium styrenesulfonate) (PSS),sulfonated poly(tetrafluoroethylene), sulfonated polymers such as thosedescribed in U.S. Pat. No. 5,840,387, including sulfonatedstyrene-ethylene/butylene-styrene triblock copolymers, sulfonatedstyrenic homopolymers and copolymers such as a sulfonated versions ofthe polystyrene-polyolefin copolymers described in U.S. Pat. No.6,545,097 to Pinchuk et al., which polymers may be sulfonated, forexample, using the processes described in U.S. Pat. Nos. 5,840,387 and5,468,574, as well as sulfonated versions of various other homopolymersand copolymers, polysulfates such as polyvinylsulfates, sulfated andnon-sulfated glycosaminoglycans as well as certain proteoglycans, forexample, heparin, heparin sulfate, chondroitin sulfate, keratan sulfate,dermatan sulfate, polycarboxylates such as acrylic acid polymers andsalts thereof (e.g., ammonium, potassium, sodium, etc.), for instance,those available from Atofina and Polysciences Inc., methacrylic acidpolymers and salts thereof (e.g., EUDRAGIT, a methacrylic acid and ethylacrylate copolymer), carboxymethylcellulose, carboxymethylamylose andcarboxylic acid derivatives of various other polymers, polyanionicpeptides and proteins such as glutamic acid polymers and copolymers,aspartic acid polymers and copolymers, polymers and copolymers of uronicacids such as mannuronic acid, galatcuronic acid and guluronic acid, andtheir salts, alginic acid and sodium alginate, hyaluronic acid, gelatin,and carrageenan, polyphosphates such as phosphoric acid derivatives ofvarious polymers, polyphosphonates such as polyvinylphosphonates,polysulfates such as polyvinylsulfates, as well as copolymers,derivatives and combinations of the preceding, among various others.

Exemplary natural polymers include naturally occurring polysaccharides,such as, for example, arabinans, fructans, fucans, galactans,galacturonans, glucans, mannans, xylans (such as, for example, inulin),levan, fucoidan, carrageenan, galatocarolose, pectic acid, pectins,including amylose, pullulan, glycogen, amylopectin, cellulose, dextran,dextrin, dextrose, glucose, polyglucose, polydextrose, pustulan, chitin,agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid,xanthan gum, starch and various other natural homopolymer orheteropolymers, such as those containing one or more of the followingaldoses, ketoses, acids or amines: erythrose, threose, ribose,arabinose, xylose, lyxose, allose, altrose, glucose, dextrose, mannose,gulose, idose, galactose, talose, erythrulose, ribulose, xylulose,psicose, fructose, sorbose, tagatose, mannitol, sorbitol, lactose,sucrose, trehalose, maltose, cellobiose, glycine, serine, threonine,cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid,lysine, arginine, histidine, glucuronic acid, gluconic acid, glucaricacid, galacturonic acid, mannuronic acid, glucosamine, galactosamine,and neuraminic acid, and naturally occurring derivatives thereof.Accordingly, suitable polymers include, for example, proteins, such asalbumin, silks, collagen, elastin, resilin, polyamino acids, soy, wheatgluten, and casein.

Non-limiting examples of polyesters include polylactic acid,polyglycolic acid, poly(lactide-co-glycolide), poly(e-caprolactone),polydioxanone, poly(ethylene terephthalate), poly(malic acid),poly(tartronic acid), polyphosphazenes, poly(orthoester), poly(valericacid), poly(buteric acid), polyhydroxybutyrate, polyhydroxyvalerate,polyanhydride, and copolymers of the monomers used to synthesize any ofthe above-mentioned polymers, e.g., poly(lactic-co-glycolic acid) (PLGA)or the copolymer of polyhydroxy butyrate with hydroxyvaleric acid.

Non-limiting examples of polyesters include polylactic acid,polyglycolic acid, poly(lactide-co-glycolide), poly(ε-caprolactone),polydioxanone, poly(ethylene terephthalate), poly(malic acid),poly(tartronic acid), polyphosphazenes, poly(orthoester), poly(valericacid), poly(buteric acid), polyhydroxybutyrate, polyhydroxyvalerate,polyanhydride, and copolymers of the monomers used to synthesize any ofthe above-mentioned polymers, e.g., poly(lactic-co-glycolic acid) (PLGA)or the copolymer of polyhydroxy butyrate with hydroxyvaleric acid.

Polyethers and poly(orthoesters) can also be used in preparing thepolymer conjugate for use in the present invention. These polymers canbe incorporated into multi-blocks resulting in block polymers havingdiverse degradation rates, mechanical strengths, porosities,diffusivities, and inherent viscosities. Examples of polyethers includepolyethylene glycol and polypropylene glycol. An example of amulti-block copolymer is poly(ether ester amide). Additionally, triblockcopolymers of poly(orthoesters) with various poly(ethylene glycol)contents are useful for their stability in water/oil (w/o) emulsions.Other useful block copolymers include diblock copolymers of poly(lactic-co-glycolic acid) and poly(ethylene glycol) (PEG), triblockcopolymers of PEG-PLGA-PEG, copolymers of PLGA and polylysine, and poly(ester ether) block copolymers.

In one aspect of the invention, the polymer is poly(ethylene glycol)(PEG) or a related poly(alkylene glycol). The term PEG includespoly(ethylene glycol) in any its forms, including linear forms (e.g.,alkoxy PEG or bifunctional PEG), branched or multi-arm forms (e.g.,forked PEG or PEG attached to a polyol core), pendant PEG, and the like.The general formula of PEG is —CH₂CH₂O—(CH₂CH₂O)_(n)—CH₂CH₂— wherein nis from about 0 to about 500, typically from about 2 to about 200.Similar polymers can also be derived from polypropylene glycol andrelated poly(alkylene) glycols.

Multi-armed or branched PEG molecules, such as those described in U.S.Pat. No. 5,932,462 can also be used as the PEG polymer. Generallyspeaking, a multi-armed, branched, or star or dendrimeric polymerspossess two or more polymer arms extending from a central branch pointthat is covalently attached, either directly or indirectly viaintervening connecting atoms, to one or more active moieties such as anopioid agonist, antagonist, or digestive enzyme inverse substrate. It isunderstood by those skilled in the art that the term poly(ethyleneglycol) or PEG represents or includes all the above forms of PEG orpoly(alkylene glycols).

Preferred scaffolds selected from those listed above most useful for theconstruction of polysubstrates of the invention (i) are readilycommercially available, (ii) comprise a sufficient number and type ofchemically accessible functionalities (e.g. carboxylate, amine, thiol,alcohol, isocyanate, etc.), (iii) efficiently undergo the requisitecoupling chemistry to attach the desired numbers of S₁, S₂, and optionalS₃ subunits, and (iv) result in polysubstrate products with the desiredphysicochemical (e.g. solubility, stability, release of opioidantagonist upon chemical tampering in vitro, etc.) and biological (e.g.selective enzymatic release of opioid agonist in vivo, overdoseprotection via enzyme saturation, release of opioid antagonist in thesystemic circulation, etc.) profiles.

Compounds of the Invention

In some embodiments, a compound of the invention has the Formula:

wherein:S₁ is a non-opioid releasing enzyme substrate or enzyme inhibitor;S₂ is an opioid agonist releasing enzyme substrate;S₃ is an optional opioid antagonist-releasing moiety;Z is a linker moiety as previously described;n is an integer ranging from 1 to 10;m is an integer ranging from 1 to 10; andeach p and r is independently an integer ranging from 0 to 10.

In some embodiments, a compound of the invention is represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;each R¹ and R² is independently R or R′; or wherein R¹ and R² can bejoined to form an optionally substituted spirocyclic ring;R³ is R″; or wherein R³ is joined with R¹ or R² to form an optionallysubstituted heterocyclic ring;each R is independently hydrogen, methyl, or alkyl, for example loweralkyl;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a natural orunnatural amino acid side chain, an amino acid side-chain mimic,—Z—(S₂)_(n), or —Z—(S_(x))_(n);

-   -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        each R″ is independently hydrogen, alkyl, aryl, substituted        alkyl, substituted aryl, heteroalkyl, substituted heteroalkyl,        acyl, substituted acyl group, polyethylene glycol containing        acyl, polyethylene glycol containing alkyl, or a natural or        unnatural amino acid, an amino acid mimic, —Z—(S₂)_(n), or        —Z—(S_(x))_(n)    -   wherein:    -   Z is a linking moiety;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        R⁴ is hydrogen, methyl, —C(═NR)—NR₂ (where each R is        independently hydrogen or methyl), or a group of formula:

each A₂ independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme;n is an integer ranging from 1 to 10; andr is an integer ranging from 1 to 6.

In some embodiments, a compound of the invention is represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;R¹, R² and R³ can be R′, orR² and R³ can be joined to form an optionally substituted spirocyclicring;R² or R³ can be joined with R¹ to form an optionally substitutedheterocyclic ring;R² or R³ can be joined with R′ to form an optionally substituted ring,orR′ can be joined with a geminal R′ so as to from an optionallysubstituted spirocyclic ring;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a polyethyleneglycol, or polyethylene glycol containing moiety, or a linking moiety Z;or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            each R″ is independently hydrogen, alkyl, aryl, substituted            alkyl, substituted aryl, heteroalkyl, substituted            heteroalkyl, acyl, substituted acyl group, polyethylene            glycol containing acyl, polyethylene glycol containing            alkyl, or a natural or unnatural amino acid, an amino acid            mimic, or —Z—(S₂)_(n), or —Z—(S_(x))_(n)    -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            each A₂ is independently an amino acid side chain or an            amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

Each compound of the invention may contain varying numbers of S₁, S₂, orS₃ subunits as described throughout. In some embodiments, the molarratio of S₁ to S₂ ranges from 1 to 2, from 1 to 4, from 1 to 8, or from1 to 10 S₁ subunits from each S₂ subunit. However, one skilled in theart will recognize that compounds of the invention with different S₁ toS₂ and S₃ ratios can be readily accomplished and are included within thescope of the invention.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is independently a non-opioid releasing GI enzyme substrate or GIenzyme inhibitor;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme; andeach Z is independently a linking moiety.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is independently a non-opioid releasing GI enzyme substrate or GIenzyme inhibitor;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme;each Z is independently a linking moiety;R is cyclopropylmethyl or allyl; andR′ are each or independently hydrogen or methyl.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a GI enzyme;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₃ is an opioid antagonist-releasing moiety;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme;each Z is a linking moiety;

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof.each Z is a linking moiety;

In some embodiments, compounds of the invention are represented by oneof the following structures:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₃ is an opioid antagonist-releasing moiety;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R′ is each or independently hydrogen or methyl.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;A₂ is an amino acid side chain or an amino acid side-chain mimic that iscapable of being recognized by a digestive enzyme; each Z is a linkingmoiety.

In some embodiments, compounds of the invention are represented by oneof the following structures:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;each Z is independently a linking moiety;each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; each R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10; r is each or            independently an integer from 1 to 6; n is an integer from 0            to 10; R′″ is hydrogen, methyl, or        -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or            methyl; or

-   -   -   -   wherein:            -   A₂ is a natural or unnatural amino acid side chain, or                an amino acid side-chain mimic that is capable of being                recognized by a digestive enzyme that directs the                regiospecific hydrolysis of the S₂ substrate prior to                the release of the appended opioid agonist from the S₂                subunit and can be, but is not limited to, the amino                acid side chain of arginine, homoarginine, lysine,                homolysine, ε-N-methyl lysine, ornithine, or                structural/functional mimics thereof; R″ is as defined                above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₃ is an opioid antagonist-releasing moiety;R is cyclopropylmethyl or allyl;each Z is independently a linking moiety;each R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, a polyethyleneglycol, or polyethylene glycol containing moiety, or a linking moiety Z;or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        each A₂ is independently an amino acid side chain or an amino        acid side-chain mimic that is capable of being recognized by a        digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₃ is an opioid antagonist releasing moiety;R is cyclopropylmethyl or allyl;each Z is independently a linking moiety;A₂ is independently an amino acid side chain or an amino acid side-chainmimic that is capable of being recognized by a digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;Each S₁ is a non-opioid releasing GI enzyme substrate or GI enzymeinhibitor subunit;each Z is independently a linking moiety;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            each A₂ is independently an amino acid side chain or an            amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;S₃ is an opioid antagonist releasing moiety;each Z is independently a linking moiety;X is OH or hydrogen;R is cyclopropylmethyl or allyl; andR′ are each or independently hydrogen or methyl.each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, compounds of the invention are represented by oneof the following structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;S₁ is a non-opioid releasing GI enzyme substrate or GI enzyme inhibitorsubunit;Z is a linking moiety;each A₂ is independently an amino acid side chain or an amino acidside-chain mimic that is capable of being recognized by a digestiveenzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In another aspect, a composition of the invention is represented by thefollowing formula:

wherein:S₁ is a non-opioid releasing enzyme substrate or enzyme inhibitor;S₂ is an opioid agonist releasing enzyme substrate;S₃ is an optional opioid antagonist-releasing moiety;M is a covalent scaffold;Z is a linker moiety as previously described;each r, m, n, is independently an integer ranging from 1 to 10, 1 to100, 1 to 1,000, 1 to 100,000, 1 to 1,000,000, or 1 to 1,000,000,000;p is an integer ranging from 0 to 10, 0 to 100, 0 to 1,000, 0 to100,000, 0 to 1,000,000, or 0 to 1,000,000,000.

In some embodiments, M is a carboxymethylcellulose or a functionalizedcellulose derivative, chitosan, or a poly[amino acid].

In some embodiments, a compound of the invention is represented by thestructure:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₃ is an optional opioid antagonist releasing substrate;each R is independently —H or —CH₂COOH;each Z is independently a linking moiety as previously defined;R′ is —OR₁, or —NR₁R₂ where R₁ and R₂ are each or independentlyhydrogen, methyl, lower alkyl, or terminally functionalized polyethyleneglycol;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

In some embodiments, the carboxymethylcellulose polymer scaffold canhave a molecular weight ranging from about 50-1000 kDa. In someembodiments, the scaffold comprises between 100 to 10,000, for examplebetween 300 to 6,000 anhydroglucose subunits. In some embodiments, thescaffold has a degree of substitution of 0.65-0.85 carboxymethyl groupsper anhydroglucose unit, for example resulting in a total of about 100to 6,000 carboxymethyl substituted monomer units. The number of S₁substituted monomer units, n, can be from about 1 to 10, 20, 30, 40, or50% of the total number of carboxymethyl substituted monomer units. Thenumber of S₂ substituted monomer units, m, can be from about 1 to 10,20, 30, 40, or 50% of the total number of carboxymethyl substitutedmonomer units. The number of S₃ substituted monomer units, r, can befrom about 0 to 10, 20, 30, 40, or 50% of the total number ofcarboxymethyl substituted monomer units. The number of R′ substitutedmonomer units, x, can be from about 0 to 10, 20, 30, 40, 50, or 90% ofthe total number of carboxymethyl substituted monomer units. Inpreferred embodiments, covalent linkage of the S₁, S₂, S₃, and R′addends to the defined functional group contained in the monomer unitsof the polymeric scaffold occurs in a regiochemically random fashion,resulting in a random distribution of the S₁, S₂, S₃, and R′ addendsonto the polymer scaffold.

In some embodiments, a compound of the invention is represented by thestructure:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₁ is a non-opioid releasing GI enzyme substrate or GI enzymeinhibitor subunit;each Z is independently a linking moiety as previously defined;R′ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural mimics thereof;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

In some embodiments, the scaffold can have a molecular weight rangingfrom about 30-300 kDa. In some embodiments, the scaffold comprisesbetween about 100 and about 3,000 glucosamine subunits, for exampleabout 150 to about 2,000 glucosamine subunits. The number of S₁substituted monomer units, n, can be from about 1 to 50% of the totalnumber of glucosamine monomer units. The number of S₂ substitutedmonomer units, m, can be from about 1 to 50% of the total number ofglucosamine monomer units. The number of S₃ substituted monomer units,r, can be from about 0 to 50% of the total number of glucosamine monomerunits. The number of R′ substituted monomer units, x, can be from about0 to 90% of the total number of glucosamine monomer units. In preferredembodiments, covalent linkage of the S₁, S₂, S₃, and R′ addends to thedefined functional group contained in the monomer units of the polymericscaffold occurs in a regiochemically random fashion, resulting in arandom distribution of the S₁, S₂, S₃, and R′ addends onto the polymerscaffold.

In some embodiments, a compound of the invention is represented by thestructure:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₃ is an opioid antagonist releasing substrate;each Z is independently a linking moiety as previously defined;R′ is —OR₁, or —NR₁R₂ where R₁ and R₂ are each or independentlyhydrogen, methyl, lower alkyl, terminally functionalized polyethyleneglycol;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

In some embodiments, the scaffold can have a molecular weight rangingfrom about 200-1000 kDa. In some embodiments, the scaffold comprises arange of about 1,000 to 7,000 polyglutamic acid subunits. The number ofS₁ substituted monomer units, n, can be from about 1 to 50% of the totalnumber of polyglutamic acid monomer units. The number of S₂ substitutedmonomer units, m, can be from about 1 to 50% of the total number ofpolyglutamic acid monomer units. The number of S₃ substituted monomerunits, r, can be from about 0 to 50% of the total number of polyglutamicacid monomer units. The number of R′ substituted monomer units, x, canbe from about 0 to 90% of the total number of polyglutamic acid monomerunits. In preferred embodiments, covalent linkage of the S₁, S₂, S₃, andR′ addends to the defined functional group contained in the monomerunits of the polymeric scaffold occurs in a regiochemically randomfashion, resulting in a random distribution of the S₁, S₂, S₃, and R′addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by thestructure:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₃ is an opioid antagonist releasing substrate;each Z is independently a linking moiety as previously defined;R′ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural mimics thereof;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

The starting polylysine polymer can have a molecular weight ranging fromabout 30-300 kDa that contains a range of 150 to 2,000 lysine subunits.The number of S₁ substituted lysine monomer units, n, can be from about1 to 50% of the total number of lysine monomer units. The number of S₂substituted monomer units, m, can be from about 1 to 50% of the totalnumber of lysine monomer units. The number of S₃ substituted monomerunits, r, can be from about 0 to 50% of the total number of lysinemonomer units. The number of R′ substituted monomer units, x, can befrom about 0 to 90% of the total number of lysine monomer units. Inpreferred embodiments, covalent linkage of the S₁, S₂, S₃, and R′addends to the defined functional group contained in the monomer unitsof the polymeric scaffold occurs in a regiochemically random fashion,resulting in a random distribution of the S₁, S₂, S₃, and R′ addendsonto the polymer scaffold.

In some embodiments, a compound of the invention is represented by thestructure:

wherein:each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;each S₂ is independently an opioid agonist releasing GI enzymesubstrate;each S₃ is an opioid antagonist releasing substrate;each Z is independently a linking moiety as previously defined;R is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, an amino acid side chain or an amino acid side-chain structuralmimic;X can be oxygen or nitrogen;R′ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, polyethylene glycol containingalkyl, or one or more amino acids;n is an integer from 1 to 10;m is an integer from 1 to 10;r is an integer from 0 to 10;x is an integer from 0 to 10.

In some embodiments, the polypeptide scaffold can be comprised of arange of 2 to 40 natural or non-natural amino acid monomer units. Thenumber of S₁ substituted monomer units, n, can be from about 1 to 50% ofthe total number of monomer units. The number of S₂ substituted monomerunits, m, can be from about 1 to 50% of the total number of monomerunits. The number of S₃ substituted monomer units, r, can be from about0 to 50% of the total number of monomer units. The number of R′substituted monomer units, x, can be from about 0 to 50% of the totalnumber of monomer units. In preferred embodiments, the S₁, S₂, S₃, andR′ substituted monomer units can be distributed in a regiochemicallyrandom fashion.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;each S₁ is a non-opioid releasing GI enzyme substrate subunit or GIenzyme inhibitor;each S₃ is an opioid antagonist releasing moiety;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof

R′ is H or —CH₂COOH;

W can be oxygen or nitrogen;

R′″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, polyethylene glycol containingalkyl, or one or more amino acids;A₂ is an amino acid side chain, or an amino acid side-chain mimic thatis capable of being recognized by a digestive enzyme; for example, A₂can be the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

In some embodiments, the carboxymethylcellulose scaffold can have amolecular weight ranging from about 50-1000 kDa. In some embodiments,the scaffold comprises a range of 300 to 6,000 anhydroglucose subunits.In some embodiments, the scaffold has a degree of substitution of0.65-0.85 carboxymethyl groups per anhydroglucose unit, resulting in atotal of about 100 to 6,000 carboxymethyl substituted monomer units. Thenumber of substituted monomer units, n, can be from about 1 to 50% ofthe total number of carboxymethyl substituted monomer units. The numberof substituted monomer units, m, can be from about 1 to 50% of the totalnumber of carboxymethyl substituted monomer units. The number ofsubstituted monomer units, r, can be from about 0 to 50% of the totalnumber of carboxymethyl substituted monomer units. The number ofsubstituted monomer units, x, can be from about 0 to 90% of the totalnumber of carboxymethyl substituted monomer units. In preferredembodiments, covalent linkage of the defined addends to the monomerunits of the polymeric scaffold occurs in a regiochemically randomfashion, resulting in a random distribution of the addends onto thepolymer scaffold.

In some embodiments, a compound of the invention is represented by thestructure:

wherein:

R′═H or —CH₂COOH.

R is cyclopropylmethyl or allyl,X is OH or hydrogen;each Z is independently a linking moiety as previously defined;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or —Z—(S₂)_(n), or —Z(S_(x))_(n)

-   -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            n is an integer such that n/(m+n+r+x) is between 0.01 and            0.5;            m is an integer such that m/(m+n+r+x) is between 0.01 and            0.5;            r is an integer such that r/(m+n+r+x) is between 0 and 0.5;            x is an integer such that x/(m+n+r+x) is between 0 and 0.9;            A₂ is independently an amino acid side chain or an amino            acid side-chain mimic that is capable of being recognized by            a digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

The carboxymethylcellulose scaffold can have a molecular weight rangingfrom about 50-1000 kDa. In some embodiments, the scaffold comprises arange of 300 to 6,000 anhydroglucose subunits. In some embodiments, thescaffold has a degree of substitution of 0.65-0.85 carboxymethyl groupsper anhydroglucose unit, resulting in a total of about 100 to 6,000carboxymethyl substituted monomer units. The number of substitutedmonomer units, n, can be from about 1 to 50% of the total number ofcarboxymethyl substituted monomer units. The number of substitutedmonomer units, m, can be from about 1 to 50% of the total number ofcarboxymethyl substituted monomer units. The number of substitutedmonomer units, r, can be from about 0 to 50% of the total number ofcarboxymethyl substituted monomer units. The number of R″ substitutedmonomer units, x, can be from about 0 to 90% of the total number ofcarboxymethyl substituted monomer units. In preferred embodiments,covalent linkage of the Z, and R″ addends to the defined functionalgroup contained in the monomer units of the polymeric scaffold occurs ina regiochemically random fashion, resulting in a random distribution ofthe addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;S₃ is an opioid antagonist-releasing moiety;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereofR′ is each or independently hydrogen or methyl;A₂ is an amino acid side chain, or an amino acid side-chain mimic thatis capable of being recognized by a digestive enzyme; for example, A₂can be the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

The chitosan scaffold can have a molecular weight ranging from about30-300 kDa that contains a range of 150 to 2,000 glucosamine subunits.The number of substituted monomer units, n, can be from about 1 to 50%of the total number of glucosamine monomer units. The number ofsubstituted monomer units, m, can be from about 1 to 50% of the totalnumber of glucosamine monomer units. The number of substituted monomerunits, r, can be from about 0 to 50% of the total number of glucosaminemonomer units. The number of R″ substituted monomer units, x, can befrom about 0 to 90% of the total number of glucosamine monomer units. Inpreferred embodiments, covalent linkage of the S₁, S₂, S₃, and R″addends to the defined functional group contained in the monomer unitsof the polymeric scaffold occurs in a regiochemically random fashion,resulting in a random distribution of the addends onto the polymerscaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:R′ are each of independently hydrogen or methyl,R is cyclopropylmethyl or allyl;each Z is independently a linking moiety as previously defined;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or —Z—(S₂), or —Z(S_(x))_(n)

-   -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;        m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;        r is an integer such that r/(m+n+r+x) is between 0 and 0.5;        x is an integer such that x/(m+n+r+x) is between 0 and 0.9;        A₂ is independently an amino acid side chain or an amino acid        side-chain mimic that is capable of being recognized by a        digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            and        -   R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

The chitosan scaffold polymer can have a molecular weight ranging fromabout 30-300 kDa that contains a range of 150 to 2,000 glucosaminesubunits. The number of substituted monomer units, n, can be from about1 to 50% of the total number of glucosamine monomer units. The number ofsubstituted monomer units, m, can be from about 1 to 50% of the totalnumber of glucosamine monomer units. The number of substituted monomerunits, r, can be from about 0 to 50% of the total number of glucosaminemonomer units. The number of R″ substituted monomer units, x, can befrom about 0 to 90% of the total number of glucosamine monomer units. R′are each or independently hydrogen or methyl. In preferred embodiments,covalent linkage of the Z, and R″ addends to the defined functionalgroup contained in the monomer units of the polymeric scaffold occurs ina regiochemically random fashion, resulting in a random distribution ofthe addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;each S₁ is independently a non-opioid releasing GI enzyme substrate orGI enzyme inhibitor;S₃ is an opioid antagonist releasing moiety;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof;A₂ is an amino acid side chain, or an amino acid side-chain mimic thatis capable of being recognized by a digestive enzyme; for example, A₂can be the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof;n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;r is an integer such that r/(m+n+r+x) is between 0 and 0.5;x is an integer such that x/(m+n+r+x) is between 0 and 0.9.

The polyglutamic acid polymer can have a molecular weight ranging fromabout 200-1000 kDa that contains a range of about 1000 to 7,000polyglutamic acid subunits. The number of substituted monomer units, n,can be from about 1 to 50% of the total number of polyglutamic acidmonomer units. The number of substituted monomer units, m, can be fromabout 1 to 50% of the total number of polyglutamic acid monomer units.The number of substituted monomer units, r, can be from about 0 to 50%of the total number of polyglutamic acid monomer units. The number of R″substituted monomer units, x, can be from about 0 to 90% of the totalnumber of polyglutamic acid monomer units. In preferred embodiments,covalent linkage of the Z and R″ addends to the defined functional groupcontained in the monomer units of the polymeric scaffold occurs in aregiochemically random fashion, resulting in a random distribution ofthe addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:X is OH or hydrogen;each Z is independently a linking moiety as previously defined;W is hydrogen or —OH; X′ is —OH, —OR″ or —NH₂, or —NHR″, or —N(R″)₂

-   -   R is cyclopropylmethyl or allyl;        R″ is independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)—, or Z—(S_(x))_(m)    -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);    -   n is an integer ranging from 1-10;        n is an integer such that n/(m+n+r+x) is between 0.01 and 0.5;        m is an integer such that m/(m+n+r+x) is between 0.01 and 0.5;        r is an integer such that r/(m+n+r+x) is between 0 and 0.5;        x is an integer such that x/(m+n+r+x) is between 0 and 0.9;        A₂ is independently an amino acid side chain or an amino acid        side-chain mimic that is capable of being recognized by a        digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            and        -   R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

The polyglutamic acid polymer can have a molecular weight ranging fromabout 200-1000 kDa that contains a range of about 1000 to 7,000polyglutamic acid subunits. The number of substituted monomer units, n,can be from about 1 to 50% of the total number of polyglutamic acidmonomer units. The number of substituted monomer units, m, can be fromabout 1 to 50% of the total number of polyglutamic acid monomer units.The number of substituted monomer units, r, can be from about 0 to 50%of the total number of polyglutamic acid monomer units. The number of R″substituted monomer units, x, can be from about 0 to 90% of the totalnumber of polyglutamic acid monomer units. In preferred embodiments,covalent linkage of the Z and R″ addends to the defined functional groupcontained in the monomer units of the polymeric scaffold occurs in aregiochemically random fashion, resulting in a random distribution ofthe addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:each Z is independently a linking moiety as previously defined;R′ are each or independently hydrogen or methyl;X is hydrogen or —OH;R is cyclopropylmethyl or allyl;R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            n is an integer such that n/(m+n+r+x) is between 0.01 and            0.5;            m is an integer such that m/(m+n+r+x) is between 0.01 and            0.5;            r is an integer such that r/(m+n+r+x) is between 0 and 0.5;            x is an integer such that x/(m+n+r+x) is between 0 and 0.9;            A₂ is independently an amino acid side chain or an amino            acid side-chain mimic that is capable of being recognized by            a digestive enzyme;

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, ε-N-methyl lysine,ornithine, or structural/functional mimics thereof.

The polylysine scaffold can have a molecular weight ranging from about30-300 kDa that contains a range of 150 to 2,000 lysine subunits. Thenumber of substituted lysine monomer units, n, can be from about 1 to50% of the total number of lysine monomer units. The number ofsubstituted monomer units, m, can be from about 1 to 50% of the totalnumber of lysine monomer units. The number of substituted monomer units,r, can be from about 0 to 50% of the total number of lysine monomerunits. The number of R″ substituted monomer units, x, can be from about0 to 90% of the total number of lysine monomer units. In preferredembodiments, covalent linkage of the Z and R″ addends to the definedfunctional group contained in the monomer units of the polymericscaffold occurs in a regiochemically random fashion, resulting in arandom distribution of the addends onto the polymer scaffold.

In some embodiments, a compound of the invention is represented by oneof the structures:

Wherein:

D is an opioid agonist, for example wherein D is a morphone, a codone,or morphine;X is OH or hydrogen;each S₁ is a non-opioid releasing GI enzyme substrate or GI enzymeinhibitor subunit;S₃ is an opioid antagonist releasing moiety;R is cyclopropylmethyl or allyl;each Z is a linking moiety;R″ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, or one or more amino acids or structural or functional mimicsthereof;R′ is hydrogen, alkyl, aryl, substituted alkyl, substituted aryl,heteroalkyl, substituted heteroalkyl, acyl, substituted acyl group,polyethylene glycol containing acyl, polyethylene glycol containingalkyl, an amino acid side chain or an amino acid side-chain structuralmimic;W is OH, O-alkyl, NH₂, NHR″, or N(R″)₂;A₂ is an amino acid side chain, or an amino acid side-chain mimic thatis capable of being recognized by a digestive enzyme; for example, A₂can be the amino acid side chain of arginine, homoarginine, lysine,homolysine, ε-N-methyl lysine, ornithine, or structural/functionalmimics thereof;n is an integer from 1 to 10;m is an integer from 1 to 10;r is an integer from 0 to 10;x is an integer from 0 to 10.

In some embodiments, the polypeptide scaffold can be comprised of arange of 2 to 40 natural or unnatural amino acid monomer units. Thenumber of substituted monomer units, n, can be from about 1 to 50% ofthe total number of monomer units. The number of substituted monomerunits, m, can be from about 1 to 50% of the total number of monomerunits. The number of substituted monomer units, r, can be from about 0to 50% of the total number of monomer units. The number of R′substituted monomer units, x, can be from about 0 to 50% of the totalnumber of monomer units. All possible regiochemical distributions of theZ and R′ containing addends on the peptide backbone are covered withinthe scope of the invention.

In some embodiments, a compound of the invention is represented by oneof the structures:

wherein:each Z is independently a linking moiety as previously defined;X is hydrogen or —OH;R is cyclopropylmethyl or allyl;R′ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or Z, a linker moiety as previously defined;each R″ is independently hydrogen, alkyl, aryl, substituted alkyl,substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,substituted acyl group, polyethylene glycol containing acyl,polyethylene glycol containing alkyl, or a natural or unnatural aminoacid, an amino acid mimic, or —Z—(S₂)_(n), or —Z—(S_(x))_(n)

-   -   wherein:    -   Z is a linker moiety as previously defined;    -   each x is independently 1 or 3 (thereby designating each S_(x)        as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;            A₂ is independently an amino acid side chain or an amino            acid side-chain mimic that is capable of being recognized by            a digestive enzyme.

In some embodiments A₂ can be:

-   -   wherein:    -   R is each or independently hydrogen or methyl; R″ is        independently hydrogen, alkyl, aryl, substituted alkyl,        substituted aryl, heteroalkyl, substituted heteroalkyl, acyl,        substituted acyl group, polyethylene glycol containing acyl,        polyethylene glycol containing alkyl, or a natural or unnatural        amino acid, an amino acid mimic, or —Z—(S₂)_(n), or        —Z—(S_(x))_(n)        -   wherein:        -   Z is a linker moiety as previously defined;        -   each x is independently 1 or 3 (thereby designating each            S_(x) as a S₁ or S₃ subunit);        -   n is an integer ranging from 1-10;    -   r is each or independently an integer from 1 to 6;    -   n is an integer from 0 to 10;    -   R′″ is hydrogen, methyl, or    -   —C(═NR)—NR₂ wherein R is each or independently hydrogen or        methyl; or

-   -   -   wherein A₂ is a natural or unnatural amino acid side chain,            or an amino acid side-chain mimic that is capable of being            recognized by a digestive enzyme that directs the            regiospecific hydrolysis of the S₂ substrate prior to the            release of the appended opioid agonist from the S₂ subunit            and can be, but is not limited to, the amino acid side chain            of arginine, homoarginine, lysine, homolysine, ε-N-methyl            lysine, ornithine, or structural/functional mimics thereof;            R″ is as defined above.

In some embodiments, A₂ directs the regiospecific hydrolysis of the S₂substrate prior to the release of the appended opioid agonist from theS₂ subunit. In some embodiments, A₂ is the amino acid side chain ofarginine, homoarginine, lysine, homolysine, s-N-methyl lysine,ornithine, or structural/functional mimics thereof.

In some embodiments, the polypeptide scaffold can be comprised of arange of 2 to 20 natural or unnatural amino acid monomer units. Thenumber of substituted monomer units, n, can be from about 1 to 50% ofthe total number of monomer units. The number of substituted monomerunits, m, can be from about 1 to 50% of the total number of monomerunits. The number of substituted monomer units, r, can be from about 0to 50% of the total number of monomer units. The number of R′substituted monomer units, x, can be from about 0 to 50% of the totalnumber of monomer units. All possible regiochemical distributions of theZ and R′ addends on the peptide backbone are covered within the scope ofthe invention.

In certain embodiments, the specification provides compounds wherein anopioid agonist is bound covalently to a GI enzyme inhibitor or substrateto attenuate the effects of the opioid agonist. The opioid agonist maybe covalently bound to the GI enzyme inhibitor through a scaffold suchas an optionally substituted alkyl or optionally substituted heteroalkylscaffold. In certain embodiments, said scaffold includes from 1 to 100atoms, such as from about 5 to 50 atoms. In certain embodiments, thescaffold is absent and the opioid agonist is bound directly to a GIenzyme inhibitor. In certain embodiments, a compound of the disclosureis represented by the structure of Formula (I):

[R¹-L¹_(n)QL²-R²]_(m)  (I)

or a salt thereof, wherein:

Q is independently selected from optionally substituted heteroalkyl andoptionally substituted alkyl;

L¹ is independently at each occurrence absent or a cleavable ornon-cleavable linker;

L² is independently at each occurrence absent or a cleavable ornon-cleavable linker;

R¹ is independently selected at each occurrence from a GI enzymesubstrate, a GI enzyme inhibitor,

R² is an opioid agonist covalently bound to a GI enzyme substrate; and

m and n are independently selected at each occurrence from 1 to1,000,000.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted heteroalkyl group.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted peptide.

In certain embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted heteroalkyl group. Heteroalkyl includes an alkylchain that is interrupted by one or more heteroatoms, such as O, N, orS. Heteroalkyl chains can include form about 4 to about 100 atoms. Aheteroalkyl chain may be optionally substituted by one or moresubstitutent. In certain embodiments, heteroalkyl is a peptide such as-ala-gly- or -arg-ala-.

In some embodiments, for the compound or salt of Formula (I), Q is anoptionally substituted peptide with from 1 to 500 amino acids. In someembodiments, for the compound or salt of Formula (I), Q is an optionallysubstituted peptide with from 1 to 50 amino acids. In some embodiments,for the compound or salt of Formula (I), Q is an optionally substitutedpeptide with from 1 to 10 amino acids. In some embodiments, for thecompound or salt of Formula (I), Q is an optionally substituted peptidewith from 1 to 3 amino acids.

In some embodiments, a compound or salt of Formula (I) is represented bya structure of Formula (IA), (IB), or (IC):

wherein W is selected from hydrogen, optionally substituted alkyl,optionally substituted acyl, and optionally substituted alkoxycarbonyl.

In some embodiments, a compound or salt of Formula (I) is represented bya structure of Formula (ID), (IE), or (IF):

In some embodiments, the compound or salt, wherein R¹ is independentlyselected at each occurrence from a GI enzyme inhibitor. In someembodiments, for the compound or salt of Formula (I), R¹ at eachoccurrence is a serine protease inhibitor. In some embodiments, for thecompound or salt of Formula (I), Q at each occurrence is a trypsininhibitor.

In some embodiments, for the compound or salt of Formula (I), R¹-L¹ isindependently selected at each occurrence from:

wherein:

Y is independently selected from an amidine, guanidine, benzylamine,alkyl substituted amidine, alkyl substituted guanidine, alkylsubstituted benzylamine, benzylguanidine, alkyl substitutedbenzylamidine, or alkyl substituted benzyl; and

Z is independently selected from hydrogen, cyano, nitro, halogen, alkyland alkoxy.

In some embodiments, for the compound or salt of Formula (I), Y isamidine.

In some embodiments, for the compound or salt of Formula (I), R¹-L¹ isrepresented by the formula:

In some embodiments, for the compound or salt of Formula (I), L¹ at eachoccurrence is selected from a cleavable or non-cleavable linkerincluding from 2 to 15 atoms.

In some embodiments, for the compound or salt of Formula (I), L¹ is—O—CH²⁻CH₂—NH— or —O—CH²⁻CH₂—O—.

In some embodiments, for the compound or salt of Formula (I), n isselected from 1 to 20. In some embodiments, for the compound or salt ofFormula (I), n is selected from 1 to 10. In some embodiments, for thecompound or salt of Formula (I), n is selected from 1 to 3.

In some embodiments, for the compound or salt of Formula (I), R²-L² isindependently selected at each occurrence from:

wherein:

D is an opioid agonist;

R¹⁰¹ and R¹⁰² are independently selected from optionally substitutedalkyl, an amino acid side chain and an amino acid side-chain mimic.

The term “substituted” refers to moieties having substituents replacinga hydrogen on one or more carbons or substitutable heteroatoms, e.g.,NH, of the structure. It will be understood that “substitution” or“substituted with” includes the implicit proviso that such substitutionis in accordance with permitted valence of the substituted atom and thesubstituent, and that the substitution results in a stable compound,i.e., a compound which does not spontaneously undergo transformationsuch as by rearrangement, cyclization, elimination, etc. In certainembodiments, substituted refers to moieties having substituentsreplacing two hydrogen atoms on the same carbon atom, such assubstituting the two hydrogen atoms on a single carbon with an oxo,imino or thioxo group. As used herein, the term “substituted” iscontemplated to include all permissible substituents of organiccompounds. In a broad aspect, the permissible substituents includeacyclic and cyclic, branched and unbranched, carbocyclic andheterocyclic, aromatic and non-aromatic substituents of organiccompounds. The permissible substituents can be one or more and the sameor different for appropriate organic compounds. For purposes of thisdisclosure, the heteroatoms such as nitrogen may have hydrogensubstituents and/or any permissible substituents of organic compoundsdescribed herein which satisfy the valences of the heteroatoms.

In some embodiments, substituents may include any substituents describedherein, for example: halogen, hydroxy, oxo (═O), thioxo (═S), cyano(—CN), nitro (—NO₂), imino (═N—H), oximo (═N—OH), hydrazino (═N—

NH₂), —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)R^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a) (where t is 1 or 2), and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2); and alkyl, alkenyl,alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl,cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl,and heteroarylalkyl any of which may be optionally substituted by alkyl,alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo(═O), thioxo (═S), cyano (—CN), nitro (—NO₂), imino (═N—H), oximo(═N—OH), hydrazine (═N—NH₂), —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)R^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2); wherein each R^(a) isindependently selected from hydrogen, alkyl, cycloalkyl,cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl,heteroaryl, or heteroarylalkyl, wherein each R^(a), valence permitting,may be optionally substituted with alkyl, alkenyl, alkynyl, halogen,haloalkyl, haloalkenyl, haloalkynyl, oxo (═O), thioxo (═S), cyano (—CN),nitro (—NO₂), imino (═N—H), oximo (═N—OH), hydrazine (═N—NH₂), —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)R^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2); and wherein each R^(b) isindependently selected from a direct bond or a straight or branchedalkylene, alkenylene, or alkynylene chain, and each R^(c) is a straightor branched alkylene, alkenylene or alkynylene chain.

In certain embodiments, a linker L¹ or L² is selected from a linker thatis cleavable in vitro or in vivo. Cleavable linkers may includechemically or enzymatically unstable or degradable linkages. Cleavablelinkers described herein rely on gastrointestinal processes, such asexposure to acidic conditions and exposure to GI enzymes to cleave thelinkers. Cleavable linkers generally incorporate one or more chemicalbonds that are either chemically or enzymatically cleavable while theremainder of the linker is noncleavable.

In certain embodiments, a linker L¹ or L² is selected from non-cleavablelinkers. In certain embodiments, noncleavable linkers are not cleaved bythe gastrointestinal processes. Exemplary linkers of the disclosureinclude:

wherein:each F is independently:

wherein:

-   -   each R is independently hydrogen, methyl, lower alkyl, aryl, or        arylalkyl;    -   X can be carbon, oxygen, or nitrogen;        L can be linear, branched, or a multivalent scaffold comprised        of alkyl, aryl, substituted alkyl, substituted aryl,        heteroalkyl, substituted heteroalkyl, polyalkylene glycol,        polypeptide, polyamide, polycarbamate, polyurea, polycarbonate,        or a combination thereof.

Preparation of Compounds of the Invention

Compounds of the invention can be synthesized using techniques andmaterials known to those of skill in the art, such as described, forexample, in Smith and March, MARCH'S ADVANCED ORGANIC CHEMISTRY:Reactions, Mechanisms, and Structure, Fifth Edition,(Wiley-Interscience, 2001), Vogel, A TEXTBOOK OF PRACTICAL ORGANICCHEMISTRY, Including Qualitative Organic Analysis, Fourth Edition, NewYork, (Longman, 1978), Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY3^(rd) Ed., Vols. A and B (Plenum 1992), and Green and Wuts, PROTECTIVEGROUPS IN ORGANIC SYNTHESIS 2^(nd) Ed. (Wiley 1991). Starting materialsfor the compounds of the invention can be obtained using standardtechniques and commercially available precursor materials, such as thoseavailable from Aldrich Chemical Co. (Milwaukee, Wis.), Sigma ChemicalCo. (St. Louis, Mo.), Lancaster Synthesis (Ward Hill, Mass.), ApinChemicals, Ltd. (New Brunswick, N.J.), Ryan Scientific (Columbia, S.C.),Maybridge (Cornwall, England) and Trans World Chemicals (Rockville,Md.).

The procedures described herein for synthesizing the compounds of theinvention can include one or more steps of protection and deprotection(e.g., the formation and removal of suitable protecting groups). Inaddition, the synthetic procedures disclosed below can include variouspurifications, such as column chromatography, flash chromatography,thin-layer chromatography (TLC), recrystallization, distillation,high-pressure liquid chromatography (HPLC), dialysis, size-exclusionchromatography, and the like. Also, various techniques well known in thechemical arts for the identification and quantification of chemicalreaction products, such as proton and carbon-13 nuclear magneticresonance (¹H and ¹³C NMR), infrared and ultraviolet spectroscopy (IRand UV), X-ray crystallography, elemental analysis (EA), HPLC and massspectroscopy (MS), and multi-angle light scattering (MALS) can be usedas well. Methods of protection and deprotection, purification andidentification and quantification are well known in the chemical arts.

In some embodiments, the synthetic methods use polymeric scaffoldshaving multiple repeating functional groups, where the functional groupscan react with a complementary functional Z group on the S₁, S₂ or S₃substrate subunits thereby providing a covalently-bonded unimolecularpolysubstrate construct. The functional groups of the polymer scaffoldcan be, for example, a carboxylic acid, an ester, an aldehyde, analcohol, an amine, an isocyanate, an epoxide, and the like.

Compounds of the invention can be collected and purified using methodsknown in the art. In general, compound of the invention as describedherein can be purified by any of the means known in the art, includingchromatographic means, such as high performance liquid chromatography(HPLC), preparative thin layer chromatography, flash columnchromatography and ion exchange chromatography, size exclusionchromatography. Any suitable stationary phase can be used, includingnormal and reversed phases as well as ionic resins. See, e.g.,Introduction to Modern Liquid Chromatography, 2nd Edition, ed. L. R.Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin LayerChromatography, ed E. Stahl, Springer-Verlag, New York, 1969.

Compound of the invention described herein can contain one or morechiral centers and/or double bonds and therefore, can exist asstereoisomers, such as double-bond isomers (i.e., geometric isomers),enantiomers or diastereomers. Accordingly, all possible enantiomers andstereoisomers of compound of the invention including thestereoisomerically pure forms (e.g., geometrically pure,enantiomerically pure or diastereomerically pure) and enantiomeric orstereoisomeric mixtures are included in the description of compound ofthe invention described herein. Enantiomeric and stereoisomeric mixturescan be resolved into their component enantiomers or stereoisomers usingseparation techniques or chiral synthesis techniques well known to theskilled artisan. The compounds can also exist in several tautomericforms including the enol form, the keto form and mixtures thereof.Accordingly, the chemical structures depicted herein encompass allpossible tautomeric forms of the illustrated compounds. The compoundsdescribed also include isotopically labeled compounds where one or moreatoms have an atomic mass different from the atomic mass conventionallyfound in nature. Examples of isotopes that can be incorporated into thecompounds disclosed herein include, but are not limited to, ²H, ³H, ¹¹C,¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, etc. Compounds can exist in unsolvated forms aswell as solvated forms, including hydrated forms. In general, compoundscan be hydrated or solvated. Certain compounds can exist in multiplecrystalline or amorphous forms. In general, all physical forms areequivalent for the uses contemplated herein and are intended to bewithin the scope of the present disclosure.

Representative synthetic routes useful for the preparation of exemplarycompounds of the invention are depicted below in the following schemes.

Specific synthetic routes used for the preparation of exemplarycompounds of the invention are depicted below in the following schemes.

Preparation of Compound B

2-Bromo isonicotinic acid (20.2 g, 100 mmol) was dissolved in DMF (500mL) at ambient temperature. Cs₂CO₃ (32.6 g, 100 mmol) was added in oneportion, followed by MeI (6.3 mL, 100 mmol). The mixture was stirred atambient temperature for 15 h, followed by the addition of water (500mL). The mixture was extracted with EtOAc (500 mL). The organic layerwas washed with water (500 mL), brine (500 mL) and then dried overNa₂SO₄. The organic layer was then filtered and concentrated to give awhite solid (18.3 g, 84.7 mmol). LC-MS: [M+H] 217.1 (CH₆BrNO₂+H, calc:216.1). The crude product was used directly without furtherpurification.

The crude product of the previous reaction was dissolved in DMF (100mL), followed by the addition of Zn(CN)₂ (3.42 g, 29.11 mmol) in oneportion. The mixture was degassed using nitrogen and then Pd(PPh₃)₄(2.82 g) was added. The mixture was degassed again and then heated in anoil bath (120° C.). After 2.5 h, the reaction was cooled to ambienttemperature and water (120 mL) was added. The mixture was stirred for 30min and then filtered through a frit. The solid collected was washedwith water (2×60 mL) and then dried under vacuum to give an off-whitesolid (5.2 g, 32.6 mmol). LC-MS: [M+H] 163.3 (C₈H₆N₂O₂+H, calc: 163.1).The crude product was used directly without further purification.

The crude product of the previous reaction (8.0 g, 49.36 mmol) wasdissolved in EtOH (200 mL). Pd/5% on barium sulfate (2.4 g) and 4N HCl(in 1,4-Dioxane; 20 mL) was added to the reaction mixture. The mixturewas hydrogenated at 55 psi for 4 h on a Parr hydrogenator. The mixturewas then filtered through a celite pad and then the celite pad waswashed with MeOH (3×50 mL). The combined filtrate was then concentratedand the residue was partitioned between EtOAc (120 mL) and water (50mL). The organic layer was washed with 10% citric acid (20 mL) and brine(20 mL), followed by drying over Na₂SO₄. Next the mixture was filteredand concentrated to afford compound B in 86% yield (10.5 g, 40.2 mmol).LC-MS: [M+H] 266.7 (C₁₃H₁₈N₂O₄+H, calc: 266.1). Compound B was useddirectly without further purification.

Preparation of Compound C

To a solution of Boc-Arg(Pbf)-OH (6.31 g, 12.0 mmol), Compound B (2.30g, 11.4 mmol) and HATU (4.43 g, 12.56 mmol) in DMF (120 mL) at 5° C. wasadded DIPEA (8.0 mL, 45.66 mmol) dropwise over 5 min. The temperature ofthe reaction mixture was raised to ambient temperature and stirring wascontinued for an additional hour. Upon reaction completion, DMF wasremoved under vacuum and the reaction mixture was then diluted DCM. Theorganic layer was washed with 1N HCl, saturated NaHCO₃, brine and thendried over MgSO₄. The organic layer was then filtered and condensed toafford an off-white solid. (7.18 g, 10.6 mmol) LC-MS: [M+H] 675.9(C₃₂H₄₆N₆O₈S+H, calc: 675.41). The crude product was used directlywithout further purification.

The crude product of the previous reaction (7.0 g, 10.36 mmol) wasdissolved in DCM (50 mL) was treated with 4 M solution of hydrogenchloride in 1,4-dioxane (50 mL). After 1 h, solvent was removed undervacuum until about ˜50 mL remained. Diethyl ether (˜500 mL) was added tothe reaction mixture, which produced a fine white precipitate. Theprecipitate was filtered off, washed with ether (3×150 mL) and driedunder vacuum to give a fine white solid. (6.42 g, 9.9 mmol) LC-MS: [M+H]575.7 (C₂₇H₃₈N₆O₆S+H, calc: 575.26). The crude product was used directlywithout further purification.

The crude product of the previous reaction (6.2 g, 9.6 mmol) wasdissolved in DMF and to the solution was added SuO-Gly-NAc (2.05 g, 9.6mmol) at 5° C. was added DIPEA (5.2 mL, 30 mmol) dropwise over 5 min.The temperature of the reaction mixture was raised to ambienttemperature and stirring was continued for an additional hour. Uponreaction completion, DMF was removed in high vacuum, and the reactionmixture was diluted with DCM (200 mL), washed with 1 N HCl (300 mL),then with sat NaHCO₃ (300 mL) and brine (500 mL). The organic phase wasdried over Na₂SO₄, filtered and the solvent was evaporated. The oilyproduct was dried under high vacuum overnight to afford compound C in92.1% yield (5.93 g, 8.8 mmol) as a yellow oil. LC-MS: [M+H] 674.7(C₃₁H₄₃N₇O₈S+H, calc: 674.29).

Preparation of Compound D

To a solution of compound C (4.40 g, 6.53 mmol) in MeOH (50 mL) wasadded, under nitrogen, 10% Pd/C (250 mg), 10% Pt/C (200 mg) and1,1,2-trichloroethane (729 mL, 7.8 mmol, 1.2 eq). The reaction mixturewas stirred at 65 psi overnight. Upon completion, the reaction mixturewas filtered through a Celite-padded glass frit and washed with MeOH(3×20 mL). The filtrate was concentrated under vacuum to the volume ˜10mL and diethyl ether (300 mL) was added. The resulting fine whiteprecipitate was filtered, washed with ether (2×100 mL) and dried underhigh vacuum. This afforded an off-white solid (3.78 g, 81%). LC-MS:[M+H] 680.6 (C₃₁H₄₉N₇O₈S+H, calc: 680.3). The crude product was useddirectly without further purification.

The crude product of the previous reaction (3.5 g, 4.89 mmol) wasdissolved in ethanol (100 mL) followed by the addition of a Boc₂O (1.07g, 4.89). The reaction mixture was stirred at ambient temperature for 1h. Next, the reaction mixture evaporated under vacuum to provide a thicklight yellow oil (3.8 g, 4.86 mmol, 99%). LC-MS [M+H] 780.7(C₃₆H₅₇N₇O₁₀S+H, calc: 780.4). The crude product was used directlywithout further purification.

The crude product of the previous reaction (3.8 g, 4.86 mmol) inmethanol (75 mL) at 5° C. was added aqueous solution of LiOH (0.29 g, 12mmol) in water (20 mL). The temperature of the reaction mixture wasraised to ambient temperature and stirring was continued for anadditional 4 h. Upon the reaction completion, the reaction mixture wasneutralized with 1N HCl to pH ˜7.0. Next, the methanol was evaporatedunder vacuum to afford an oily liquid, which was dried under high vacuumto give compound D in 79.9% yield (2.98 g, 3.88 mmol). LC-MS, [M+H]766.8 (C₃₅H₅₅N₇O₁₀S+H, calc: 766.4).

Preparation of Compound F

A solution of compound E (Mesylate salt, 10.0 g, 35.5 mmol),4-(2-((tert-butoxycarbonyl)amine)ethoxy) benzoic acid (10.0 g, 35.5mmol) and DCC (11.0 g, 53.3 mmol) in pyridine (100 mL) was stirredovernight. Solvent was evaporated in vacuo. The residue was thendissolved in 4N hydrogen chloride in 1,4-dioxane (100 mL). After 1 h,solvent was removed under vacuum until about ˜50 mL remained. Diethylether (˜500 mL) was added to the reaction mixture, which produced anoff-white/light tan precipitate. The precipitate was filtered off,washed with ether (3×150 mL) and dried under vacuum to give an off-whitesolid. The crude product triturated in acetone, followed by triturationin MTBE, filtered and dried to afford an off-white/light tan precipitate(11.1 g, 74%). LC-MS, [M+H] 350.4 (C₂₀H₁₉N₃O₃+H, calc: 350.1). The crudeproduct was used without additional purification.

The crude product of the previous reaction (10.0 g, 24.2 mmol) wasdissolved in DMF and to the solution was added SuO-Lys(Boc)-NCBZ (11.6g, 24.2 mmol) at 5° C. was added DIPEA (17.4 mL, 100 mmol) dropwise over5 min. The temperature of the reaction mixture was raised to ambienttemperature and stirring was continued for an additional hour. Uponreaction completion, DMF was removed under high vacuum, and the reactionmixture was diluted with DCM (300 mL), washed with 1N HCl (500 mL), thenwith sat. NaHCO₃ (500 mL) and brine (750 mL). The organic phase wasdried over MgSO₄, filtered and the solvent was evaporated. The oilyproduct was dissolved in 4N hydrogen chloride in 1,4-dioxane (50 mL).After 1 h, solvent was removed under vacuum until about ˜10 mL remained.Diethyl ether (˜500 mL) was added to the reaction mixture, whichproduced an off-white/light tan precipitate. The precipitate wasfiltered off, washed with ether (3×150 mL) and dried under vacuum togive compound F (15.04 g, 91%). LC-MS, [M+H] 611.7 (C₃₄H₃₇N₅O₆+H, calc:611.3). The crude product was used without additional purification.

Preparation of Compound G

To a solution of Compound F (1.96 g, 2.86 mmol), Compound D (2.19 g,2.86 mmol) and HATU (1.30 g, 3.43 mmol) in DMF (200 mL) at −20 OC wasadded NMM (0.94 mL, 9 mmol) dropwise over 5 min. The temperature of thereaction mixture was raised to ambient temperature and stirring wascontinued for an additional hour. Upon reaction completion, DMF wasremoved under vacuum and the reaction mixture was then diluted DCM. Theorganic layer was washed with 1N HCl, saturated NaHCO₃, brine and thendried over MgSO4. The organic layer was then filtered and condensed toafford an off-white solid. (4.11 g) LC-MS: [M+H] 1360.0(C₆₉H₉₀N₁₂O₁₅S+H, calc: 1359.6). The crude product was dissolved in 4Nhydrogen chloride in 1,4-dioxane (50 mL). After 1 h, solvent was removedunder vacuum until about ˜10 mL remained. Diethyl ether (˜500 mL) wasadded to the reaction mixture, which produced an off-white/light tanprecipitate. The precipitate was filtered off, washed with ether (3×150mL) and dried under vacuum to give a solid (Compound F′) (3.12 g, 82%).LC-MS, [M+H] 1259.9 (C₆₄H₈₂N₁₂O₁₃S+H, calc: 1259.6). The crude product(Compound F′) was used directly without further purification.

Preparation of Activated Hydrocodone

A solution of hydrocodone-free base (7.6 g, 25.36 mmol) in THF (200 mL)was cooled to −78° C. and then 0.5 M toluene solution of KHMDS (50.7 mL,25.36 mmol) was added dropwise over 5 min under nitrogen. The reactionmixture was stirred for 30 min, and then added to a solution of4-nitrophenyl chloroformate (5.1 g, 25.4 mmol) in THF (100 mL) dropwiseover 5 min under nitrogen and cooling with dry ice/acetone. Uponcompletion, 2 M HCl in diethyl ether (100 mL) and ether (400 mL) wasadded dropwise to the reaction mixture to produce a fine whiteprecipitate. The precipitate was filtered on a glass frit and washedwith ether (3×200 mL). The solid was dried under high vacuum overnight,then dissolved in 5% aq KH₂PO₄ solution (800 mL) and extracted with DCM(2×200 mL). The organic phase was dried over Na₂SO₄ (anh.), filtered,and the solvent was concentrated under vacuum to the volume ˜10 mL. Tothe mixture was added 2 M solution of HCl in diethyl ether (80 mL) andether (400 mL). The resulting fine white precipitate was filtered off,washed with ether (2×200 mL) and dried under high vacuum to affordActivated Hydrocodone in 67% yield (8.4 g, 16.8 mmol). LC-MS [M+H]:465.3 (C₂₅H₂₄N₂O₇+H, calc: 464.2).

Compound F′ (2.0 g, 1.5 mmol) and Activated Hydrocodone (750 mg, 1.5mmol) were dissolved in DMF (40 mL) and DIPEA (0.780 mL, 4.5 mmol) wasadded. The reaction mixture was stirred at 40° C. overnight. Uponreaction completion, the DMF was evaporated and the resulting oilyproduct was dissolved in DCM (700 mL). The mixture was then washed with5% sodium phosphate (2×100 mL), 0.1 N aq. HCl (100 mL) and brine (150mL). The organic phase was dried over Na₂SO₄, filtered and the solventwas evaporated. The oily product was dried in high vacuum overnight toafford crude compound G in 88.7% yield. (2.15 g, 1.33 mmol) LC-MS: [M+H]1585.1 (C₈₃H₁₀₁N₁₃O₁₇S+H, calc: 1584.7). The crude reaction mixture wasthen purified by preparative HPLC to afford the desired product(compound G) in 61% yield (1.51 g, 0.91 mmol).

Preparation of Compound 1

To a solution of compound G (1.50 g, 0.91 mmol) in MeOH (25 mL) wasadded, under nitrogen, 10% Pd/C (150 mg), 4N hydrogen chloride (in1,4-Dioxane, 2 mL). The reaction mixture was stirred at 40 psi for 3 h.Upon completion, the reaction mixture was filtered through aCelite-padded glass frit and washed with MeOH (3×20 mL). The filtratewas concentrated under vacuum to the volume ˜10 mL and diethyl ether(200 mL) was added. The resulting fine white precipitate was filtered,washed with ether (2×50 mL) and the resulting solution was evaporatedunder vacuum and dried under high vacuum overnight to afford a lightyellow solid (1.39 g). LC-MS: [M+H]1451.1 (C₇₅H₉₅N₁₃O₁₅S+H, calc:1450.7). The crude solid was dissolved in DCM (30 mL) and to the mixturewas added NMM (1.0 mL, 5.5 mmol), followed by acetic anhydride (0.18 mL,0.91 mmol). The reaction was allowed to stir for 1 h at ambienttemperature. Next, the reaction was condensed and to the crude reactionmixture was added 5% Cresol in TFA (15 ml). The reaction was allowed tostir at room temperature for 4 h. Upon completion, the reaction mixturewas condensed, taken up in 20% ACN/H2O (20 mL) and purified viapreparative HPLC to afford compound 1 (890 mg, 0.63 mmol, 69.7% yieldover 3 steps) as a white solid. LC-MS: [M+H] 1331.9 (C₃₂H₄₃N₃O₈+H, calc:1331.6).

Preparation of Compound 2

To compound G (1.2 g, 0.741 mmol) was added 5% Cresol in TFA (10 ml).The reaction was allowed to stir at room temperature for 4 h. Uponcompletion, the reaction mixture was condensed, taken up in 20% ACN/H2O(20 mL) and purified via preparative HPLC to afford Compound 2 (0.73 g,0.52 mmol, 70.2% yield) as an off-white solid. LC-MS: [M+H] 1332.9(C₇₀H₈₅N₁₃O₁₄+H, calc: 1332.6).

Preparation of Compound 3

Compound F′ (3.0 g, 4.0 mmol) was dissolved in EtOH (40 mL). 10%Pd(OH)₂/C (0.3 g) and 4N HCl (in 1,4-Dioxane; 3 mL) was added to thereaction mixture. The mixture was hydrogenated at 40 psi for 4 h on aParr hydrogenator. The mixture was then filtered through a celite padand then the celite pad was washed with MeOH (3×10 mL). The reaction wascondensed under vacuum. Next, the crude reaction mixture was dissolvedin DMF (25 mL) and to the solution was added SuO-Lys(Boc)-NAc (1.91 g,4.0 mmol) at 5° C., followed by DIPEA (2.08 mL, 12 mmol) dropwise over 5min. The temperature of the reaction mixture was raised to ambienttemperature and stirring was continued for an additional 1 h. Uponreaction completion, DMF was removed under high vacuum, and the reactionmixture was diluted with DCM (100 mL), washed with 1N HCl (100 mL), thenwith aqueous NaHCO₃ (100 mL) and brine (250 mL). The organic phase wasdried over Na₂SO₄, filtered and the solvent was evaporated to afford anoff-white solid (3.10 g, 3.3 mmol) LC-MS: [M+H] 940.8 (C₅₀H₆₅N₇O₁₁+H,calc: 940.5). The crude product was used directly without furtherpurification.

The crude product of the previous reaction (3.10 g, 3.3 mmol) wasdissolved in EtOH (100 mL). 10% Pd(OH)₂/C (0.3 g) and 4N HCl (in1,4-Dioxane; 4 mL) was added to the reaction mixture. The mixture washydrogenated at 40 psi for 4 h on a Parr hydrogenator. The mixture wasthen filtered through a celite pad and then the celite pad was washedwith MeOH (3×25 mL). The reaction was condensed under vacuum. Next, thecrude reaction mixture was dissolved in DMF (25 mL) and to the solutionwas added SuO-Lys(Boc)-NAc (1.57 g, 3.3 mmol) at 5° C., followed byDIPEA (2.42 mL, 14 mmol) dropwise over 5 min. The temperature of thereaction mixture was raised to ambient temperature and stirring wascontinued for an additional 2 h. Upon reaction completion, DMF wasremoved under high vacuum, and the reaction mixture was diluted with DCM(300 mL), washed with 1N HCl (200 mL), then with aqueous NaHCO₃ (200 mL)and brine (250 mL). The organic phase was dried over Na₂SO₄, filteredand the solvent was evaporated to afford an off-white solid. (3.85 g,3.3 mmol) LC-MS: [M+H] 1168.9 (C₆₁H₈₅N₉O₁₄+H, calc: 1168.6). The crudeproduct was used directly without further purification.

The crude product of the previous reaction (3.85 g, 3.3 mmol) wasdissolved in DCM (100 mL) was treated with 4 M solution of hydrogenchloride in 1,4-dioxane (15 mL). After 1 h, solvent was removed undervacuum until about ˜50 mL remained. Diethyl ether (˜300 mL) was added tothe reaction mixture, which produced a fine white precipitate. Theprecipitate was filtered off, washed with ether (3×75 mL) and driedunder vacuum to give compound H as a fine white solid. (3.3 g, 3.3 mmol)LC-MS: [M+H] 868.8 (C₄₆H₆₁N₉O₈+H, calc: 868.5). Crude compound H wasused directly without further purification.

To a solution of Compound H (2.1 g, 2.0 mmol), Compound D (4.81 g, 6.3mmol) and HATU (2.87 g, 7.56 mmol) in DMF (40 mL) at −20 OC was addedDIPEA (3.95 mL, 22.7 mmol) dropwise over 5 min. The temperature of thereaction mixture was raised to ambient temperature and stirring wascontinued for an additional hour. Upon reaction completion, DMF wasremoved under vacuum and the reaction mixture was then diluted DCM. Theorganic layer was washed with 1N HCl, saturated NaHCO3, brine and thendried over MgSO4. The organic layer was then filtered and condensed toafford an off-white solid. (6.68 g) LC-MS: [M+H] 2939.9(C₁₄₅H₂₁₁N₂₇O₃₂S₃+H, calc: 2939.5). The crude product was dissolved in4N hydrogen chloride in 1,4-dioxane (50 mL). After 1 h, solvent wasremoved under vacuum until about ˜10 mL remained. Diethyl ether (˜500mL) was added to the reaction mixture, which produced an off-white/lighttan precipitate. The precipitate was filtered off, washed with ether(3×100 mL) and dried under vacuum to give a solid (Compound H′) in 84%yield over 2 steps (4.67 g, 1.68 mmol). LC-MS: [M+H] 2639.7(C₁₃₀H₁₈₇N₂₇O₂₆S+H, calc: 2639.3). The crude product (Compound H′) wasused directly without further purification.

Compound H′ (3.0 g, 1.08 mmol) and Activated Hydrocodone (1.62 g, 3.23mmol) were dissolved in DMF (40 mL) and DIPEA (1.68 mL, 9.7 mmol) wasadded. The reaction mixture was stirred at 40° C. overnight. Uponreaction completion, the DMF was evaporated and the resulting oilyproduct was dissolved in DCM (200 mL). The mixture was then washed with5% sodium phosphate (2×200 mL), 0.1 N aq. HCl (500 mL) and brine (250mL). The organic phase was dried over Na₂SO₄, filtered and the solventwas evaporated. The oily product was dried in high vacuum overnight toafford crude compound I in 89.5% yield. (3.75 g, 0.967 mmol) LC-MS:[M+H] 3885.8 (C₁₈₇H₂₄₈Cl₄IN₃₀O₃₈S₃+H, calc: 3885.5). The crude reactionmixture was then purified by preparative HPLC to afford the desiredproduct (compound I) in 62% yield (2.51 g, 0.67 mmol).

To compound I (1.50 g, 0.40 mmol) was added to 5% Cresol in TFA (10 ml).The reaction was allowed to stir at room temperature for 4 h. Uponcompletion, the reaction mixture was condensed, taken up in 20% ACN/H2O(20 mL) and purified via preparative HPLC to afford Compound 3 as anoff-white solid in 83% yield (1.03 g, 0.33 mmol). LC-MS: [M+H] 578.6(C₃₂H₄₃N₃O₈+H, calc: 578.7).

Pharmaceutical Compositions

Also embraced within this invention are pharmaceutical compositionscomprising one or more compounds described above in association with oneor more non-toxic, pharmaceutically acceptable carriers and/or diluentsand/or adjuvants (collectively referred to herein as “carrier”materials) and, if desired, other active ingredients. The compounds andcompositions of the present invention can be administered orally,preferably in the form of a pharmaceutical composition adapted to oraladministration, and in a dose effective for the prevention or treatmentof pain.

For oral administration, the pharmaceutical composition can be in theform of, for example, a tablet, capsule, a soft gelatin (softgel)capsule, a hard gelatin capsule, suspension or liquid.

The amount of each therapeutically active compound that is administeredand the dosage regimen for treating or preventing of pain with thecompounds and/or compositions of this invention depends on a variety offactors, including the age, weight, sex and medical condition of thesubject, the severity of the disease, the route and frequency ofadministration, and the particular compound employed, and thus may varywidely. The pharmaceutical compositions may contain compounds of theinvention in the range of about 0.1 to 2000 mg, preferably in the rangeof about 0.5 to 1000 mg and most preferably between about 1 and 500 mg.A daily dose of about 0.01 to 100 mg/kg body weight, preferably betweenabout 0.1 and about 50 mg/kg body weight and most preferably from about0.5 to about 20 mg/kg body weight, may be appropriate. The daily dosecan be administered in one to four to six to eight or more doses perday.

For therapeutic purposes, the compounds of this invention are ordinarilycombined with one or more excipients appropriate to the indicated routeof administration. The compounds may be admixed with lactose, sucrose,starch powder, cellulose esters of alkanoic acids, cellulose alkylesters, talc, stearic acid, magnesium stearate, magnesium oxide, sodiumand calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum,sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, andthen tableted or encapsulated for convenient administration. Suchcapsules or tablets may contain a controlled-release formulation as maybe provided in a dispersion of active compound in hydroxypropylmethylcellulose.

The pharmaceutical composition of this invention may be prepared byuniformly mixing predetermined amounts of the active ingredient, theabsorption aid and optionally the base, etc. in a stirrer or a grindingmill, if required.

The pharmaceutical compositions disclosed herein comprise a compound ofthe invention disclosed herein with a suitable amount of apharmaceutically acceptable vehicle, so as to provide a form for properadministration to a subject.

Suitable pharmaceutical vehicles include excipients such as starch,glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silicagel, sodium stearate, glycerol monostearate, talc, sodium chloride,dried skim milk, glycerol, propylene, glycol, water, ethanol and thelike. The present pharmaceutical compositions, if desired, can alsocontain minor amounts of wetting or emulsifying agents, or pH bufferingagents. In addition, auxiliary, stabilizing, thickening, gelling,lubricating and coloring, and/or agents designed to deter oral andnon-oral abuse (e.g. gelling and or irritant agents) may be used.

Pharmaceutical compositions may be manufactured by means of conventionalmixing, dissolving, granulating, dragee-making, levigating, emulsifying,encapsulating, entrapping or lyophilizing processes. Pharmaceuticalcompositions may be formulated in a conventional manner using one ormore physiologically acceptable carriers, diluents, excipients orauxiliaries, which facilitate processing of compositions and compoundsdisclosed herein into preparations that can be used pharmaceutically.

The present pharmaceutical compositions can take the form of solutions,suspensions, emulsion, tablets, pills, pellets, capsules, capsulescontaining liquids, powders, sustained-release formulations, emulsions,suspensions or any other form suitable for use known to the skilledartisan. In some embodiments, the pharmaceutically acceptable vehicle isa capsule (see e.g., Grosswald et al., U.S. Pat. No. 5,698,155). Otherexamples of suitable pharmaceutical vehicles have been described in theart (see Remington's Pharmaceutical Sciences, Philadelphia College ofPharmacy and Science, 19th Edition, 1995).

Pharmaceutical compositions for oral delivery may be in the form oftablets, lozenges, aqueous or oily suspensions, granules, powders,emulsions, capsules, syrups, slurries, suspensions or elixirs, forexample. Orally administered compositions may contain one or moreoptional agents, for example, sweetening agents such as fructose,aspartame or saccharin, flavoring agents such as peppermint, oil ofwintergreen, or cherry coloring agents and preserving agents, to providea pharmaceutically palatable preparation.

Moreover, when in tablet or pill form, the compositions may be coated todelay disintegration and absorption in the gastrointestinal tract,thereby providing a sustained action over an extended period of time.Oral compositions can include standard vehicles such as mannitol,lactose, starch, magnesium stearate, sodium saccharine, cellulose,magnesium carbonate, sucrose, sorbitol, maize starch, wheat starch, ricestarch, potato starch, gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/orpolyvinylpyrrolidone (PVP), granulating agents, binding agents anddisintegrating agents such as the cross-linked polyvinylpyrrolidone,agar, or alginic acid or a salt thereof such as sodium alginate etc.

The methods that involve oral administration of compounds disclosedherein of can also be practiced with a number of different dosage forms,which provide sustained release.

In some embodiments, the dosage form is comprised of beads that ondissolution or diffusion release compositions and/or compounds disclosedherein over an extended period of hours, preferably, over a period of atleast 6 hours, more preferably, over a period of at least 8 hours andeven more preferably, over a period of at least 12 hours and mostpreferably, over a period of at least 24 hours. The beads may have acentral composition or core comprising compounds disclosed herein andpharmaceutically acceptable vehicles, including optional lubricants,antioxidants and buffers. The beads may be medical preparations with adiameter of about 1 to about 2 mm. Individual beads may comprise dosesof the compounds disclosed herein. The beads, in some embodiments, areformed of non-cross-linked materials to enhance their discharge from thegastrointestinal tract. The beads may be coated with a releaserate-controlling polymer that gives a timed-release profile.

The time-release beads may be manufactured into a tablet fortherapeutically effective administration. The beads can be made intomatrix tablets by direct compression of a plurality of beads coatedwith, for example, an acrylic resin and blended with excipients such ashydroxypropylmethyl cellulose. The manufacture of beads has beendisclosed in the art (Lu, Int. J. Pharm. 1994, 112, 117-124;Pharmaceutical Sciences by Remington, 14^(th) ed, pp 1626-1628 (1970);Fincher, J. Pharm. Sci. 1968, 57, 1825-1835; Benedikt, U.S. Pat. No.4,083,949) as has the manufacture of tablets (Pharmaceutical Sciences,by Remington, 17^(th) Ed, Ch. 90, pp 1603-1625 (1985).

In other embodiments, an oral sustained release pump may be used(Langer, supra; Sefton, 1987, CRC Crit Ref Biomed. Eng. 14:201; Saudeket al., 1989, N. Engl. J Med. 321:574).

In still other embodiments, polymeric materials can be used (See“Medical Applications of Controlled Release,” Langer and Wise (eds.),CRC Press, Boca Raton, Fla. (1974); “Controlled Drug Bioavailability,”Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, NewYork (1984); Langer et al., 1983, J Macromol. Sci. Rev. Macromol Chem.23:61; Levy et al., 1985, Science 228: 190; During et al., 1989, Ann.Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). In someembodiments, polymeric materials are used for oral sustained releasedelivery. Such polymers include, for example, sodiumcarboxymethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose and hydroxyethylcellulose (most preferred,hydroxypropylmethylcellulose). Other cellulose ethers have beendescribed (Alderman, Int. J. Pharm. Tech. & Prod. Mfr. 1984, 5(3) 1-9).Factors affecting drug release are well known to the skilled artisan andhave been described in the art (Bamba et al., Int. J. Pharm. 1979, 2,307).

In still other embodiments, enteric-coated preparations can be used fororal sustained release administration. Coating materials include, forexample, polymers with a pH-dependent solubility (i.e., pH-controlledrelease), polymers with a slow or pH-dependent rate of swelling,dissolution or erosion (i.e., time-controlled release), polymers thatare degraded by enzymes (i.e., enzyme-controlled release) and polymersthat form firm layers that are destroyed by an increase in pressure(i.e., pressure-controlled release).

In yet other embodiments, drug-releasing lipid matrices can be used fororal sustained release administration. For example, solid microparticlesof compositions and/or compounds disclosed herein may be coated with athin controlled release layer of a lipid (e.g., glyceryl behenate and/orglyceryl palmitostearate) as disclosed in Farah et al., U.S. Pat. No.6,375,987 and Joachim et al., U.S. Pat. No. 6,379,700. The lipid-coatedparticles can optionally be compressed to form a tablet. Anothercontrolled release lipid-based matrix material which is suitable forsustained release oral administration comprises polyglycolizedglycerides as disclosed in Roussin et al., U.S. Pat. No. 6,171,615.

In yet other embodiments, waxes can be used for oral sustained releaseadministration. Examples of suitable sustained releasing waxes aredisclosed in Cain et al., U.S. Pat. No. 3,402,240 (carnauba wax,candedilla wax, esparto wax and ouricury wax); Shtohryn et al., U.S.Pat. No. 4,820,523 (hydrogenated vegetable oil, bees wax, caranuba wax,paraffin, candelillia, ozokerite and mixtures thereof); and Walters,U.S. Pat. No. 4,421,736 (mixture of paraffin and castor wax).

In still other embodiments, osmotic delivery systems are used for oralsustained release administration (Verma et al., Drug Dev. Ind. Pharm.2000, 26:695-708). In some embodiments, OROS® systems made by AlzaCorporation, Mountain View, Calif. are used for oral sustained releasedelivery devices (Theeuwes et al., U.S. Pat. No. 3,845,770; Theeuwes etal., U.S. Pat. No. 3,916,899).

In still other embodiments, the dosage form comprises compoundsdisclosed herein coated on a polymer substrate. The polymer can be anerodible or a nonerodible polymer. The coated substrate may be foldedonto itself to provide a bilayer polymer drug dosage form. For example,compounds disclosed herein can be coated onto a polymer such as apolypeptide, collagen, gelatin, polyvinyl alcohol, polyorthoester,polyacetyl, or a polyorthocarbonate and the coated polymer folded ontoitself to provide a bilaminated dosage form. In operation, thebioerodible dosage form erodes at a controlled rate to dispense thecompounds over a sustained release period. Representative biodegradablepolymers comprise a member selected from the group consisting ofbiodegradable poly(amides), poly (amino acids), poly(esters),poly(lactic acid), poly(glycolic acid), poly(carbohydrate),poly(orthoester), poly (orthocarbonate), poly(acetyl), poly(anhydrides),biodegradable poly(dihydropyrans), and poly(dioxinones) which are knownin the art (Rosoff, Controlled Release of Drugs, Chap. 2, pp. 53-95(1989); Heller et al., U.S. Pat. No. 3,811,444; Michaels, U.S. Pat. No.3,962,414; Capozza, U.S. Pat. No. 4,066,747; Schmitt, U.S. Pat. No.4,070,347; Choi et al., U.S. Pat. No. 4,079,038; Choi et al., U.S. Pat.No. 4,093,709).

In other embodiments, the dosage form comprises compounds disclosedherein loaded into a polymer that releases the drug(s) by diffusionthrough a polymer, or by flux through pores or by rupture of a polymermatrix. The drug delivery polymeric dosage form comprises aconcentration of 10 mg to 2500 mg homogenously contained in or on apolymer. The dosage form comprises at least one exposed surface at thebeginning of dose delivery. The non-exposed surface, when present, iscoated with a pharmaceutically acceptable material impermeable to thepassage of the drug(s). The dosage form may be manufactured byprocedures known in the art. An example of providing a dosage formcomprises blending a pharmaceutically acceptable carrier likepolyethylene glycol, with a known dose of compositions and/or compoundsdisclosed herein at an elevated temperature, (e.g., 37° C.), and addingit to a silastic medical grade elastomer with a cross-linking agent, forexample, octanoate, followed by casting in a mold. The step is repeatedfor each optional successive layer. The system is allowed to set forabout 1 hour, to provide the dosage form. Representative polymers formanufacturing the dosage form comprise a member selected from the groupconsisting of olefin, and vinyl polymers, addition polymers,condensation polymers, carbohydrate polymers, and silicone polymers asrepresented by polyethylene, polypropylene, polyvinyl acetate,polymethylacrylate, polyisobutylmethacrylate, poly alginate, polyamideand polysilicone. The polymers and procedures for manufacturing themhave been described in the art (Coleman et al., Polymers 1990, 31,1187-1231; Roerdink et al., Drug Carrier Systems 1989, 9, 57-10; Leonget al., Adv. Drug Delivery Rev. 1987, 1, 199-233; Roff et al., Handbookof Common Polymers 1971, CRC Press; Chien et al., U.S. Pat. No.3,992,518).

In other embodiments, the dosage form comprises a plurality of tinypills. The tiny time-release pills provide a number of individual dosesfor providing various time doses for achieving a sustained-release drugdelivery profile over an extended period of time up to 24 hours. Thematrix comprises a hydrophilic polymer selected from the groupconsisting of a polysaccharide, agar, agarose, natural gum, alkalialginate including sodium alginate, carrageenan, fucoidan, furcellaran,laminaran, hypnea, gum arabic, gum ghatti, gum karaya, gum tragacanth,locust bean gum, pectin, amylopectin, gelatin, and a hydrophiliccolloid. The hydrophilic matrix comprises a plurality of 4 to 50 tinypills, each tiny pill comprises a dose population of from 10 ng, 0.5 mg,1 mg, 1.2 mg, 1.4 mg, 1.6 mg, 5.0 mg, etc. The tiny pills comprise arelease rate-controlling wall of 0.001 mm up to 10 mm thickness toprovide for the timed release of drug(s). Representative wall formingmaterials include a triglyceryl ester selected from the group consistingof glyceryl tristearate, glyceryl monostearate, glyceryl dipalmitate,glyceryl laureate, glyceryl didecenoate and glyceryl tridenoate. Otherwall forming materials comprise polyvinyl acetate, phthalate,methylcellulose phthalate and microporous olefins. Procedures formanufacturing tiny pills are disclosed in Urquhart et al., U.S. Pat. No.4,434,153; Urquhart et al., U.S. Pat. No. 4,721,613; Theeuwes, U.S. Pat.No. 4,853,229; Barry, U.S. Pat. No. 2,996,431; Neville, U.S. Pat. No.3,139,383; Mehta, U.S. Pat. No. 4,752,470.

In other embodiments, the dosage form comprises an osmotic dosage form,which comprises a semipermeable wall that surrounds a therapeuticcomposition comprising compounds disclosed herein. In use within asubject, the osmotic dosage form comprising a homogenous composition,imbibes fluid through the semipermeable wall into the dosage form inresponse to the concentration gradient across the semipermeable wall.The therapeutic composition in the dosage form develops osmotic pressuredifferential that causes the therapeutic composition to be administeredthrough an exit from the dosage form over a prolonged period of time upto 24 hours (or even in some cases up to 30 hours) to provide controlledand sustained release. These delivery platforms can provide anessentially zero order delivery profile as opposed to the spikedprofiles of immediate release formulations.

In other embodiments, the dosage form comprises another osmotic dosageform comprising a wall surrounding a compartment, the wall comprising asemipermeable polymeric composition permeable to the passage of fluidand substantially impermeable to the passage of compounds disclosedherein present in the compartment, a drug-containing layer compositionin the compartment, a hydrogel push layer composition in the compartmentcomprising an osmotic formulation for imbibing and absorbing fluid forexpanding in size for pushing the drug composition layer from the dosageform, and at least one passageway in the wall for releasing thecomposition. The method delivers compounds disclosed herein by imbibingfluid through the semipermeable wall at a fluid imbibing rate determinedby the permeability of the semipermeable wall and the osmotic pressureacross the semipermeable wall causing the push layer to expand, therebydelivering the compounds disclosed herein from the dosage form throughthe exit passageway to a subject over a prolonged period of time (up to24 or even 30 hours). The hydrogel layer composition may comprise 10 mgto 1000 mg of a hydrogel such as a member selected from the groupconsisting of a polyalkylene oxide of 1,000,000 to 8,000,000weight-average molecular weight which are selected from the groupconsisting of a polyethylene oxide of 1,000,000 weight-average molecularweight, a polyethylene oxide of 2,000,000 molecular weight, apolyethylene oxide of 4,000,000 molecular weight, a polyethylene oxideof 5,000,000 molecular weight, a polyethylene oxide of 7,000,000molecular weight and a polypropylene oxide of the 1,000,000 to 8,000,000weight-average molecular weight; or 10 mg to 1000 mg of an alkalicarboxymethylcellulose of 10,000 to 6,000,000 weight average molecularweight, such as sodium carboxymethylcellulose or potassiumcarboxymethylcellulose. The hydrogel expansion layer comprises 0.0 mg to350 mg, in present manufacture; 0.1 mg to 250 mg of ahydroxyalkylcellulose of 7,500 to 4,500,000 weight-average molecularweight (e.g., hydroxymethylcellulose, hydroxyethylcellulose,hydroxypropylcellulose, hydroxybutylcellulose or hydroxypentylcellulose)in present manufacture; 1 mg to 50 mg of an osmagent selected from thegroup consisting of sodium chloride, potassium chloride, potassium acidphosphate, tartaric acid, citric acid, raffinose, magnesium sulfate,magnesium chloride, urea, inositol, sucrose, glucose and sorbitol; 0 to5 mg of a colorant, such as ferric oxide; 0 mg to 30 mg, in a presentmanufacture, 0.1 mg to 30 mg of a hydroxypropylalkylcellulose of 9,000to 225,000 average-number molecular weight, selected from the groupconsisting of hydroxypropylethylcellulose, hydroxypropypentylcellulose,hydroxypropylmethylcellulose, and hydropropylbutylcellulose; 0.00 to 1.5mg of an antioxidant selected from the group consisting of ascorbicacid, butylated hydroxyanisole, butylated hydroxyquinone,butylhydroxyanisole, hydroxycoumarin, butylated hydroxytoluene, cephalm,ethyl gallate, propyl gallate, octyl gallate, lauryl gallate,propyl-hydroxybenzoate, trihydroxybutyrophenone, dimethylphenol,dibutylphenol, vitamin E, lecithin and ethanolamine; and 0.0 mg to 7 mgof a lubricant selected from the group consisting of calcium stearate,magnesium stearate, zinc stearate, magnesium oleate, calcium palmitate,sodium suberate, potassium laurate, salts of fatty acids, salts ofalicyclic acids, salts of aromatic acids, stearic acid, oleic acid,palmitic acid, a mixture of a salt of a fatty, alicyclic or aromaticacid and a fatty, alicyclic or aromatic acid.

In the osmotic dosage forms, the semipermeable wall comprises acomposition that is permeable to the passage of fluid and impermeable tothe passage of compounds disclosed herein. The wall is non-toxic andcomprises a polymer selected from the group consisting of a celluloseacylate, cellulose diacylate, cellulose triacylate, cellulose acetate,cellulose diacetate and cellulose triacetate. The wall comprises 75 wt %(weight percent) to 100 wt % of the cellulosic wall-forming polymer; or,the wall can comprise additionally 0.01 wt % to 80 wt % of polyethyleneglycol, or 1 wt % to 25 wt % of a cellulose ether selected from thegroup consisting of hydroxypropylcellulose or ahydroxypropylalkylcellulose such as hydroxypropylmethylcellulose. Thetotal weight percent of all components comprising the wall is equal to100 wt %. The internal compartment comprises the drug-containingcomposition alone or in layered position with an expandable hydrogelcomposition. The expandable hydrogel composition in the compartmentincreases in dimension by imbibing the fluid through the semipermeablewall, causing the hydrogel to expand and occupy space in thecompartment, whereby the drug composition is pushed from the dosageform. The therapeutic layer and the expandable layer act together duringthe operation of the dosage form for the release of compounds disclosedherein to a subject over time. The dosage form comprises a passageway inthe wall that connects the exterior of the dosage form with the internalcompartment. The osmotic powered dosage form can be made to deliver drugfrom the dosage form to the subject at a zero order rate of release overa period of up to about 24 hours.

The expression “passageway” as used herein comprises means and methodssuitable for the metered release of the compounds disclosed herein fromthe compartment of the dosage form. The exit means comprises at leastone passageway, including orifice, bore, aperture, pore, porous element,hollow fiber, capillary tube, channel, porous overlay, or porous elementthat provides for the osmotic controlled release of the compoundsdisclosed herein. The passageway includes a material that erodes or isleached from the wall in a fluid environment of use to produce at leastone controlled-release dimensioned passageway. Representative materialssuitable for forming a passageway, or a multiplicity of passagewayscomprise a leachable poly(glycolic) acid or poly(lactic) acid polymer inthe wall, a gelatinous filament, poly(vinyl alcohol), leach-ablepolysaccharides, salts, and oxides. A pore passageway, or more than onepore passageway, can be formed by leaching a leachable compound, such assorbitol, from the wall. The passageway possesses controlled-releasedimensions, such as round, triangular, square and elliptical, for themetered release of compositions and/or drugs from the dosage form. Thedosage form can be constructed with one or more passageways in spacedapart relationship on a single surface or on more than one surface ofthe wall. The expression “fluid environment” denotes an aqueous orbiological fluid as in a human patient, including the gastrointestinaltract. Passageways and equipment for forming passageways are disclosedin Theeuwes et al., U.S. Pat. No. 3,845,770; Theeuwes et al., U.S. Pat.No. 3,916,899; Saunders et al., U.S. Pat. No. 4,063,064; Theeuwes etal., U.S. Pat. No. 4,088,864 and Ayer et al., U.S. Pat. No. 4,816,263.Passageways formed by leaching are disclosed in Ayer et al., U.S. Pat.No. 4,200,098 and Ayer et al., U.S. Pat. No. 4,285,987.

In order to decrease dosing frequency and augment the convenience to thesubject and increase subject compliance, the sustained release oraldosage form (regardless of the specific form of the sustained releasedosage form) preferably, provides therapeutic concentrations of thecompounds disclosed herein in the patient's blood over a period of atleast about 6 hours, more preferably, over a period of at least about 8hours, even preferably, over a period of at least about 12 hours andmost preferably, over a period of at least 24 hours.

For oral liquid preparations such as, for example, suspensions, elixirsand solutions, suitable carriers, excipients or diluents include water,saline, alkyleneglycols (e.g., propylene glycol), polyalkylene glycols(e.g., polyethylene glycol) oils, alcohols, slightly acidic buffersbetween pH 4 and pH 6 (e.g., acetate, citrate, ascorbate at betweenabout 5 mM to about 50 mM), etc. Additionally, flavoring agents,preservatives, coloring agents, bile salts, acylcarnitines and the likemay be added.

When used to treat and/or prevent diseases the compounds disclosedherein and/or pharmaceutical compositions thereof may be administeredalone or in combination with other pharmaceutical agents includingcompounds disclosed herein and/or pharmaceutical compositions thereof.The compounds disclosed herein may be administered or applied per se oras pharmaceutical compositions.

The amount of compounds disclosed herein and/or pharmaceuticalcompositions thereof that will be effective in the treatment orprevention of diseases in a patient will depend on the specific natureof the condition and can be determined by standard clinical techniquesknown in the art. The amount of compounds disclosed herein and/orpharmaceutical compositions thereof administered will, of course, bedependent on, among other factors, the subject being treated, the weightof the subject, the severity of the affliction, and the judgment of theprescribing physician.

In certain embodiments, compounds disclosed herein and/or pharmaceuticalcompositions thereof can be used in combination therapy with at leastone other therapeutic agent. The compounds disclosed herein and/orpharmaceutical compositions thereof and the therapeutic agent can actadditively or, more preferably, synergistically. In some embodiments,compounds disclosed herein and/or pharmaceutical compositions thereofare administered concurrently with the administration of anothertherapeutic agent. For example, compounds disclosed herein and/orpharmaceutical compositions thereof may be administered together withanother therapeutic agent (e.g. including, but not limited to,peripheral opioid antagonists, laxatives, non-opioid analgesics and thelike). In other embodiments, compounds disclosed herein and/orpharmaceutical compositions thereof are administered prior or subsequentto administration of other therapeutic agents.

Thus, in one aspect of the invention, the oral dosage form can containone or more compounds of the invention and non-opioid drugs. Suchnon-opioid drugs would preferably provide additional analgesia and/oranti-inflammatory effects, and include, for example, aspirin,acetaminophen, non-steroidal anti-inflammatory drugs (“NSAIDS”) such as,for example, naproxen, ibuprofen, ketoprofen, N-methyl-D-aspartate(NMDA) receptor antagonists, such as, for example, a morphinan such asdextromethorphan or dextrorphan, or ketamine, a cycooxygenase-IIinhibitors (“COX-II inhibitors”); and/or glycine receptor antagonists.

All printed patents and publications referred to in this application arehereby incorporated herein in their entirety by this reference. Whilethe preferred embodiment of the invention has been illustrated anddescribed, it will be appreciated that various changes can be madetherein without departing from the spirit and scope of the invention.

Pharmacokinetic and Pharmacodynamic Measurements

Pharmacokinetic and pharmacodynamic data can be obtained by variousexperimental techniques. Appropriate pharmacokinetic and pharmacodynamicprofile components describing a particular composition can vary due tovariations in drug metabolism in different subjects. Pharmacokinetic andpharmacodynamic profiles can be based on the determination of the meanparameters of a group of subjects. The group of subjects includes anyreasonable number of subjects suitable for determining a representativemean, for example, 5 subjects, 10 subjects, 15 subjects, 20 subjects, 25subjects, 30 subjects, 35 subjects, or more. The mean is determined bycalculating the average of all subject's measurements for each parametermeasured.

A dose can be modulated to achieve a desired pharmacokinetic orpharmacodynamic profile, such as a desired or effective blood profile,as described herein. A compound of the invention can be present in acomposition in a range of from about 1 mg to about 2000 mg; from about 5mg to about 1000 mg, from about 10 mg to about 500 mg, from about 50 mgto about 250 mg, from about 100 mg to about 200 mg, from about 1 mg toabout 50 mg, from about 50 mg to about 100 mg, from about 100 mg toabout 150 mg, from about 150 mg to about 200 mg, from about 200 mg toabout 250 mg, from about 250 mg to about 300 mg, from about 300 mg toabout 350 mg, from about 350 mg to about 400 mg, from about 400 mg toabout 450 mg, from about 450 mg to about 500 mg, from about 500 mg toabout 550 mg, from about 550 mg to about 600 mg, from about 600 mg toabout 650 mg, from about 650 mg to about 700 mg, from about 700 mg toabout 750 mg, from about 750 mg to about 800 mg, from about 800 mg toabout 850 mg, from about 850 mg to about 900 mg, from about 900 mg toabout 950 mg, or from about 950 mg to about 1000 mg. To bettercharacterize the enzyme kinetics of a compound of the invention in vitrothe K_(m) and V_(max) of a unimolecular entity can be described asillustrated in FIG. 2.

The outcome of treating a human subject with a combination therapy canbe measured by calculating pharmacodynamic and pharmacokineticparameters. Non-limiting examples of pharmacodynamic and pharmacokineticparameters that can be used to determine the effect of treatment of asubject with a composition of the disclosure include: a) the amount ofopioid agonist drug delivered, which can be represented as a dose D; b)the dosing interval, which can be represented as τ; c) the apparentvolume in which a drug is distributed, which can be represented as avolume of distribution V_(d), where V_(d)=D/C₀; d) the amount of drug ina given volume of plasma, which can be represented as concentration C₀or C_(ss), where C₀ or C_(ss)=D/Vd; e) the half-life of a drug t_(1/2),where t_(1/2) ln(2)/k_(e); f) the rate at which a drug is removed fromthe body k_(e), where k_(e) ln(2)/t_(1/2)=CL/V_(d); g) the rate ofinfusion required to balance the equation K_(in), whereK_(in)=C_(ss)·CL; h) the integral of the concentration-time curve afteradministration of a single dose, which can be represented as AUC_(0-∞),wherein ∫₀ ^(∞) C dt, or in steady-state, which can be represented asAUCτ, _(ss), wherein ∫_(t) ^(t+π) C dt; i) the volume of plasma clearedof the drug per unit time, which can be represented as CL (clearance),wherein CL=V_(d)·k_(e)=D/AUC; j) the systemically available fraction ofa drug, which can be represented as f, where

${f = \frac{{AUCpo} \cdot {Div}}{{AUCiv} \cdot {Dpo}}};$

k) the peak plasma concentration of a drug after administration C_(max);l) the time taken by a drug to reach C_(max), T_(max); m) the lowestconcentration that a drug reaches before the next dose is administeredC_(min); and n) the peak trough fluctuation within one dosing intervalat steady state, which can be represented as % PTF=100.

${\frac{\left( {{C\; \max},{{ss} - {C\; \min}},{ss}} \right)}{{Cav},{ss}}\mspace{14mu} {where}\mspace{14mu} C_{{av},{ss}}} = {\frac{{{AUC}\; \tau},{ss}}{\tau}.}$

The pharmacokinetics parameters can be any parameters suitable fordescribing the plasma profiles of the opioid agonist delivered by acompound of the invention. For example, the pharmacokinetic profile ofan opioid agonist delivered by a compound of the invention can beobtained at a time after dosing of, for example, about zero minutes,about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17minutes, about 18 minutes, about 19 minutes, about 20 minutes, about 21minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33minutes, about 34 minutes, about 35 minutes, about 36 minutes, about 37minutes, about 38 minutes, about 39 minutes, about 40 minutes, about 41minutes, about 42 minutes, about 43 minutes, about 44 minutes, about 45minutes, about 46 minutes, about 47 minutes, about 48 minutes, about 49minutes, about 50 minutes, about 51 minutes, about 52 minutes, about 53minutes, about 54 minutes, about 55 minutes, about 56 minutes, about 57minutes, about 58 minutes, about 59 minutes, about 60 minutes, aboutzero hours, about 0.5 hours, about 1 hour, about 1.5 hours, about 2hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours,about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours,about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours,about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours,about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours,about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours,about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours,about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours,about 23 hours, about 23.5 hours, or about 24 hours.

The pharmacokinetic parameters can be any parameters suitable fordescribing an opioid agonist, or agonists, delivered from compounds ofthe invention. The C_(max) can be, for example, not less than about 1ng/mL; not less than about 5 ng/mL; not less than about 10 ng/mL; notless than about 15 ng/mL; not less than about 20 ng/mL; not less thanabout 25 ng/mL; not less than about 50 ng/mL; not less than about 75ng/mL; not less than about 100 ng/mL; not less than about 200 ng/mL; orany other C_(max) appropriate for describing a pharmacokinetic profileof an opioid agonist described herein. The C_(max) can be, for example,about 1 ng/mL to about 5 ng/mL; about 1 ng/mL to about 10 ng/mL; about 1ng/mL to about 30 ng/mL; about 1 ng/mL to about 50 ng/mL; about 1 ng/mLto about 75 ng/mL; about 1 μg/mL to about 100 ng/mL; about 1 ng/mL toabout 150 ng/mL; about 1 ng/mL to about 200 ng/mL; or about 1 ng/mL toabout 300 ng/mL.

The AUC_((0-inf)) or AUC_((0-.)) of a compound of the invention, oropioid agonist, or agonists, delivered therefrom as described herein canbe, for example, not less than about 10 ng·hr/mL, not less than about 25ng·hr/mL, not less than about 50 ng·hr/mL, not less than about 100ng·hr/mL, not less than about 150 ng·hr/mL, not less than about 200ng·hr/mL, not less than about 300 ng·hr/mL, not less than about 350ng·hr/mL, not less than about 400 ng·hr/mL, not less than about 500ng·hr/mL, not less than about 600 ng·hr/mL, not less than about 700ng·hr/mL, not less than about 800 ng·hr/mL, not less than about 900ng·hr/mL, not less than about 1000 ng·hr/mL, not less than about 2000ng·hr/mL, not less than about 3000 ng·hr/mL, not less than about 4000ng·hr/mL, or any other AUC_((0-inf)) appropriate for describing apharmacokinetic profile of a unimolecular polysubstrate entity or opioidagonist, or agonists, delivered therefrom as described herein.

EXAMPLES Example 1: In Vitro Characterization of an Overdose ProtectionMechanism with Compounds of the Disclosure

This example describes in vitro experiments with a compound of thedisclosure to provide a mechanism of overdose protection. Specifically,this study was designed to assess the ability of increasingconcentrations of compounds 2 and 3 to progressively inhibit trypsinactivity.

The effect of increasing concentrations of compounds 2 and 3 on the rateand extent of the trypsin-catalyzed hydrolysis of a commerciallyavailable trypsin substrate N_(α)-Benzoyl-L-arginine 4-nitroanilidehydrochloride was evaluated in the presence of trypsin (2,000 BAEEactivity) in a pH 7.4 phosphate buffer at 37° C. in vitro. Both bufferalone (i.e. no trypsin) and trypsin (i.e. no compound 2 or 3) controlswere run contemporaneously. The data are presented below in the Tablesbelow, and clearly demonstrates the ability of compounds 2 and 3 toprogressively inhibit trypsin in a concentration dependent manner with asteep concentration vs. inhibition relationship. Based on this data, itis reasonable to assume that compounds 2 and 3 are capable of rapidlyauto-attenuating the trypsin-mediated release of their appended opioidagonists in vivo as multiple doses are co-ingested.

TABLE 1 Percent N_(α)-Benzoyl-L-arginine 4-nitroanilide hydrochlorideremaining vs. Time Time (Minutes) 2 13 24 80 102 119 234 Com- Concen-Percent N_(α)-Benzoyl-L-arginine pound tration 4-nitroanilidehydrochloride remaining 2 1 mM 100 100 99 100 100 100 100 100 uM 100 98100 99 99 99 99 10 uM 100 98 96 94 93 94 87 1 uM 100 39 0 0 0 0 0Trypsin Control 100 0 0 0 0 0 0 Buffer control 100 100 99 99 99 99 98(no Trypsin)

TABLE 2 Percent N_(α)-Benzoyl-L-arginine 4-nitroanilide hydrochlorideremaining vs. Time Time (Minutes) 2 14 24 32 70 100 145 156 247 PercentN_(α)-Benzoyl-L-arginine 4-nitroanilide Compound Concentrationhydrochloride remaining 3 1 mM 100 99 98 99 99 98 98 97 96 100 uM 100 99100 100 100 100 100 100 100 10 uM 100 98 96 98 97 95 96 96 93 1 uM 10020 11 0 0 0 0 0 0 Trypsin Control 100 0 0 0 0 0 0 0 0 Buffer control (noTrypsin) 100 100 100 100 100 99 99 98 98

Example 2: In Vivo Demonstration of Non-Linear Pharmacokinetics (i.e.Overdose Protection) with Compounds of the Disclosure

This example describes in vivo experiments with a compound of thedisclosure to demonstrate overdose protection (i.e. non-linearpharmacokinetics of delivered hydrocodone).

The effect of increasing oral doses of compounds 2 and 3 on thepharmacokinetics of delivered hydrocodone (i.e. measured plasmahydrocodone concentrations vs. time) was evaluated in dogs. Specificpharmacokinetics parameters of the delivered opioid were calculated(e.g. Cmax, Tmax, AUC) and are presented below in the Table below. Thisdata clearly demonstrates the ability of increasing oral doses ofcompounds 2 and 3 of the invention to progressively attenuate therelease of hydrocodone in vivo.

PK Parameter Maximum concentration Time of maximum concentrationAUC_(0-8 h) of hydrocodone (Cmax) of hydrocodone (Tmax) of hydrocodonein dog plasma in dog plasma in dog plasma Dose AUC_(0-8 h) Cmax TmaxCompound (umol/kg) (ng · h/mL) SD (ng/mL HC) SD (h) SD 1 5 7.51 1.392.58 0.57 0.96 0.39 10 12.59 5.55 4 1.72 1.04 0.34 35 27.8 1.76 6.760.88 2.25 0.96 2 1.66 7.79 1.12 2.87 0.16 0.96 0.39 5 27 7.43 6.49 1.281.38 1.19 10 37.68 9.25 8.37 1.94 2.08 1.69 35 64.38 18.36 11.87 2.892.13 1.31

What is claimed is:
 1. A composition comprising at least one GIenzyme-labile opioid agonist releasing subunit capable of releasing anopioid agonist upon the action of a GI enzyme, wherein the at least oneGI enzyme-labile opioid agonist releasing subunit is covalently linkedto at least one non-opioid agonist releasing GI enzyme subunit capableof being cleaved by said GI enzyme.
 2. A composition comprising at leastone GI enzyme-labile opioid agonist releasing subunit capable ofreleasing an opioid agonist upon the action of a GI enzyme, wherein theat least one GI enzyme-labile opioid agonist releasing subunit iscovalently linked to at least one GI enzyme inhibitor subunit capable ofinhibiting said GI enzyme.
 3. The composition of claim 1, wherein the atleast one GI enzyme-labile opioid releasing subunit and the at least onenon-opioid releasing GI enzyme subunit are covalently linked via ascaffold moiety.
 4. The composition of claim 2, wherein the at least oneGI enzyme-labile opioid releasing subunit and the at least one GI enzymeinhibitor subunit are covalently linked via a scaffold moiety.
 5. Thecomposition of claim 3, wherein the scaffold moiety comprises apolypeptide or polysaccharide.
 6. The composition of claim 4, whereinthe scaffold moiety comprises a polypeptide or polysaccharide.
 7. Thecomposition of claim 1, wherein the at least one non-opioid releasing GIenzyme subunit is an inverse-substrate.
 8. The composition of claim 1,wherein the GI enzyme is trypsin.
 9. The composition of claim 1, whereinthe GI enzyme is chymotrypsin.
 10. The composition of claim 1, whereinthe GI enzyme-labile opioid releasing subunit releases the opioidagonist in the presence of the GI enzyme.
 11. The composition of any oneof claim 2, wherein the opioid agonist is selected from the groupconsisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine,levorphanol, meperidine, methadone, oxymorphone, dihydrocodeine,tramadol, tapentadol, buprenorphine, and pharmaceutically acceptablesalts, prodrugs, and mixtures thereof.
 12. The composition of claim 11,wherein the opioid agonist is oxycodone.
 13. The composition of claim11, wherein the opioid agonist is hydrocodone.
 14. The composition ofclaim 11, wherein the opioid agonist is morphine.
 15. The composition ofclaim 1, wherein the non-opioid agonist releasing subunit is capable ofsaturating or inhibiting the GI enzyme.
 16. The composition of claim 2,wherein the GI enzyme inhibitor subunit is capable of inhibiting the GIenzyme.
 17. The composition of claim 16, wherein the non-opioid agonistreleasing subunit is capable of reducing the expected systemic exposuresof delivered opioid agonist when doses of the opioid agonist greaterthan the prescribed dose are orally administered.